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Human African Trypanosomiasis (HAT) is a neglected disease endemic in sub-
Saharan Africa. HAT is caused by the parasite Trypanosoma brucei, which is 
transmitted by the tsetse fly, and is fatal if left untreated. HAT occurs in two stages, 
the first being the haemolymphatic stage which progresses to the second stage once 
the parasite crosses the blood-brain barrier and enters the central nervous system. 
Currently effective treatments are available for the first stage of the disease, however 
treatment of the second stage is much more difficult. Only two drugs are currently 
available for treatment of stage two and they suffer from major drawbacks, namely 
toxicity and rigorous administration schemes which are not often possible in a rural 
setting. The lack of any new drugs being introduced for the treatment of HAT has led 
to growing resistance of the limited number of drugs which are currently available. 
New drugs are therefore desperately needed, which can effectively and efficiently 
treat HAT. This research describes the exploration of a new scaffold with the 
potential to be developed into an anti-HAT drug. The image below shows an 
isoquinoline scaffold which when substituted at the phenolic position with a benzyl 
or cyclohexylmethyl group showed preliminary activity against T. b. rhodesiense in 
the micromolar range. 
 
In this research over 90 derivatives of the above isoquinoline scaffold were 
synthesised and evaluated for their in vitro activity against T. b. rhodesiense as well 
as their cytotoxicity towards mammalian cells. Synthesis of derivatives was focussed 
around modifications of four main parts of the scaffold which are summarised in the 




substitution directly at the aromatic ring at the same position (1). Modification of the 
benzylic alcohol (2) and the nitrogen atom (3) were explored, as well as the addition 
of substituents to the methylene carbon (4) and combinations of these. Synthesis of 
these derivatives and evaluation of their ability to inhibit T. b. rhodesiense allowed a 
structure-activity relationship to be developed for this isoquinoline scaffold. Five 
derivatives were identified with inhibition of T. b. rhodesiense in the sub-micromolar 
range with good selectivity over mammalian cells. These five derivatives provide 
good leads for further optimisation of this scaffold. All of the derivatives were also 
evaluated for their inhibition of two strains of P. falciparum, the causative agent of 
malaria. Two of these were found to be promising, showing inhibition of both strains 
of P. falciparum in the low micromolar range with good selectivity over mammalian 
cells. 
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The health of over a billion people in some of the world’s poorest countries is 
affected as a consequence of neglected tropical diseases. Neglected tropical diseases 
are a group of 17 communicable diseases which are present in tropical and 
subtropical countries worldwide.2 The prevalence of these diseases is strongly 
dependant on control measures which are often neglected during periods of political 
instability, commonly leading to resurgence.3 These diseases are considered 
neglected as they mostly affect impoverished populations in developing countries, 
and consequently interest from western governments and the pharmaceutical industry 
is low. As a result, research into these diseases is limited due to the prospect of little 
or no financial gain.4–6 One of the most complex endemic neglected tropical diseases 
is known as Human African Trypanosomiasis, or more commonly African sleeping 
sickness.2  
1.1 Human African Trypanosomiasis 
Human African Trypanosomiasis (HAT) is a parasitic disease which occurs in sub-
Saharan Africa. It is caused by the protozoan parasite Trypanosoma brucei which is 
transmitted by the tsetse fly.3,7 It is a vector borne disease and is usually fatal if left 
untreated.2  
1.1.1 Types of HAT 
There are two subspecies of Trypanosoma brucei that are pathogenic for humans, T. 
b. gambiense and T. b. rhodesiense; a third type T. b. brucei infects only animals.8 T. 
b. gambiense is prevalent in central and west Africa and causes a more chronic form 
of the disease. It is reported to be responsible for 98% of reported cases of HAT.9 T. 
b. rhodesiense is prevalent in east and southern Africa and causes a more acute 
rapidly progressing form of the disease.3 
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1.1.2 Symptoms of HAT/clinical Features 
For both types of HAT mentioned above there are two stages of infection: the 
haemolymphatic stage and the neurological stage. The haemolymphatic stage 
describes the stage where trypanosomes are restricted to the blood and lymphatic 
system.3,9 Symptoms of this stage of the disease are generally non-specific and 
include malaise, headache, weight loss, fever, and fatigue.5,10 The neurological stage 
is when trypanosomes cross the blood-brain barrier and invade the central nervous 
system (CNS).9,11 One of the main symptoms of the second stage is a disruption of 
the sleep cycle, which gives this disease its more common name (sleeping 
sickness).12 Many other symptoms can be observed, some of these being confusion, 
tremor, general motor weakness, psychiatric symptoms, as well as sensory and motor 
disturbances.5,7,8 Due to the clinical manifestation of HAT the symptoms of both 
stages overlap and distinction between stages is difficult. Another consequence of the 
non-specific symptoms is misdiagnosis with other fever causing diseases and 
neuropsychiatric problems.13,14 The symptoms of HAT are generally the same for the 
two forms of the disease, however they differ in terms of their severity and duration. 
T. b. gambiense is a more chronic form of the disease with an average duration of 3 
years which is evenly divided between the first and second stages.15 T. b. rhodesiense 
is a more acute form of the disease, with the first stage lasting only a few weeks, and 
leading to death within a few months.16 Without treatment both types of HAT will 
ultimately lead to death.3,5 
1.1.3 Transmission of HAT 
The trypanosomes which cause HAT are transmitted by the tsetse fly from one 
mammalian host to another. Humans are the main reservoir for T. b. gambiense, 
while animals are the main reservoir for T. b. rhodesiense.5,8 Trypanosome 
transmission begins with the tsetse fly feeding on an infected animal or human, 
followed by several differentiation steps of the trypanosome within the mid-gut of 
the fly. This leads to the development of an infective form of the trypanosome which 
subsequently reaches the fly’s salivary glands and is transmitted to the human host 
by a bite.3,5 
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1.1.4 History  
Reports of what is thought to be HAT have been recorded as early as the 14th 
century.17 In the 20th century, multiple disastrous sleeping sickness epidemics were 
reported.18 It was during these epidemics that the parasite which was responsible for 
the disease was discovered and linked with the tsetse fly.17 Following this discovery, 
several control measures were set up which helped to control the disease. By the 
1960s, the number of cases reported was very low,19 which resulted in a slackening 
of control measures and eventually led to a resurgence of the disease by the 1990s. 
At this time the total number of cases of HAT was estimated to be 300,000.20 By 
2009, the number of reported cases of HAT had dropped to below 10,000 new 
cases.21 




Figure 1 Map showing the number of reported cases of HAT in 2014. A: T. b. 
rhodesiense. B: T. b. gambiense. Image from WHO global health observatory map 
gallery.22 
The current number of reported cases of HAT is summarised in Figure 1. In 2013, 
the number of reported cases of T. b. gambiense dropped to 6,228,21 and the areas at 
high or very high risk dropped by 60% between 2008 and 2012.23 The number of 
reported cases of T. b. rhodesiense in 2013 was less than 100, and the number of 
people at risk dropped by 95% during 2008-2012.24 Although the number of cases of 
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T. b. rhodesiense has recently dropped dramatically, the zoonotic nature of this form 
of the disease means that it still holds its epidemic potential.25  
1.1.5.1 Current treatments  
Effective treatment of HAT relies on early detection while the patient is still in stage 
1 of the disease, however most patients do not receive treatment until the disease has 
already progressed well past this point. This is due to two main reasons, the mild and 
non-specific symptoms present in the first stage of the disease, and the fact that the 
vast majority of people who are at risk are generally part of poor and neglected 
populations living in rural areas with limited access to healthcare.2 Currently there 
are only 4 drugs registered for the treatment of HAT (see Figure 2).26 Of these 
pentamidine 1 and suramin 2 are effective only in the first stage of the disease, 
against T. b. gambiense and T. b. rhodesiense respectively. However, neither of these 
drugs are effective against the second stage of the disease due to their inability to 
cross the blood-brain barrier, which results from the fact that they are highly charged 

















Figure 2 Four drugs registered for the treatment of HAT: pentamidine, suramin, 
melarsoprol, and eflornithine. 
The second two drugs, melarsoprol 3 and eflornithine 4, are used in the treatment of 
the second stage of the disease. Melarsoprol is effective against both types of the 
disease, however it is an arsenic based drug and is highly toxic. In approximately 5% 
of patients Melarsoprol causes adverse effects which lead to fatality.20 Over the last 
decade there has been an increase in reports of melarsoprol resistance,28 which is a 
cause for concern as it is currently the only effective treatment for T. b. rhodesiense. 
Eflornithine is less toxic than Melarsoprol, however it is only effective against T. b. 
gambiense, and is difficult to administer. Successful treatment with eflornithine 
requires that patients are administered one slow intravenous infusion of the drug 
every 6 hours for 14 days, resulting in a total of 56 infusions.29 This rigorous 
administration scheme makes treatment with eflornithine expensive and difficult in a 
rural setting.30 Recently a drug called nifurtimox 5 has been used in the treatment of 
HAT (Figure 3). Nifurtimox is an orally administered drug registered for the 
treatment of Chagas disease, a trypanosomal disease caused by the parasite 
Trypanosoma cruzi, which is endemic in Latin America.31 Orally administered 
Nifurtimox is used in combination with intravenous eflornithine, resulting in a 
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significant reduction in the time and cost of treatment.29 However, the combination 
therapy is still only effective against T. b. gambiense, and is still limited by the need 
for intravenous administration.32 This combination therapy has been the only 
advance made in the treatment of HAT in the last 25 years.32  
 
5  
Figure 3 Nifurtimox, a drug registered for the treatment of Chagas disease. 
1.1.6 Significance 
The drugs currently available to treat HAT are few, and suffer a number of 
drawbacks. Currently the only drug available to treat the second stage of T. b. 
rhodesiense is a toxic arsenic based drug which causes a number of adverse side 
effects which lead to death in some patients. The best available treatment for T. b. 
gambiense currently is the nifurtimox-eflornithine combination therapy. This is a 
step forward from the use of eflornithine by itself, however the treatment is still 
expensive and suffers from the drawback of requiring intravenous administration of 
the eflornithine. The lack of new drugs for the treatment of HAT in recent years has 
resulted in growing resistance to the currently available drugs, which are already 
limited in number and efficacy.33 For these reasons it is important that new drugs are 
sought that work via different modes of action, and are cheaper and easier to 
administer than those currently available. 
1.1.7 Current Clinical Trials 
In the last 10 to 20 years there has been an increase in interest from the research 
community in novel treatments for HAT. Currently the most advanced candidate is 
an orally available drug by the name of fexinidazole 6 (Figure 4), which is 
administered orally once a day for 10 days.34 In late 2012, it entered phase II/III 
clinical trials,35 no outcomes have yet been reported. However, in 2016 additional 
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trials were started involving both adults and children as well as a phase IIIb trial 
including pregnant and lactating women.36 
 
6  
Figure 4 Structure of fexinidazole. 
Another oral candidate is known as oxaborole SCYX-715837 7 (Figure 5). The 
benefit of this candidate over fexinidazole is that it could potentially be given as a 
single oral dose due to its long half-life.34 This candidate recently completed phase I 
clinical trials, and there are plans to proceed with phase II/III trials in 2016.38 
However, there have been no updates as yet on the commencement of these trials. As 
well as oxaborole SCYX-7158 there are two other similar candidates known as 
SCYX-1330682 and SCYX-1608210 (Figure 5).39 The clinical development of these 
two candidates has currently been halted but will proceed in the event of any 










Figure 5 Structure of oxaborole HAT candidates. 
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1.2 Recent HAT drug discovery 
1.2.1 New molecules inspired by known antitrypanosomal agents 
One approach to drug discovery is to take existing drugs or classes of compounds 
and use these as a starting point for drug discovery. This could include molecules 
that are known to be active against the intended target or a related target. This 
approach is usually known as target repurposing and has been coined by some as 
chemocentric drug discovey.42 
1.2.1.1 Diamidines 
There has been recent interest in diamidines (Figure 6) based on the currently used 
stage I HAT drug pentamidine 1. Parfuramidine 10 was identified as a potentially 
orally available treatment for stage I HAT, and entered into clinical trials in 2000.43 
Parfuramidine advanced to phase III clinical trials but the trials were halted due to a 
later extended phase I trial which revealed delayed nephrotoxicity.44 More recently 
an analogue of parafuramidine known as DB844 11 has shown promising results in 
the oral treatment of second stage HAT, curing approximately 40% of cases in a 
monkey model.45 A number of other diamidines have also been reported to have 
good antitrypanosomal activity with one such compound 12 resulting in 4/4 cures in 














Figure 6 Recently reported diamidines showing activity for HAT. 
1.2.1.2 Nitroheterocycles 
Another area of interest in antitrypanosomal research are nitroheterocycles, inspired 
by the success of fexinidazole. Nitroheterocycles have been successful in the 
treatment of Chagas disease, a neglected parasitic disease endemic in areas of 21 
Latin American countries, the current treatment for which is a nitroheterocycle 
known as benznidazole 13 (Figure 7).2,9 In a general sense, the use of nitro 
containing compounds in drug discovery is usually avoided due to the high 
likelihood of toxicity issues arising,47 however nitro groups are still found in many 
currently used drug molecules.48–51 Many of these nitro containing drugs act as pro-
drugs and must be activated within the pathogen, by nitroreductase enzymes (NTR), 
to have cytotoxic effects.52 A parasite type I NTR is critical for trypanocidal activity 
of nitrohetereocycles. Parasites with lower levels of NTR were more resistant to nitro 
compounds, while those with elevated levels of NTR were hypersensitive. This 
enzyme, which is absent in mammalian cells, catalyses the two electron reduction of 
the nitro group to produce toxic metabolites.52,53 It has been shown that nifurtimox 
acts in this way and is activated by these NTR’s. Evidence has been reported which 
suggests that fexinidazole is also activated by the same NTR’s.53 This has raised 
concern that resistance could potentially be observed for fexinidazole before the drug 
has even been registered for use. This is because resistance seen in nifurtimox is 
believed to be due to down regulation of these NTR’s and could be potentially be 
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translated to fexinidazole.54 A laboratory generated T. brucei cell line resistant to 
nifurtimox was found to show cross resistance to fexinidazole.47 
Nitronaphthoquinones 14 have also been reported to have antitrypanosomal 
properties (Figure 7).55 However, in this case it seems that the nitro group is not 
essential to T. brucei activity, rather it is the electron withdrawing nature of the nitro 
group that is important, with other electron withdrawing groups such as CF3 and Cl 
also showing good activity. A class of nitroimidazoles 15 (Figure 7) have also been 
reported to show antitrypanosomal activity.56 A SAR study was undertaken on a 
series of fifty 1-aryl-4-nitro-1H-imidazoles, with two of these compounds having 
curative action in mouse models of both T. b. rhodesiense and T. b. brucei. With no 
toxicity observed in this study, these compounds are promising leads for further 
development. A nitrotriazole based piperazide 16 has also been shown to have 
antitrypanosomal activity.57 This compound was reported to be selectively active 
against T. b. rhodesiense with an IC50 of 0.23 μM. A number of similar compounds 














Figure 7 Nitroaryls showing anti-HAT activity. 
1.2.2 Target-based screening 
Target-based screening is a popular drug discovery approach describing the 
identification and subsequent optimisation of a molecule that acts on a particular 
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target, usually an enzyme.58 Generally such molecules are identified by high 
throughput screening methods against the desired target. Once identified the new 
lead compound can be optimised using structure based methods, including x-ray 
crystallography and computational modelling. This allows the binding mode of the 
lead compound to be explored and optimised. Target based screening is an important 
approach being used in the discovery of new anti-HAT agents. 
1.2.2.1 Trypanothione reductase inhibitors 
There has been a lot of recent interest into developing molecules to inhibit 
trypanothione reductase (TryR). TryR is an enzyme involved in the trypanothione 
based redox metabolism of T. brucei as well as some other parasites. In humans this 
system is not present and is instead carried out by glutathione and glutathione 
reductases (GR), and consequently it has been proposed as a good target for the 
selective inhibition of T. brucei.59 A high throughput screen of the Sigma 
LOPAC1280 library of 1266 compounds was undertaken against TryR, with hits 
then being screened against T. brucei and human GR resulting in the identification of 
three new compounds (Figure 8) with properties warranting further investigation.59 
SAR studies were undertaken on one of these compounds, GBR-12935 17, which 
had an original EC50 of 9.3 μM against T. brucei. These studies resulted in the 
discovery of a competitive inhibitor of TbTryR with a much improved potency 
against T. brucei (EC50 = 0.775 μM).
59 BTCP 18, an analogue of a known anaesthetic 
drug phencyclidine, was also identified as a potential target. A small library of 
phencyclidine analogues were synthesised and inhibition of TbTryR as well as T. 
brucei were determined. A detailed SAR was developed, however the activity of the 
compounds as compared to the original hit were only marginally improved and 
overall showed poor selectivity compared to mammalian cells.60 The third hit 
compound indatraline 19, a monoamine reuptake inhibitor, was derivatised in order 
to develop a SAR for this class of compound. However, it proved difficult to increase 
the potency of these derivatives as compared to indatraline, and it was discovered 















Figure 8 Three compounds identified from the LOPAC1280 library with TryR 
inhibition and trypanocidal activity.  
A series of 3,4-dihydroquinazolines (Figure 9) has been reported as TryR 
inhibitors,62 with the initial screening hit 20 having an IC50 of 6.8 μM against TryR 
and an EC50 of 40 μM against T. brucei. High resolution crystal structures of TryR 
alone, and TryR in complex with a number of inhibitors in this series were reported. 
These revealed that the enzyme undergoes a conformational change upon binding to 
the substrate, creating a new pocket which is then occupied by an aryl group on the 
ligand. This information on the structure and binding of TryR gave the opportunity to 
adopt a structure based design approach leading to more potent inhibitors, with the 
most potent inhibitor 21 having an IC50 of 0.23 μM against TryR and an EC50 of 0.73 





Figure 9 A series of 3,4-dihydroquinazolines with activity against TryR. 
A small library of 4-aminoquinoline heterodimers of three different structural classes 
was recently reported showing antitrypanosomal activity (Figure 10).63 All of the 
compounds tested showed submicromolar IC50 values against T. brucei, with the 
most active compound having an IC50 of 0.12 μM, with good blood-brain barrier 
permeability. Mechanistic studies showed that inhibition of TryR is involved in the 












Figure 10 Three structural classes of 4-aminoquinoline heterodimers identified as 
having antitrypanosomal activity.  
1.2.2.2 Rhodesain /cysteine protease Inhibitors 
Another group of targets which have been popular recently in HAT drug discovery 
are cysteine proteases. Cysteine proteases have been suggested as good targets for 
the treatment of HAT. Parasitic organisms generally rely on cysteine proteases 
whereas humans rely on serine proteases, therefore cysteine proteases have been 
proposed as potential targets for selective antiparasitic drug design. Rhodesain is the 
major cysteine protease expressed by T. b. rhodesiense, and in the past few decades 
many compounds have been identified as rhodesain inhibitors.64 There are three main 
classes of rhodesain inhibitors that have been reported, peptide-based inhibitors, 
peptidomimetic inhibitors, and nonpeptidyl inhibitors. 
1.2.2.3 Peptide based rhodesain inhibitors 
Peptide-based inhibitors are generally made up of a peptide segment for recognition 
by the enzyme, and what is termed as a warhead which is usually an electrophilic 
moiety that can undergo nucleophilic attack of the cysteine residue in the active 
site.64 A series of heptapeptides 25 based on fumaric acid (Figure 11) have been 
identified as cysteine protease inhibitors via high throughput screening.65 These 
peptides contain fumaric acid as the electrophilic moiety, which irreversibly binds to 
the active site cysteine residue of rhodesain via a conjugate addition reaction, 
effectively inhibiting rhodesain. Further studies of this series of inhibitors led to the 
identification of a number of compounds with inhibition of T. b. brucei in the 
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micromolar range, including a reversible inhibitor.66 Another series of rhodesain 
inhibitors reported consists of dipeptidyl enoates 26 containing a 4-oxoenoate moiety 
acting as a Michael acceptor (Figure 11). These compounds have been shown to be 
potent rhodesain inhibitors, inhibiting rhodesain in the best case with an IC50 of 16.4 
nM, however these compounds have yet to be tested in vitro against the parasite.67 A 
rhodesain inhibitor 27 which combines a previously reported α-β-epoxy residue with 
a Cbz-Phe-HPhe sequence known to be selective for cruzain (cysteine protease 
present in Trypanosoma cruzi) has also been reported (Figure 11).68 The best of 
these inhibitors was reported to have an IC50 for rhodesain of 3.5 nM and inhibition 
of T. b. brucei in vitro of 42%. Azadipeptide nitriles 28 have also been shown to 
inhibit rhodesain.69 A library of azadipeptide nitriles (Figure 11) were recently 
shown to be nanomolar inhibitors of rhodesain, these compounds also showed 
trypanocidal effects, with the best compound showing an IC50 of 1.1 μM in a 
bloodstream form of T. b. brucei. Proteomics studies were also undertaken on these 












Figure 11 Peptide based inhibitors of rhodesain.  
1.2.2.4 Peptidomimetic rhodesain inhibitors 
Peptidomimetics are another class of cysteine protease inhibitors which have been of 
recent interest. Peptidomimetics mimic peptides but have an advantage over them in 
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that they can be designed with particular features giving them the potential to 
overcome some of the limitations of peptide based inhibitors. These features can 
include improving stability at physiological pH, improving selectivity through 
rigidity, as well as modifications allowing for better absorption through the blood-
brain barrier. It is possible to achieve this in a number of ways including using 
unnatural amino acids, using amide bond isosteres, or locking the peptide into a rigid 
conformation.64 Peptidomimetics based on a 1,4 benzodiazepine scaffold 29 have 
been reported as cysteine protease inhibitors (Figure 12).64 It was suggested that 
these mimic a β-turn, which has been proposed as the active form of linear peptides. 
The most effective inhibitors of this kind included a vinyl ester as the warhead to 
inactivate rhodesain via a Michael addition. The most promising inhibitor from this 
series was reported to have excellent selectivity for rhodesain with an IC50 value of 
4.8 μM for T. b. brucei. Another series of vinyl sulfone containing compounds 30 
has also been shown to inhibit rhodesain.70 In these compounds the peptide chain is 







Figure 12 Peptidomimetic inhibitors of rhodesain.  
1.2.2.5 Nonpeptidyl rhodesain inhibitors 
The final class of rhodesain inhibitors that has been reported are nonpeptidyl 
inhibitors. A series of thiosemicarbazones (Figure 13) has been shown to inhibit 
rhodesain with good antitrypanosomal activity against T. brucei.71 A library of 
thiosemicarbazones 31 was synthesised and screened against rhodesain as well as T. 
b. brucei. Of the compounds tested most showed activity against T. b. brucei in the 
low micromolar range. The best compound in this series showed no correlation in 
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activity against T. b. brucei and inhibition of rhodesain indicating another 
mechanism of action. More recently another series of thiosemicarbazones 32 (Figure 
13) was reported to show good inhibition of rhodesain. Of these compounds the best 
showed micromolar activity against T. b. brucei with good selectivity as compared to 





Figure 13 Two classes of thiosemicarbazone inhibitors of rhodesain. 
Triazine nitriles have also been identified as inhibitors of rhodesain (Figure 14). 
High throughput screening identified a class of triazine nitriles 33 as inhibitors of 
rhodesain.73 Initial hits were micromolar inhibitors of rhodesain, however they 
showed no activity against T. b. brucei. Activity against T. b. brucei was 
significantly improved by a number of structural modifications of the original hits, 
leading to compounds with activity against T. b. brucei in the micromolar range. 
Another series of triazine nitriles 34 has also been reported to have activity against 
rhodesain. Structure based design techniques and computer aided modelling were 
employed to design and synthesise a series of functionalised triazine nitriles. These 
compounds were found to show good inhibition of rhodesain but limited activity 
against the parasite.74 Further structure based design resulted in compounds showing 
a significant improvement in antitrypanosomal activity with the best compound 
having an IC50 in the sub-micromolar range (Figure 14).
75 N-Protected guanidine 
compounds containing either a pyrrole or furan ring 35 (Figure 14) have also been 
reported to be antitrypanosomal, with the mechanism of action being inhibition of 
rhodesain. A structure activity relationship study of N-protected guanidines led to the 
development of rhodesain inhibitors with activity against T. b. brucei in the low 
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Figure 14 Triazine nitriles and guanidines with activity against rhodesain. 
1.2.2.6 Tryparedoxin Inhibitors 
Tryparedoxin has also been identified as another important protein in the redox 
metabolism of T. brucei, and could be a possible target for T. brucei inhibition.77 A 
high throughput screen and subsequent studies led to the identification of 12 covalent 
inhibitors of tryparedoxin, which were classed into 5 groups (Figure 15). The 
compounds were reported to show inhibition of T. brucei down to 1 μM with 83 fold 





















Figure 15 Representatives of five classes of compounds found to inhibit 
tryparedoxin.  
1.2.2.7 GSK3 inhibitors 
Recently a series of antitrypanosomal compounds which inhibit the T. brucei protein 
kinase GSK3 (TbGSK3) have been identified.78 TbGSK3 has been shown to be 
important to the growth of T. brucei parasites in vitro, and is hence a potential target 
for the development of antitrypanosomal compounds. Initially high throughput 
screening identified a number of efficient inhibitors of TbGSK3 with sub-
micromolar potency, two of these are shown in (Figure 16). The most active series 
was a series of 2,4-diaminothiazoles 41 which were found to be active against the 
parasite T. b. brucei with EC50 values in the sub-micromolar range. Aminopyrazole 
derivatives 42 have also been reported as TbGSK3 inhibitors.79 A SAR investigation 
of an initial lead aminopyrazole led to the development of a series of aminopyrazole 
amides showing low nanomolar inhibition of TbGSK3 and high selectivity. 
However, activity against the parasite T. b. brucei was significantly lower with EC50 








Figure 16 Diaminothiazoles and aminopyrazoles as TbGSK3 inhibitors.  
1.2.2.8 N-Myristoyl transferase inhibitors 
Pyrazole sulfonamide derivatives have been reported to inhibit T. brucei N-myristoyl 
transferase (TbNMT).80 There has been recent evidence that TbNMT is a good target 
for the treatment of HAT due to it being essential for parasite growth.81 Initial high 
throughput screening studies reported a pyrazole sulfonamide derivative 43 as an 
inhibitor of TbNMT, however this compound showed very poor blood-brain barrier 
permeability (Figure 17).80 More recently optimisation of this lead compound via an 
extensive SAR study, has led to a new lead compound 44 (Figure 17) with much 
improved blood-brain barrier permeability. However, this compound only proved 





Figure 17 Pyrazole sulfonamide inhibitors of N-myristoyl transferase. 
In the same high throughput screen thiazolidinone and benzomorpholine type 
compounds (Figure 18) were also reported as hits for TbNMT. The thiazolidinone 
hit 45 was optimised by expanding the original hit into a series of compounds, 
resulting in the discovery of a new potential lead compound with an EC50 (T. brucei) 
of 6.3 μM, as well as discovery of the binding mode in the form of a crystal structure 
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which will be an important tool for future structure based optimisation.83 The 
benzomorpholine hit 46 was also optimised using a structure based approach, as well 
as SAR studies. Compounds from this study showed very potent activity (EC50 T. 








Figure 18 Two series of initial Hit compounds for TbNMT. 
1.2.2.9 Trypanothione synthetase inhibitors 
A series of indazoles which inhibit trypanathione synthetase (TryS) has been 
reported.84 TbTryS has been reported as being essential for T. brucei growth making 
it a good drug target.85 A high throughput screen of a compound library containing 
over 62000 compounds was undertaken to identify inhibitors of TbTryS. This 
resulted in the identification of six novel TbTryS inhibitors. Three of these 
compounds 47, 48, 49 (Figure 19) were identified as having an overlapping 
pharmacophore for TbTryS activity and were hybridised to give a new core scaffold 
50 (Figure 19). Optimisation of this scaffold led to compounds with tenfold 
improved TbTryS activity (<100 nM) over the original hits. However, these 













Figure 19 TryS inhibitors: Identification of three initial hit compounds and 
development of a new core scaffold.  
1.2.2.10 Ornithine decarboxylase inhibitors 
Another enzyme which has been targeted in HAT drug discovery is ornithine 
decarboxylase, which catalyses the first step of polyamine synthesis in T. brucei.86 
Eflornithine, which is currently used in the treatment of HAT, is an inhibitor of 
ornithine decarboxylase (ODC).87 A high throughput screen for inhibitors of TbODC 
resulted in the identification of four novel series of TbODC inhibitors (Figure 20) 
with previously uncharacterised binding modes.86 Of these series the benzothiazoles 
51, indoles 53, and bisbiguanides 54 were shown to be good inhibitors of TbODC 
however they were nonselective inhibiting both TbODC and human ODC. The 
dithioamidines 52 showed the most promise having the ability to selectively inhibit 















Figure 20 Ornithine decarboxylase inhibitors.  
1.2.2.11 Phosphofructokinase Inhibitors 
The T. brucei parasite is dependent on the metabolism of glucose for ATP 
generation, and the glycolytic enzyme phosphofructokinase (PFK) is essential for 
this process. Consequently PFK has been suggested as a potential drug target for 
HAT.88 High throughput screening identified an amidosulfonamide 55 (Figure 21) 
with micromolar inhibition of TbPFK.88 SAR and optimisation studies led to the 
most potent compound 56 in the series with an IC50 of 15 nM against TbPFK, 
however this compound showed no activity against T. b. rhodesiense. Another 
compound 57 showed less potency for TbPFK, with an IC50 of 0.37 μM, but had an 
ED50 of 16.3 μM against T. b. rhodesiense with low cytotoxicity (Figure 21). This 









Figure 21 Amidosulfonamide inhibitors of TbPFK. 
1.2.3 Phenotypic screening 
Before the introduction of target based drug discovery phenotypic drug discovery 
was the main approach.58 Phenotypic screening, similar to target based screening 
usually involves high throughput methods, however rather than screening molecules 
against specific targets and measuring a binding response, molecules are screened 
against a whole cell or organism and any phenotypic changes assessed.42 Phenotypic 
changes can include any biological effect. In the case of HAT, parasite growth 
inhibition is usually the monitored phenotypic change. An advantage of phenotypic 
screening is that it can be used even when limited knowledge is known about the 
mechanism of the disease being targeted. 
1.2.3.1 Oxazolopyridines, pyridyl benzamides and pyrazine carboxamides 
Eight new compounds of five different chemical classes were identified as being 
potential candidates for HAT drug discovery via a high throughput screen of a library 
of 87,296 compounds.89 From this screen three classes of compounds have been 
further optimised. An oxazolopyridine derivative was reported to have an IC50 of 
0.22 μM for T. b. brucei and 0.59 μM for T. b. rhodesiense. A SAR study led to the 
identification of the most active compound 58 (Figure 22) with an IC50 of 91 nM for 
T. b. rhodesiense and much greater selectivity for T. b. rhodesiense as compared to a 
mammalian cell line.90 A pyridyl benzamide with an initial IC50 of 12 μM was also 
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identified from this screen. Optimisation studies led to a significant improvement in 
activity with the best compound 59 (Figure 22) having an IC50 of 45 nM and a 
selectivity for T. b. rhodesiense over 4000 times greater than that of a mammalian 
cell line.91 Pyrazine carboxamides were also identified as potential targets for HAT 
from this screen. The original hit compound was reported with an IC50 of 0.49 μM. 
Following SAR optimisation the best compound 60 (Figure 22) was reported to have 
an EC50 of 24 nM and a selectivity for T. b. rhodesiense 1500 times greater than that 










Figure 22 Three compounds from the optimisation of hits identified through high 
throughput screening. 
1.2.3.2 Adamantanes 
A class of adamantanes has also been reported to have antitrypanosomal activity. The 
antitrypanosomal activity of substituted adamantanes has been correlated with 
hydrophobic substitutions on the adamantane ring. Alkyl aminoadamantanes (Figure 
23) were reported to have antitrypanosomal activity with IC50 values as low as 90 
nM, however no toxicity data was reported.93,94 The most active adamantane was 
substituted with a guanylhydrazone and an alkyl chain 10 carbons in length. It is 
hypothesised that these molecules block a parasite membrane localised ion channel.93  
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A small library of naphthoquinone 62 and anthraquinone 63 derivatives (Figure 24) 
has been reported to show antitrypanosomal activity.95 The best compound showed 
an IC50 of 50 nM against T. b. rhodesiense, however most derivatives were found to 
be considerably cytotoxic. One derivative showed an IC50 of 80 nM and a selectivity 
index of 74, providing a potential hit compound. Through further study of this 
compound it was found that it involved a multi-target mechanism of action, including 






Figure 24 Naphthoquinone and anthraquinone derivatives with antitrypanosomal 
activity. 
1.2.3.4 Quinolones 
A library of 4-quinolone-3-carboxamides was synthesised and tested for 
antitrypanosomal activity.97 Subsequent structure activity relationship studies led to 
the identification of a potent inhibitor of T. b. rhodesiense with an IC50 of 9 nM 64 
(Figure 25), which is thought to act by inhibiting proteins involved in kinetoplast 
segregation. This compound was found to have low cytotoxicity but was 
unfortunately ineffective when administered orally in an animal model, however it is 
a promising structure for further optimisation. Another series of 4-(1H)-quinolone 
derivatives 65 has also been reported to have antitrypanosomal activity (Figure 
25).98 These compounds showed micromolar inhibition of T. b. rhodesiense, with the 










Figure 25 Quinolone inhibitors of T. b. rhodesiense. 
1.2.3.5 Anilinoquinazolines 
Lapatinib 66 is a 4-anilinoquinazoline registered as an epidermal growth factor 
receptor (EGFR) inhibitor, but was recently reported to show activity against HAT 
(Figure 26). Following this, lapatinib was optimised leading to the synthesis of a 
new potent HAT inhibitor 67 with an EC50 of 42 nM (Figure 26).
99 This compound 
was shown to have good selectivity and bioavailability as well as showing modest 
effects when tested in a mouse model of HAT. The method of action is unclear, 










2,4-Diaminopyrimidines (Figure 27) have been shown to have activity against HAT, 
with kinase inhibition being suggested as the mode of action.100 A SAR study of 
these 2,4-diaminopyrimidines 68 led to the discovery of three compounds which had 
IC50 values in the low micromolar to nanomolar range and were able to cure 100% of 
mice tested in a bloodstream model of T. b. brucei. The ability of these compounds 
to cross the blood-brain barrier was assessed through in vitro permeability studies. 
The compounds were found to show poor in vitro permeability, suggesting they 
would not be able to cross the blood-brain barrier. This led to the development of a 
series of 4-des-amino pyrimidines 69 (Figure 27) with improved in vitro 
permeability. Unfortunately this new set of compounds did not give consistent cure 





Figure 27 Diamino and Des-amino pyrimidines with HAT activity.  
1.2.3.7 Imidazopyridines 
A substituted 2-(3-aminophenyl)oxazolopyridine 70 was identified from a high 
throughput screen of 700,000 compounds as a potential lead compound for the 
treatment of HAT (Figure 28). This compound had an EC50 of 22 nM against T. b. 
brucei in vitro. Through the optimisation of this compound, imidazopyridines were 
identified as being highly potent antitrypanosomal compounds. The most potent of 
these, 71, had an EC50 of 2 nM against T. b. brucei in vitro and was able to cure T. b. 









Figure 28 Oxazolo and imidazopyridines with HAT activity. 
1.2.3.8 Indoline carboxamide derivatives 
A series of indoline-2-carboxamides (Figure 29) has been found to have potent 
activity against T. b. brucei.103 This series of compounds was identified from 
screening of a focussed protease library against T. b. brucei in vitro. Optimisation of 
this series led to the development of nanomolar inhibitors of T. b. brucei with 
excellent selectivity over mammalian cells. One particular compound in the series 
was able to cure a stage one animal model of HAT. Some compounds in the series 
were found to be brain penetrant and were able to partially cure a stage two animal 
model of HAT.  
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Figure 29 Indoline carboxamide derivatives with HAT activity. 
1.2.3.9 Thiazol-2-ethylamines 
A phenotypic high-throughput screen performed by the Genomics Institute of the 
Novartis Research Foundation identified 2-(benzamido)ethyl-4-phenylthiazole 73 as 
having inhibition of T. brucei below 0.63 μM and being non-toxic to mammalian 
cells.104 Analogues of this were synthesised, and of these 42 out of 72 were found to 
be more potent inhibitors of T. brucei than the original hit compound. Of these a 
series of piperidyl derivatives were found to be the most promising, with one 
derivative 74 having an IC50 of 9 nM and excellent selectivity for T. brucei over 
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mammalian cells (SI>18,000). When tested in vivo some of these compounds were 
able to cause temporary reduction in parasitemia, however none were able to cure 
infected mice. The lack of potency in vivo was thought to be caused by poor 





Figure 30 Thiazol-2-ethylamines with activity against T. brucei. 
1.2.3.10 Tyrosol and hydroxytyrosol derivatives 
Tyrosol 75 has been reported to have mild activity against T. b. rhodesiense.105 More 
recently a study of derivatives of tyrosol 75 and hydroxyltyrosol 76 found that many 
derivatives showed good activity against T. brucei.106 The most potent inhibitors 
were decanoate and dodecanoate esters of hydroxytyrosol 77 which exhibited sub-
micromolar inhibition of T. brucei. Both derivatives were also reported to be more 









Where n=8 or 10 
Figure 31 Structures of tyrosol and hydroxytyrosol. 
1.2.3.11 Natural products 
There has been a lot of interest recently in the use of natural products in HAT drug 
discovery. Cynaropicrin 78 a natural product from the herb Centaurea salmantica L. 
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(Asteraceae), was identified through a high throughput screen of 1800 plant and 
fungal extracts as a potent in vitro inhibitor of HAT (Figure 32).107 Cynaropicrin 
was reported to have an IC50 of 0.3 μM against T. b. rhodesiense in vitro, as well as 
having potent in vivo activity. The mechanism of action was later determined to be 
inhibition of trypanosomal ornithine decarboxylase as well as intracellular 
trypanothione depletion. 108 A SAR study was also undertaken but did not lead to the 
discovery of any derivatives with significantly increased activity as compared to 
cynaropicrin.109 Another natural product ascofuranone 79 has also been shown to be 
active against T. b. brucei in vivo.110 Ascofuranone acts by inhibiting the cyanide-
insensitive trypanosome alternative oxidase (TAO). TAO is vital for trypanosome 
aerobic respiration but is not present in humans, and hence provides a potential 
selective target. Ascofuranone and its derivatives have been shown to have sub-
nanomolar inhibition of TAO, providing an excellent lead compound for the 
treatment of HAT.111 Analogues of salviandulin E 80, originally isolated from the 
plant Salvia leucantha (Lamiaceae), have been reported to show antitrypanosomal 
effects.112 Of these analogues the most potent was reported to have an IC50 of 0.14 











Figure 32 Natural products with anti-HAT activity.  
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Cordycepin 81 (Figure 33), isolated from the parasitic fungus Cordyceps militari, 
has been known to have antitrypanosomal properties since the 1970’s.113 More 
recently cordycepin was reported as a selective inhibitor of T. b. brucei with an IC50 
of 32 nM in vitro, however it is inactive in vivo.114 A SAR study of cordycepin led to 
the identification of 2-fluorocordycepin which was shown to retain reasonable 
activity and selectivity for T. b. brucei in vitro, and more importantly when tested in 
vivo was able to cure a mouse model of T. b. brucei. Sesquiterpene lactones (STL’s) 
have been shown recently to have potent activity against T. b. rhodesiense.115 A 
quantitative structure activity relationship (QSAR) analysis was undertaken on a set 
of 69 STL’s for activity against T. b. rhodesiense.116 This QSAR model was then 
used to predict the activity of a virtual library of 1750 STL structures. A group of 
furanoheliangolide type STL’s 82 (Figure 33) were predicted to have high in vitro 
activity for T. b. rhodesiense and four representatives were then subjected to in vitro 
testing. Of these compounds all four showed activity against T. b. rhodesiense in the 
nanomolar range with the most potent compound having an IC50 of 15 nM and a 






Furanoheliangolide type STL's 
Figure 33 Natural products with anti-HAT activity.  
1.2.3.12 Organometallics 
There have also been some reports in the literature of organometallic compounds 
having antitrypanosomal properties. Ruthenium compounds 83 and 84 have recently 
been reported to have antitrypanosomal activity (Figure 34).117,118 These compounds 
incorporate a bioactive nitrofuran containing thiosemicarbazone ligand, which is 
known to have antitrypanosomal activity.119,120 They showed activity against T. b. 
brucei with IC50 values in the low micromolar range and good selectivity over 
mammalian cells.  
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Ferrocenyl containing compounds 85 have also been shown to have activity against 
HAT (Figure 34).121 The ferrocene group was incorporated into a benzyl diamine 
resulting in increased antitrypanosomal activity, with the best compounds having 
IC50 values against T. b. brucei in the low micromolar range.  
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Figure 34 Organometallic compounds with antitrypanosomal activity.  
There have been a number of promising compounds reported recently, many 
showing activity in the low nanomolar range in vitro and some also showing 
promising activity in vivo. Some particuarly interesting compounds are 46, 59, 60, 
64, 67, 71, 74, and 82 which all show activity below 50 nM against either T. b. 
brucei or T. b. rhodesiense. Of these 67 and 71 also show promising activity when 
administered orally in mouse models.
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1.3 Preliminary work and lead compound 
1.3.1 Lead Compound 
Unpublished work carried out by Epichem Pty Ltd has shown that two derivatives of 
(4R)-4,6-dihydroxy-N-methyl-1,2,3,4-tetrahydroisoquinoline (86) display 
antitrypanosomal activity (Figure 35). These compounds (87 and 88) were tested in 
vitro for activity against T. b. rhodesiense by the Murdoch University Parasitology 
group, and were found to have IC50 values of 4.9 and 4.8 μM respectively (Figure 
35). The parent compound 86 did not show any activity. Isoquinoline 86 is a 
derivative of the common decongestant phenylephrine122 and can be easily 







IC50 (T. b. rhodesiense) = 4.9 μM  




IC50 (T. b. rhodesiense) = 4.8 μM  
IC50 (cytotoxicity) =60 μM 
Figure 35 Lead compound and preliminary results.  
1.3.2 Research Aims 
The aim of this research was to synthesise derivatives of 86 in order to develop a 
structure activity relationship, and potentially aid in the design of a new candidate for 
the treatment of HAT. The approach was to synthesise derivatives of 86 and evaluate 
these derivatives for their activity against T. b. rhodesiense in vitro. The biological 
results would then dictate the next series of derivatives that should be explored. The 
initial plan for the synthesis of derivatives of 86 is outlined below in section 1.3.2.2. 
1.3.2.1 Synthesis of 86 
Isoquinoline 86 can be easily synthesised from phenylephrine, making it a useful 
starting point for a potential drug candidate due to the ease of access to the starting 
material. A Pictet-Spengler cyclisation of phenylephrine hydrochloride with aqueous 
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formaldehyde (Scheme 1) gives the desired para* product (86) as well as the ortho* 
product (90), which can be readily separated from one another.123 The ortho product 
precipitates from the reaction mixture and can be obtained by filtration, while the 
para product can be obtained by concentration of the filtrate and subsequent 
recrystallisation. However, for this research isoquinoline 86 was supplied by 












Scheme 1 Synthesis of 86 via a Pictet Spengler cyclisation.  
1.3.2.2 Modifications of lead compound 
Due to the lack of any information about the mode of action of this compound, as 
well as the large number of potential derivatives, four key parts of the molecule were 
focused on when designing these derivatives as can be seen in Figure 36. 
Derivatives would be synthesised based on modifications to these four key parts of 
the molecule, and biological results would then dictate the next series of derivatives 
that should be explored. Focussing on the first part of the molecule the most obvious 
derivatives that could be synthesised are those substituted at the phenol, in order to 
explore the scope of the initial active compounds (87 and 88) mentioned previously. 
Conversion of the phenol to a triflate would also allow coupling directly to the 
aromatic ring eliminating the phenolic oxygen and providing information about the 
importance of the oxygen at this position. For the second part of the molecule the 
benzylic alcohol could be substituted in a similar way to the phenol or could be 
removed completely. With the possibility of adding substituents directly to the 
benzylic carbon and either removing the benzylic alcohol or leaving it in place. The 
third part of the molecule could be derivatised by removing the methyl group from 
the nitrogen to observe the effect of a secondary amine, or by replacing the methyl 
                                                          
* Relative to the phenolic OH. 
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group with a more bulky substituent. The nitrogen atom could also be removed 
completely to assess its importance in activity. For the fourth part of the molecule it 
is possible to add substituents to the methylene carbon by using different aldehydes 
in place of formaldehyde in the initial synthesis of the lead compound as described 
previously. This could provide an opportunity for adding substituents to the molecule 
without altering any of the other main functional groups. The exploration of 
combinations of these different modifications mentioned could also be of interest.  
 
 
Figure 36 Four areas for potential modification of 86. 
 
1.4 Similar molecules 
A similarity search was conducted using PubChem to survey if there were any 
similar molecules with reported activity towards other pathogens. A search for 
molecules with a Tanimoto threshold of greater than or equal to 90% was conducted 
for both compound 87 and 88. This search resulted in the identification of 305 
similar molecules for compound 87. Of these four (91 to 94) were reported to have 
activity to against various targets (see Figure 37). The similarity search for 
compound 88 found 183 similar molecules, of these two (91 and 92) were reported to 













Figure 37 Similar structures showing biological activity. 
Compound 91 was reported, by the Broad Institute, to show activity against the 
RanGTP-Importin-beta complex.124 The assay conducted was a fluorescence 
resonance energy transfer assay which resulted in compound 91 being reported to be 
active with an EC50 of 84.83 µM. The RanGTP-Importin-beta complex is a key 
regulator of protein transport into and out of the nucleus during interphase. It has also 
been implicated in several mitotic events including spindle assembly, kinetochore 
assembly, and nuclear envelope assembly. Inhibitors of the RanGTP-Importin-beta 
complex could have the potential to disrupt the Ran pathway at particular stages in 
mitosis and have potential therapeutic value in cancer treatment.125 The Scripps 
Research Institute reported that compound 91 showed inhibition of the fructose-
biphosphate aldolase (FBA) of mycobacterium tuberculosis.126 FBA is a likely target 
in the inhibition of mycobacterium tuberculosis. It is responsible for catalysing the 
conversion of fructose biphosphate into glyceraldehyde phosphate and 
dihydroxyacetone phosphate in a reversible manner.127 Compound 91 showed an 
inhibition of 40.93% at a concentration of 1µM. Compound 91 has also been 
reported to activate the chymotrypsin-like serine protease kallikrein-7 (K7) 
zymogen.128 The Scripps Research Institute reported compound 91 with a 56.38% 
activation of K7 zymogen at a concentration of 7 µM. K7 has been associated with 
psoriasis and atopic dermatitis.129 Elevated K7 expression has been observed in many 
cancer types130–132 and has also been associated with the progression of Alzheimer’s 
disease.133,134 Activation of K7 zymogen could therefore lead to the development of 
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new drugs for skin diseases, cancer, and Alzheimer’s disease. Compound 92 has 
been reported as acting as a dual histamine H3/serotonin transporter ligand.
135–137 
Serotonin reuptake inhibitors are commonly used to treat depression. However, these 
treatments can induce fatigue.138,139 Histamine H3 receptor antagonists are known to 
increase wakefulness.140 Therefore, blocking both the histamine H3 receptor and 
serotonin reuptake could potentially lead to better treatment of depression. 
Compound 92 was reported to have a Ki of 3.8 nM for human sodium dependant 
serotonin transporter and a Ki of 11 nM for human H3.
135 Compound 93 has been 
reported as an inhibitor of the potassium ion channel Kir 2.1.141 Potassium ion 
channels have been recognised as targets in the treatment of a number of disorders 
including cardiovascular, neurological, renal, and metabolic disorders.142,143 
Specifically, inhibition of the Kir 2.1 channel could lead to the development of 
treatments for arrhythmia, short and long-QT syndromes, and Andersen syndrome. 
Both compounds 93 and 94 were reported to be inhibitors of the D3 dopamine 
receptor.144 Inhibition of this receptor represents a possible treatment for addiction 
and related disorders. It has also been suggested to be a potential treatment pathway 
for schizophrenia or psychosis as well as motor disorders associated with late stage 
Parkinson’s disease treatment. There are a number of molecules similar to those 
discussed in this study which show potential in the treatment of various diseases. 
Testing of some of the compounds synthesised in this study against some of the 




2 Substitution of the phenol and 
antitrypanosomal activity 
The initial focus of this research was to synthesise analogues of 86 by substituting 
the phenol with various alkyl halides to form the corresponding ether derivatives 
(Figure 38). First to be explored was substituting the phenol with simple substituted 
benzyl groups, as well as increasing the chain length between the phenolic oxygen 
and the phenyl group. The phenol was also substituted with a cyclohexyl group 
having two different chain lengths, however phenyl substituents were the main focus 
due to the greater possibility of derivatisation. A range of nitrogen containing 
heterocycles was also explored as substituents for phenolic substitution, including 
some nitro-imidazoles. Also investigated were a number of biphenyls, obtained 
through Suzuki coupling reactions, as well as some biphenyl ethers, available 
through Chan-Lam coupling. 
 
Figure 38 Substitution of the phenol. 
2.1 Benzyl substituents 
Substituents were added to the phenol via alkylation with the corresponding alkyl 
halides to give the corresponding ether derivatives. Since there are three potential 
sites on the tetrahydroisoquinoline 86 where alkylation could occur (the phenol, 
benzylic alcohol, and amine) care was taken to control the conditions in order to 
ensure selective alkylation of the phenol was favoured. This was accomplished by 
treating tetrahydroisoquinoline 86 with sufficient sodium hydride to completely 
deprotonate the phenol without also deprotonating the benzylic alcohol. Since 
isoquinoline 86 was used as the hydrochloride salt 2.2 equivalents of sodium hydride 
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were required. Substitution of the phenol with a benzyl group, in order to remake one 
of the preliminary active compounds 87 (see section 0, pg. 32), was the starting point 
for phenolic substitution. Under the conditions described above, treatment of 
tetrahydroisoquinoline 86 with a slight excess of benzyl bromide in 
dimethylformamide gave the desired product 87 in 56% yield (Scheme 2). Use of a 
weak base such as potassium carbonate resulted in N-alkylation (i.e. formation of a 










Scheme 2 Synthesis of 87.  
The 1H NMR spectrum of the benzyl substituted phenol 87 in deuterated chloroform 
is shown in Figure 39. This spectrum is discussed in detail below. For all of the 
derivatives substituted at the phenolic position reported herein their 1H NMR spectra 
all showed similar patterns for the isoquinoline scaffold. On the spectrum, signal A 
can be seen as an AB quartet with a geminal coupling constant of 14.4 Hz, which 
represents the two methylene protons labelled A. The two signals labelled C can be 
assigned to the methylene protons closest to the OH group. From the spectrum these 
can be observed as a doublet of doublets and a doublet of doublet of doublets which 
are coupling to each other with a geminal coupling constant of 11.8 Hz. Separate 
signals are seen for each of these protons due to the twisted nature of the saturated 
ring, resulting from it being attached to the rigid aromatic ring. These protons are 
also coupling to signal D which represents the methine proton labelled D, all of these 
signals have a vicinal coupling constant of 2.8 Hz. Signal B corresponds to the N-
methyl group which is downshifted (2.28 ppm) as compared to a regular methyl 
group. The three aromatic protons on the isoquinoline can be easily distinguished 
from one another based on their coupling patterns. Proton E can be seen as a doublet 
with 4 bond coupling (2.8 Hz) to proton F. Proton F is also coupled to proton G (8.4 
Hz) and can be observed as a doublet of doublets, proton G can be seen as a doublet. 
As for the benzyl group, a singlet can be seen at 5.08 ppm corresponding to the 
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methylene protons which are slightly downshifted due to the attachment of the 
benzylic carbon to oxygen. Finally the aromatic protons of the benzyl group can be 
seen as a large multiplet labelled I. Substitution of the phenol was confirmed through 
HMBC which showed a correlation between the benzylic carbon labelled H and the 
aromatic ring of the isoquinoline, confirming that 86 had been substituted at the 
phenol and not at the benzylic alcohol.  
 
 
Figure 39 1H NMR spectrum of 87.  
Some simple substituted benzyl groups were used as alkylating agents. Electron 
withdrawing, electron donating, and neutral groups were used in order to assess any 
effect, on anti-HAT activity, of these different groups on the phenyl ring. An electron 
withdrawing nitro group was chosen as well as an electron donating methoxy group. 
Some methyl substituted phenyl rings were also explored, as well as some bromo 
substituted benzyl groups which could be useful for further functionalisation. 
Synthesis of the aforementioned compounds was achieved as described above for the 
synthesis of 87, from the corresponding alkyl bromides or chlorides. The alkyl 
halides and bromides used were from commercial sources except 1-(chloromethyl)-
4-methoxybenzene and 1-(chloromethyl)-3-methylbenzene which were prepared 
from the corresponding alcohols according to standard procedures.145 A summary of 
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the synthesised compounds can be found below (Table 1). All compounds were 
obtained in moderate to good yields, and substitution of the phenolic oxygen was 
confirmed by NMR spectroscopy as described above for benzyl derivative 87. 













Br 2 hrs 58% 
 
97 
Cl 5 days 29% 
 
98 
Br 24 hrs 60% 
 
99 
Br 2 days 65% 
 
100 
Cl 2.5 days 66% 
 
101 
Cl 24 hrs 43% 
*Reaction conditions were not optimised. 
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Increasing the length of the chain between the phenolic oxygen and the phenyl ring 
to two and three carbons in length was also explored (see Scheme 3 and Scheme 4). 
This was achieved as described above, using the corresponding alkyl tosylate and 
alkyl bromide respectively to give derivatives 103 and 105 in moderate yield. The 
alkyl tosylate 102 was prepared from 2-phenylethanol according to standard 




















Scheme 4 Synthesis of phenylpropyl derivative 105. 
2.2 Cyclohexyl substituents 
Compound 88, with a cyclohexylmethyl group substituted at the phenolic position 
(see Figure 35, pg. 33), was also synthesised along with the cyclohexylethyl 
compound (see Scheme 5 and Scheme 6). These were synthesised as described 
above, using the corresponding bromide or alkyl tosylate respectively, to give the 
desired ether products 88 and 108 in moderate yields. (Bromomethyl)cyclohexane 
106 was obtained from a commercial source. Alkyl tosylate 107 was synthesised 






















Scheme 6 Synthesis of cyclohexylethyl derivative 108. 
2.3 Antitrypanosomal activity of benzyl and cyclohexyl 
derivatives 
The compounds mentioned above as well as the parent isoquinoline 86 were 
evaluated for their cytotoxicity to T. b. rhodesiense and mammalian cells. The parent 
isoquinoline 86 showed no toxicity to T. b. rhodesiense or mammalian cells. 
Nitrophenyl derivative 96 and methoxyphenyl derivative 97 showed almost identical 
activity against T. b. rhodesiense, with both also having comparable activity to 
benzyl substituted derivative 87. This showed that having a substituent in the para 
position on the phenyl ring increases the activity slightly, however there is no 
difference in having an electron withdrawing or donating group. Having a bromo 
substituent on the phenyl ring in either the para or meta (98 or 99) position increases 
the activity against T. b. rhodesiense by tenfold, while still maintaining reasonable 
selectivity against mammalian cells. A methyl group on the phenyl ring in either the 
meta or ortho (100 or 101) position had no effect on activity. Increasing the chain 
length between the phenolic oxygen (103 and 105) and the phenyl ring seemed to 
have no significant effect on activity. Cyclohexyl derivatives 88 and 108 showed 
more activity than the corresponding benzyl derivatives, however again the length of 
the chain seemed to have no effect. 
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Table 2 In vitro activity of benzyl and cyclohexyl derivatives. 
 
No.  R 
IC50  










>100 >100  
87  25.6 ± 0.9 >100 >3.9 
96 
 
16.9 ± 1.2 >50 >3.0 
97  17.5 ± 0.7 >50 >2.9 
98 
 
2.5 ± 0.1 37.0 ± 6.0 14.8 
99 
 
2.2 ± 0.1 60.3 ± 34.8 27.4 
100 
 
20.3 ± 0.9 >50 >2.5 
101  20.7 ± 0.6 >100 >4.8 
103 
 
17.9 ± 1.7 >50 >2.8 
105  18.7 ± 0.9 >50 >2.7 
88  2.8 ± 0.1 65.6 ± 2.3 23.4 
108 
 
2.5 ± 0.1 >50 >20 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 




2.4 Nitrogen-containing heterocycles 
Nitrogen-containing heterocycles are a common motif in many biologically active 
compounds including some anti-HAT agents.9,34,55–57 With this in mind a range of 
nitrogen containing-heterocycles was substituted onto the phenol of 86 in order to 
provide some information about the effect on biological activity of having a nitrogen 
atom in the phenyl or cyclohexyl ring. The nitrogen-containing heterocycles that 
were explored include piperidine, piperazine, morpholine, and pyridine. The specific 
derivatives that were synthesised were based on availability of starting materials (see  
Table 3).  













OMs 24 hrs 32% 
 
110 




Cl 3 days 17% 
 
112 
*3.2 eq of NaH used 
Cl 2 days 58% 
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The piperidine derivative 109 was synthesised from the mesylate of the 
corresponding BOC protected piperidine, as described previously. The mesylate was 
prepared from commercially available BOC protected 4-piperadinemethanol under 
standard conditions.147 The piperazine derivative 110 was synthesised from the 
chloride of the corresponding BOC protected piperazine 115 (see Scheme 7), as 
described previously. A propyl chain was used as the linking group between the 
nitrogen atom of the heterocycle and the phenol, avoiding issues associated with 
installation of an ethyl group, namely elimination. This was achieved by reacting the 
BOC protected piperazine 113 with 1-bromo-3-chloropropane, as described in 










Scheme 7 Synthesis of chloropropylpiperazine 115. 
The morpholine derivative 111 was synthesised from N-3-chloropropylmorpholine as 
described previously to give the morpholine derivative in 17% yield. The poor yield 
can be attributed to difficulty in purification. N-3-Chloropropylmorpholine was 
synthesised by reacting morpholine 116 with 1-bromo-3-chloropropane 114 as 
described in Scheme 8 to give N-3-chloropropylmorpholine 117 in good yield. A 









Scheme 8 Synthesis of N-3-chloropropylmorpholine. 
The pyridine derivative was synthesised from commercially available 2-
(chloromethyl)pyridine hydrochloride using a slightly modified procedure than 
described for the previous substitution reactions. Due to the starting material being 
available as the HCl salt, the pyridine salt was treated with 3.2 equivalents sodium 
hydride prior to the addition of isoquinoline 86, in order to neutralise the HCl salt of 
48 
 
both the isoquinoline and the pyridine as well as deprotonating the phenol. This was 
necessary to avoid the extra step involved in neutralizing the salt, and allowing the 
reaction to be done in one pot with only one addition of base, while still taking care 
to selectively deprotonate only the phenol. Following this modified procedure 
pyridine derivative 112 was obtained in 58% yield.  
Derivatives 109 and 110 were then deprotected with trifluoroacetic acid (see Scheme 
9 and Scheme 10)148 to give the corresponding secondary amines 118 and 119 in 














Scheme 10 BOC deprotection of 110. 
2.4.1 Nitroimidazoles 
Nitroimidazoles are another motif that can be found in some successful anti-Hat 
compounds,9,34,56 and as such two nitroimidazole derivatives of 86 were synthesised. 
2-Nitroimidazole and 4-nitroimidazole were substituted with 1-bromo-3-
chloropropane to give the corresponding chloropropyl derivatives as seen in Scheme 
11 and Scheme 12. The 1H NMR spectra for derivatives 122 and 125 showed the 
expected signals for the product as well as another set of signals. The second set of 
signals were determined to be the terminal alkene product, resulting from elimination 
of one of the halides. The spectra showed a multiplet at ~6 ppm and two doublets of 


















Scheme 12 Synthesis of chloropropyl imidazole derivative 125. 
The chloropropyl imidazole derivatives were then used as alkylating agents for 
phenolic substitution. Phenolic substitution with 3-chloropropyl-2-nitroimidazole 
using conditions similar to that described previously gave derivative 126 in 11% 
yield (see Scheme 13). The 4-nitroimidazole derivative 127 was obtained in better 
yield (see Scheme 14). The high polarity of these compounds resulted in difficulty in 
purification and streaking on the column during chromatography. These factors 



















Scheme 14 Synthesis of nitroimidazole derivative 127. 
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2.5 Antitrypanosomal activity of nitrogen-containing 
heterocycles 
Evaluation of the above mentioned nitrogen-containing heterocycles for their 
cytotoxicity to T. b. rhodesiense and mammalian cells showed very little activity 
(Table 4). The pieridine and piperazine derivatives (118 and 119) showed no activity 
against T. b. rhodesiense. Interestingly the pyridine derivative 112 proved to be 
inactive, despite its similarity to benzyl derivative 87. This suggests the possibility of 
a hydrophobic pocket in which the benzyl derivative can fit favourably, while the 
introduction of a polar nitrogen atom into the ring results in this interaction being 
unfavourable. Significantly, at physiological pH the nitrogen atom would be 
protonated making the pyridine group charged and polar, possibly resulting in an 
unfavourable interaction between the positively charged pyridine group and another 
positively charged residue in the active site. Conflictingly, the morpholine derivative 
111, which also contains a polar nitrogen atom which would also be protonated at 
physiological pH as well as a polar oxygen, showed some activity. However, the 
chain length is increased by 2 carbons relative to the pyridine derivative which could 
account for this change in activity, although the nitrogen atom is still the same 
number of bonds from the phenolic oxygen in both the pyridine and morpholine 
derivative. Synthesis of some carboxylic acid derivatives which would be negatively 
charged at physiological pH could prove interesting. Of the nitroimidazole 
derivatives the derivative with the nitro group in the 2 position (126) showed some 
activity, while the 4-nitro derivative 127 appears to be inactive. 
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Table 4 In vitro activity of nitrogen-containing heterocycles. 
 











111  27.6 ± 0.2 >50 1.8 
112  >50 >50  
118  >100 >100  
119  >100 >100  
126 
 
21.7 ± 1.0 >50 2.3 
127  >50 >50  
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 
Ellipticine was used as a positive control for cytotoxcicity (see appendix A). 
2.6 Biphenyls 
A biphenyl group was substituted onto the phenolic oxygen using conditions as 
described previously to give 129 in 54% yield. This derivative proved to have 









Scheme 15 Synthesis of biphenyl derivative 129. 
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Suzuki coupling, which involves the coupling of an aryl halide and a boronic acid in 
the presence of a palladium catalyst, is a common way to access biphenyls.149,150 In 
this case aryl bromide substituted isoquinoline 98 was the aryl halide used in the 
coupling reaction. This was coupled with a range of boronic acids to give the 
corresponding biphenyl derivatives (Table 5).  








R Pd source Reaction conditions % Yield 
 
130 
Pd(PPh3)4 Microwave reactor 









Pd(dppf)Cl2 Microwave reactor 







Initially the palladium catalyst that was used for the Suzuki coupling reactions above 
was tetrakis(triphenylphosphine)palladium(0). Using this catalyst and under the 
reaction conditions described in Table 5, biphenyl 130 was obtained in poor yield 
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and was difficult to purify by chromatography. The use of the same catalyst and 
reaction conditions in the synthesis of biphenyl 132 gave similar results. Analysis of 
the reaction mixture of biphenyl 132 via LCMS showed a major and minor peak with 
m/z [M+H]+ of 380.20 and 456.20 respectively. The first peak, with a m/z [M+H]+ 
of 380.20, corresponds to the desired product as expected. Surprisingly the second 
peak, with a m/z [M+H]+ of 456.20, corresponds to the overcoupled product 134 as 





m/z [M+H]+ expected = 456.16 
Figure 40 Structure of 133 and resulting overcoupled product. 
Changing the catalyst to bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(Pd(dppf)Cl2) eliminated the overcoupled by-product and also increased the yield 
and ease of purification of the desired product. Therefore in the synthesis of the rest 
of the biphenyl derivatives Pd(dppf)Cl2 was used as a catalyst, and the remaining 
biphenyl derivatives were obtained in good yields using the conditions described in  
Table 5. Confirmation of the products was obtained through observation of the extra 
aromatic peaks seen in the 1H and 13C NMR spectra, corresponding to the newly 
introduced aromatic rings. Two biphenyl derivatives were also synthesised using aryl 
bromide substituted isoquinoline 99, to give some meta-biphenyl derivatives (136 
and 138). This was achieved as described in Scheme 16 and Scheme 17 using 
Pd(dppf)Cl2 as the palladium source to give the desired biphenyl derivatives in good 
yields. Confirmation of the products was obtained through observation of the extra 
aromatic peaks seen in the 1H and 13C NMR spectra, corresponding to the newly 























Scheme 17 Synthesis of meta-biphenyl derivative 138. 
Also synthesised by Suzuki coupling were triphenyl and naphthyl derivatives 140 
and 142 (see Scheme 18 and Scheme 19). These derivatives were synthesised in the 
same way described above using the 4-bromobenzyl derivative 98 as the aryl halide 
and the corresponding boronic acid. Palladium acetate was used as the palladium 
source with the addition of triphenylphosphine, to give triphenyl derivative 140 in 




















Scheme 19 Synthesis of naphthyl derivative 142. 
2.7 Diphenyl ethers 
Two diphenyl ether derivatives were also synthesised as potentially interesting 
phenolic substituents, these were accessed via a Chan-Lam coupling. Chan-Lam 
coupling involves in this case the coupling of an arylboronic acid with an O-H 
containing compound in air. The reaction is facilitated by a stoichiometric amount of 
copper(II), and can be undertaken at room temperature.151 






a, R = H 




a, R= H, 27% 
a, R = F, 18% 
 
 







a, R= H, 92% 
b, R = F, >95% 
 
147 
a, R = H, >95% 
b, R = F, 85% 
 
The synthesis of diphenyl ether derivatives began with Chan-Lam coupling152 of 4-
hydroxybenzaldehyde 143 with the corresponding arylboronic acid in the presence of 
56 
 
a stoichiometric amount of copper(II) acetate and excess triethylamine. The reaction 
was undertaken at room temperature and the reaction mixture stirred open to air with 
the addition of 4Å molecular sieves to keep the reaction anhydrous. In this way, the 
diphenyl ethers 145a and 145b were obtained in low yields. The product was 
confirmed by 1H NMR spectroscopy which showed 4 signals corresponding to a total 
of 9 protons as expected for the product as well as the formation of a new spot by 
TLC (EtOAc:PS; 1:9). In order for these diphenyl ethers to be used as phenolic 
substituents it was necessary to convert the aldehyde into a good leaving group. This 
was achieved by first reducing the aldehyde to an alcohol using sodium 
borohydride,153 to give the corresponding benzyl alcohols 146a and 146b in excellent 
yields. Conversion of the aldehyde to the alcohol was confirmed by 1H NMR 
spectroscopy which showed the disappearance of the aldehyde signal (~ 10 ppm) as 
well as the upfield shift of the aromatic protons on the benzylic ring, and a new 
signal at ~ 4.7 ppm corresponding to the benzylic protons. Following this, the 
alcohols were reacted with mesyl chloride, however rather than the expected 
mesylates the chlorides (147a and 147b) were obtained. Conversion of the alcohols 
to the chlorides was confirmed based on there being no significant change in the 1H 
NMR spectra accompanied by the formation of a new spot by TLC (EtOAc:PS; 1:9) 
with a large difference in RF (~ 0.7) value. If the mesylate were being formed a new 
peak in the 1H NMR spectrum would be observed for the methyl protons. What most 
likely occurred was the formation of the desired mesylate followed by the 
displacement of the mesylate by a chloride ion, this displacement has been reported 
to occur with tosylation using tosyl chloride.154 Confirmation of the chloride 
products could also be achieved through mass spectroscopy, however this was not 
undertaken due to limited access to mass spectrometry facilities. With the chloride 
also being a reasonably good leaving group these chloro derivatives were used in the 
phenolic substitution reaction with isoquinoline 86, as described in Scheme 20 and 




















Scheme 21 Synthesis of diphenylether derivative 149. 
2.8 Antitrypanosomal activity of biphenyl and diphenyl 
ether derivatives 
Evaluation of the biphenyl and diphenyl ether derivatives discussed above for their 
activity against T. b. rhodesiense and mammalian cells showed some interesting 
results. As compared to the original lead compound, benzyl substituted isoquinoline 
87 (IC50 = 25.6 ± 0.9), biphenyl 129 showed a tenfold increase in activity against T. 
b. rhodesiense. However, this is accompanied by a significant increase in 
cytotoxicity. The substituted biphenyl derivatives (130-133) all showed almost 
identical activity to unsubstituted biphenyl derivative 129 with similar cytotoxicity. 
Exceptions to this are substituted biphenyl derivatives 132 and 133 which showed 
increased activity against T. b. rhodesiense, both of these derivatives have more of a 
linear structure as compared to the other substituted biphenyl derivatives. In the case 
of biphenyl derivative 132 an almost tenfold increase in antitrypanosomal activity is 
observed, as compared to the unsubstituted biphenyl derivative. However, the 
cytotoxicity remains comparable resulting in a significant increase in selectivity for 
T. b. rhodesiense over mammalian cells (SI = 86.1). Derivatives 136 and 138 also 
showed similar activity to unsubstituted biphenyl derivative 129. Derivatives 140 and 
142 showed good activity against T. b. rhodesiense with IC50 values in the 
submicromolar range, however they were also highly toxic to mammalian cells. The 
two diphenyl ether derivatives 148 and 149 showed almost identical activity. In 
comparison to unsubstituted biphenyl derivative 129, the activity against T. b. 




Table 7 In vitro activity of biphenyl and diphenyl ether derivatives. 
 
No.  R 
IC50  










2.9 ± 0.1 23.0 ± 2.1 7.9 
130 
 
2.8 ± 0.1 10.8 ± 4.2 3.9 
131 
 
2.8 ± 0.1 25.5 ± 3.0 9.1 
132 
 
0.28 ± 0.01 24.1 ± 4.3 86.1 
133 
 
1.4 ± 0.1 33.8 ± 16.7 11.9 
136 
 
2.9 ± 0.1 24.3 ± 3.8 8.4 
138 
 
2.8 ± 0.1 27.3 ± 2.6 10.5 
140 
 
0.28 ± 0.01 0.28 ± 0.04 1 
142 
 
0.24 ± 0.01 0.31 ± 0.01 1.3 
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No.  R 
IC50  










2.7 ± 0.2 3.4 ± 0.8 1.3 
149 
 
2.7 ± 0.2 5.6 ± 0.1 2.1 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 
Ellipticine was used as a positive control for cytotoxcicity (see appendix A). 
 
2.9 Other phenolic substituents 
A number of other groups were also substituted onto the phenolic oxygen to give the 
corresponding ether derivatives (Table 8). 2-Phenoxyethanol was treated with tosyl 
chloride according to standard procedures146 to give the tosylate which was then used 
in the phenolic substitution reaction to give the corresponding ether derivative 150 in 
65% yield. Trityl chloride was used in the phenolic substitution reaction to give the 
corresponding triphenylmethyl derivative 151 in 21% yield. Difficulties in purifying 
this derivative, namely loss of the trityl group through purification by column 
chromatography due to its acid sensitive nature, resulted in a lower than expected 
yield. Treatment of the phenol with tert-butylchlorodiphenylsilane gave the TBDPS 
protected phenol 152 in excellent yield. Treatment of the phenol with 
methoxyethoxymethyl chloride gave the MEM protected phenol 153 in 61% yield. 
Substitution with 2-chloro-N,N-dimethylethylamine gave the corresponding ether 
154 in 52% yield. Alkylation of the phenol with 1-bromododecane gave the dodecyl 
ether 155 in good yield. 
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R X Reaction time % Yield 
 
150 
OTs 5 days 65% 
 
151 
Cl 3 days 21% 
 
152 
Cl 2.5 days 80% 
 
153 
Cl 24 hrs 61% 
 
154 
Cl 2 days 52% 
 
155 
Br 24 hrs 74% 
Finally, treatment of 2 equivalents of isoquinoline 86 with 1 equivalent of diethylene 
glycol bis(p-toluenesulfonate) gave the isoquinoline dimer 157 in moderate yield. 
Diethylene glycol bis(p-toluenesulfonate) was prepared according to a literature 
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procedure.155 The rationale behind making this derivative was that this derivative 
being a dimer joined by a long chain looks similar to pentamidine (1 see pg. 5), 
which is used to treat type 1 HAT, and other pentamidine inspired HAT active 









2.10 Antitrypanosomal activity of other phenolic 
substituents 
Evaluation of the above mentioned derivatives (150-157) for their activity in vitro 
against T. b. rhodesiense and mammalian cells showed that both the TBDPS 
derivative 152 and dodecyl derivative 155 had good activity against T. b. 
rhodesiense. However, this activity is accompanied by increased cytotoxicity with 
these derivatives having poor selectivity for T. b. rhodesiense over mammalian cells 
with selectivity indexes of 6.8 and 7.8 respectively. Trityl derivative 151 also showed 
some activity but interestingly was approximately tenfold less active than the TBDPS 
derivative which has similar bulk on the phenol. This could be due to possible 
hydrolysis of the trityl group in vitro. This was again accompanied by high 
cytotoxicity. Derivative 150 was somewhat active while derivatives 153, 154, and 
157 showed no antitrypanosomal activity.  
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Table 9 In vitro activity of other phenolic derivatives. 
 
No.  R 
IC50  










17.9 ± 0.2 >100 5.6 
151 
 
20.8 ± 0.4 87.9 ± 7.1 4.2 
152 
 
2.8 ± 0.1 19.1 ± 0.6 6.8 
153  >50 >50  
154  >50 >50  
155  2.4 ± 0.1 18.8 ± 3.7 7.8 
157 
 
>100 >100  
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 





2.11 Derivatives of isoquinoline 90 and their 
antitrypanosomal activity 
From the synthesis of the parent isoquinoline 86 via a Pictet-Spengler cyclisation the 
ortho isomer 90 is also obtained (see Scheme 1, pg. 34). A small number of 
derivatives of this isoquinoline were synthesised to compare to the derivatives of 
isoquinoline 86. The phenolic oxygen was substituted in the same way described 
above instead using isoquinoline 90. Four derivatives were synthesised, the methoxy 
158, benzyl 159, cyclohexylethyl 160, and the biphenylmethyl 161 to give a range of 
different derivatives. 







R X Reaction time % Yield 
 
158 
I 24 hrs 30% 
 
159 
Br 24 hrs 68% 
 
160 
OTs 24 hrs 50% 
 
161 
Cl 24 hrs 45% 
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The above compounds were evaluated for their activity against T. b. rhodesiense and 
mammalian cells in vitro. Interestingly, the benzyl substituted derivative 159 showed 
no activity, while biphenyl substituted derivative 161 showed comparable activity to 
the biphenyl derivative of isoquinoline 86 (derivative 129) but with less toxicity to 
mammalian cells. The methyl derivative 158 showed no activity, however the 
cyclohexylethyl derivative 160 showed comparable activity and cytotoxicity to the 
same derivative of isoquinoline 86 (derivative 108). The inactivity of the benzyl and 
methyl derivatives and activity of the biphenylmethyl and cyclohexylethyl could be 
due to the size or reach of the substituted groups, with both the cyclohexylethyl and 
biphenylmethyl groups being slightly larger than the benzyl group. Synthesis of the 




Table 11 In vitro activity of derivatives of 90.  
 
No.  R 
IC50  










>100 >100  
158  >100 >100  
159  67.8 ± 0.5 >100 >61.5 
160 
 
13.0 ± 0.2 62.7 ± 9.1 4.8 
161 
 
3.1 ± 0.1 >50 >16 
 
87  25.6 ± 0.9 >100 >3.9 
108 
 
2.5 ± 0.1 >50 >20 
129 
 
2.9 ± 0.1 23.0 ± 2.1 7.9 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 




2.12 Summary of derivatives substituted at the phenol 
In summary, 37 derivatives of isoquinoline 86 substituted at the phenolic position 
with various motifs have been synthesised and evaluated for their in vitro 
antitrypanosomal activity against T. b. rhodesiense and mammalian cells. 
Substituting the phenol with substituted benzyl groups results in no significant 
difference in activity as compared to the unsubstituted benzyl group, an exception 
being bromobenzyl substituents (98 and 99) which increase activity against T. b. 
rhodesiense tenfold. Increasing the chain length between the phenolic oxygen and 
the phenyl group has no effect. Cyclohexyl substituents showed good activity, with 
increased activity as compared to their phenyl counterparts. Derivatives substituted 
with a biphenyl group at the phenol showed the best activity against T. b. 
rhodesiense, however they generally showed a high level of cytotoxicity. An 




3 Modification of the benzylic alcohol and the 
effect on antitrypanosomal activity 
Modification of the benzylic alcohol was the next area of interest. Derivatives of 86 
were synthesised by substituting the benzylic alcohol with a range of substituents to 
give the corresponding ethers (Figure 41 A). The effect of substituting both the 
benzylic and phenolic oxygens with various groups was also examined (Figure 41 
B). Finally removal of the benzylic alcohol was explored to give the deoxy version of 
86, including substitution of the phenol of this deoxy derivative (Figure 41 C) in 







Figure 41 Modification of the benzylic alcohol. 
3.1 Substitution of the benzylic alcohol  
 Substitution of the benzylic alcohol of 86 was first attempted using a large excess of 
sodium hydride and one equivalent of the desired alkyl halide. The rationale being 
that both the phenol and benzylic alcohol would be fully deprotonated, and since the 
benzylic alcohol should be the superior nucleophile substitution would occur 
preferentially at the benzylic alcohol as opposed to the phenol. However, under these 
conditions the disubstituted product was isolated. This was confirmed through the 1H 
NMR spectrum which showed double the number of aromatic signals expected in the 
region in which the benzyl group is observed. Following this result it was decided 
that a protecting group would need to be installed on the phenol before the 








   
162 
Scheme 22 Synthesis of 162. 
A tert-butydiphenylsilyl (TBDPS) group was installed onto the phenol as described 
previously (see Table 8 pg. 60) to give the TBDPS protected phenol 152. This was 
deprotonated using an excess of sodium hydride, subsequent addition of a slight 
excess of methyl iodide then gave the desired methyl ether derivative as the free 
phenol rather than the expected TBDPS protected phenol. The instability of the 
TBDPS group on phenols under strongly basic conditions156 was rationalised as the 
reason for its loss. Substitution of the benzylic alcohol was confirmed via HMBC 
which showed a correlation between the signal for the methyl hydrogens and the 
methine carbon (4) of the saturated ring, and no correlation was seen between the 
methyl hydrogens and the aromatic ring. Using benzyl bromide in place of methyl 
iodide in the above reaction gave a complex mixture from which a small amount of 
product substituted with a benzyl group at the phenol, rather than at the benzylic 
alcohol, was isolated. This result was inconsistent with the synthesis of the methyl 
ether derivative 162 which was obtained under these same conditions as the free 
phenol. It can be rationalised that in the case of the methyl ether, due to the higher 
reactivity of methyl iodide as compared to benzyl bromide, the substitution reaction 
was able to take place on the benzylic alcohol before the TBDPS group came off the 
phenol. In the case of the benzyl ether the TBDPS group was probably removed 
under the strongly basic conditions before the substitution reaction with benzyl 
bromide could take place. This also explains why the phenolic substituted product 
was obtained rather than the product substituted at the benzylic alcohol. To overcome 
this problem the 2-methoxyethoxymethyl (MEM) group was used in place of the 
TBDPS group due to its stability in the presence of strong bases.156  
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Br 1.5 hrs 36% 
 
164 
Cl 1 hr 83% 
 
165 
OMs 4 hrs 46% 
A MEM group was installed onto the phenol as described previously (see Table 8 
pg. 60) to give the MEM protected phenol 153. Deprotonation of the benzylic 
alcohol with an excess of sodium hydride followed by substitution with the 
corresponding alkylating agents gave the desired ether products. It was found that if 
the reaction mixture was left for too long then a complex mixture was obtained; 1-4 
hours was the optimum time. The benzyl 163, biphenylmethyl 164, and 
cyclohexylethyl 165 derivatives were synthesised in this way to give the desired 
products in moderate to good yields (see Table 12). This was confirmed through 
observation of the 1H NMR spectra which showed extra signals for the 
corresponding alkyl groups. The MEM group was easily removed using 
trifluoroacetic acid (TFA)157 to give the free phenol derivatives 166, 167, and 168 in 
moderate yields (see Table 13). Removal of the MEM group was confirmed through 
1H NMR spectroscopy by the loss of the signals attributed to the protons of the MEM 
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group as well as the new signal at ~9.2 ppm corresponding to the phenolic proton 
(DMSO-d6). 
Table 13 MEM deprotection. 
   
R Reaction time % Yield 
 
166 
45 min 50% 
 
167 
1 hr 32% 
 
168 
1 hr 53% 
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3.2 Disubstituted derivatives  
So far derivatives substituted at either the phenolic or benzylic alcohol have been 
synthesised. Derivatives substituted at both of these positions to give a disubstituted 
product were explored next. From the synthesis of benzyl substituted derivative 87 
(see Scheme 2 pg. 40) a small amount of the disubstituted product 169 was also 
isolated from the reaction mixture via column chromatography. This was confirmed 
through 1H NMR spectroscopy which showed a multiplet integrating for 10 protons 




The biphenylmethyl and cyclohexylethyl disubstituted derivatives were also 
synthesised. This was achieved through deprotonation of both the phenol and 
benzylic alcohol with a slight excess of sodium hydride, followed by substitution 
with the appropriate alkylating agent. Following this procedure the desired 
disubstituted products 170 and 172 were obtained in poor yield (see Scheme 23 and 
Scheme 24). TLC indicated a large amount of the monosubstituted product in the 
reaction mixture. If these derivatives were to be synthesised in future an improved 
procedure would need to be explored to improve the poor reaction yields. 
Confirmation of these products was obtained through the 1H NMR spectra which 
showed the correct integration for having two of the corresponding alkyl groups on 




















Scheme 24 Synthesis of cyclohexylethyl-disubstituted derivative 172. 
3.3 Antitrypanosomal activity of benzylic alcohol 
substituted derivatives and disubstituted 
derivatives.  
The benzylic alcohol substituted and disubstituted derivatives above were evaluated 
in vitro for their activity against T. b. rhodesiense and mammalian cells. Both methyl 
and benzyl substituted derivatives 162 and 166 showed no anti-HAT activity, 
however both the biphenyl 167 and cyclohexyl 168 derivatives showed moderate 
activity against T. b. rhodesiense with no cytotoxicity to mammalian cells. Both the 
biphenylmethyl and cyclohexylethyl groups are larger and have a longer reach as 
compared to the benzyl group which could be contributing to their observed activity. 
The disubstituted derivatives (169, 170, and 172) showed almost identical activity. A 
comparison with the corresponding phenol substituted (i.e. mono substituted) 
derivatives (87, 129, and 108) showed the disubstituted benzyl derivative 87 having 
significantly increased activity while conflictingly the biphenyl 170 and cyclohexyl 
172 derivatives had almost identical activity to their counterparts. Although the 
biphenyl disubstituted derivative 170 was more cytotoxic. 
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Table 14 In vitro activity of benzylic alcohol substituted derivatives and disubstituted 
derivatives. 
 











162 H  >100 >100  
166 
H 








19.1 ± 0.2 >50 >2.6 
169   2.8 ± 0.2 23.5 ± 1.4 8.4 
170 
  
2.8 ± 0.2 >10 3.6 
172 
  
2.3 ± 0.2 23.6 ± 1.5 10.3 
87 
 








2.5 ± 0.1 >50 >20 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 
Ellipticine was used as a positive control for cytotoxcicity (see appendix A). 
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3.4 Removal of the benzylic alcohol and phenolic 
substitution 
Removal of the benzylic alcohol from isoquinoline 86 would allow information to be 
obtained on the importance of the benzylic alcohol for anti-HAT activity. The 
benzylic alcohol of 86 was removed serendipitously while attempting to remove the 
N-methyl group of 86 via a Polonovski reaction (see section 5.1.1 pg. 94). 
Isoquinoline 86 as the free base was treated with an excess of aqueous hydrogen 
peroxide to give the N-oxide 173 , as a mixture of two diastereomers (7:3), in >99% 
yield. Formation of the N-oxide was confirmed through 1H NMR spectroscopy which 
showed two sets of signals corresponding to the two diastereomers of 173. The 
downfield shift of the protons on the saturated ring as well as the downfield shift of 
the N-methyl signal from 2.5 to ~3.4 confirmed the N-oxide had been formed. 
Treatment of the N-oxide with an excess of acetic anhydride was expected to furnish 
the N-acetyl derivative via a Polonovski reaction, however this was not observed. A 
very polar (TLC 15% MeOH, 2% sat. NH3, in DCM) bright yellow compound which 
fluoresced under UV light was obtained. This compound was determined to be the 
isoquinolone 174, which was isolated in 64% yield. Other than the N-methyl signal 
the 1H NMR spectrum of this compound showed only signals in the aromatic region. 
The 13C NMR spectrum also showed only aromatic signals, apart from the N-methyl 
signal, with a signal at ~180 ppm corresponding to a carbonyl carbon which fits with 
the structure proposed for 174. A search of the literature revealed that this compound 
had been reported previously by Fourneau et al.158 The structure of isoquinolone 174 
was then confirmed by comparison with the reported 1H NMR spectrum. Fourneau et 
al. also reported that reaction of this isoquinoline 174 with potassium borohydride 
gave the saturated isoquinoline 175. Following treatment of isoquinoline 174 with an 
excess of sodium borohydride the desired 4-deoxy derivative 175 was obtained. This 
was confirmed by 1H NMR spectroscopy which showed two triplets for the two sets 
of coupling methylene protons (position 3 and 4). The protons on the methylene 
























Scheme 25 Removal of the benzylic alcohol. 
Substitution of the phenol of deoxy isoquinoline 175 was undertaken similarly to that 
described previously. The phenol was deprotonated using a slight excess of sodium 
hydride, followed by substitution with the corresponding alkylating agent. Following 
this procedure the benzyl 176, biphenylmethyl 177, cyclohexylethyl 178, and N-
propylmorpholine 179 derivatives of 175 were synthesised in moderate to good yield 
(see Table 15). Synthesis of these derivatives was confirmed via 1H NMR and 13C 
NMR spectroscopy which showed new signals for the new substituents in the 
appropriate regions of the spectrum. 
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Br 2 days 69% 
 
177 
Cl 2 days 30% 
 
178 
OTs 2.5 days 82% 
 
179 
Cl 24 hrs 57% 
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3.5 Antitrypanosomal activity of phenolic substituted 
derivatives of 175 
Deoxyisoquinoline 175 and its phenolic substituted derivatives were evaluated for 
their activity against T. b. rhodesiense and mammalian cells. Deoxyisoquinoline 175 
showed no activity against T. b. rhodesiense. This result was expected as the oxy 
version 86 showed no activity. All derivatives showed some inhibition of T. b. 
rhodesiense with reasonable selectivity as compared to mammalian cells. 
Comparison of these derivatives (176-179) with the corresponding derivatives with 
the benzylic alcohol still intact (87, 129, 108, and 111) showed no significant 
difference. The benzyl derivative 176 was slightly more active than its counterpart 
with the benzylic alcohol intact. The biphenyl 177, cyclohexyl 178, and morpholine 
179 derivatives showed almost identical activity to their counterparts with the 
benzylic alcohol intact. These results suggest that the benzylic alcohol is not having a 
significant effect on the anti-HAT activity of this series of compounds, and is 
unlikely to be important to the mode of action.  
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Table 16 In vitro activity of phenolic substituted derivatives of 175. 
 
No.  R 
IC50  








175 H >100 >100  
176  4.4 ± 0.3 >100 22.7 
177 
 
2.3 ± 0.1 16.5 ± 2.8 14.2 
178 
 
2.9 ± 0.1 25.0 ± 3.9 8.6 
179  25.9 ± 2.2 >50 >1.9 
 
87  25.6 ± 0.9 >100 >3.9 
129 
 
2.9 ± 0.1 23.0 ± 2.1 7.9 
108 
 
2.5 ± 0.1 >50 >20 
111  27.6 ± 0.2 >50 1.8 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 




3.6 Changing the stereochemistry 
Although from the results above it seems that the benzylic alcohol has no effect on 
anti-HAT activity, when substituted, the resulting derivatives still showed some 
activity. Therefore it was thought that it might be valuable to look at the 
stereochemistry of the benzylic alcohol. So far it has been assumed that the benzylic 
alcohol retains the original stereochemistry from its original synthesis from (R) 
phenylephrine. The benzoate of 129 and its enantiomer were synthesised in order to 
provide a comparison of the two possible positions of the benzylic alcohol R and S. 
Biphenyl substituted phenol 129 was used rather than isoquinoline 86 as it showed 
good anti-HAT activity and would provide a basis to make a comparison. Synthesis 
of the benzoate was achieved through a simple esterification reaction with benzoyl 
chloride to give the desired benzoate 180 in 81% yield (Scheme 26). The 1H NMR 
spectrum 180 showed the methine proton on the same carbon as the benzylic alcohol 
(position 4) shift downfield significantly from the starting material (4.62 - 6.22 ppm) 
confirming the attachment of the electron withdrawing benzoyl group to the benzylic 








Scheme 26 Synthesis of the benzoate of 129. 
The use of Mitsunobu chemistry159,160 allowed for the synthesis of the benzoate of 
129 with inverted stereochemistry. The Mitsunobu reaction involves the conversion 
of in this case a secondary alcohol to an ester, with inversion of stereochemistry, 
using an azodicarboxylate and triphenyl phosphine. Benzoic acid was used as the 
nucleophile in order to furnish the benzoyl ester. DIAD (diisopropyl 
azodicarboxylate) was used as the azodicarboxylate which reacts with 
triphenylphosphine to form a phosphonium intermediate which then bonds to the 
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alcohol. Substitution of the benzoic acid and elimination of triphenylphosphine oxide 
then generates the stereochemically inverted ester. Treatment of 129 with benzoic 
acid in the presence of DIAD and triphenylphosphine161 gave the desired benzoate 
181 in 42% yield. The 1H and 13C NMR spectra of this derivative were both identical 
to derivative 180. Optical rotation was used to confirm that the stereochemistry of 
derivatives 180 and 181 were opposite. The specific rotation for derivative 180 was 
measured at +29.8° which is approximately opposite to that measured for derivative 
181 at -37.4°, confirming the stereochemistry of both derivatives. Chiral HPLC for 
each of these derivatives showed only one peak with the elution times being 
significantly different for derivative 180 (12.73 min) and 181 (10.21 min) again 
confirming that the two opposite isomers had been synthesised (see chapter 7, pg. 








 Scheme 27 Synthesis of the Mitsunobu benzoate of 129. 
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3.7 Effect of changing the stereochemistry on 
antitrypanosomal activity 
Evaluation of derivatives 180 and 181 for their activity against T. b. rhodesiense and 
mammalian cells gave identical results. There was no difference seen between the 
activity of the derivative with the original stereochemistry 180 and that with inverted 
stereochemistry 181 against T. b. rhodesiense. Hovever, both derivatives proved to 
be very cytotoxic, with equivalent cytotoxicities. Comparison of these derivatives 
against biphenyl derivative 129 showed that they were slightly less active and 
considerably more toxic to mammalian cells. These results suggest that the 
stereochemistry of the benzylic alcohol has no effect on the anti-HAT activity, as 
was expected from the previous results which showed that the benzylic alcohol plays 
no role in the anti-HAT activity. 
Table 17 In vitro activity of 180 and 181 derivatives. 













16.4 ± 0.7 10.5 ± 4.1 0.6 
181 
 
16.3 ± 0.7 12.9 ± 2.3 0.8 
129 
 
2.9 ± 0.1 23.0 ± 2.1 7.9 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 
Ellipticine was used as a positive control for cytotoxcicity (see appendix A). 
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3.8 Grignard chemistry 
Conversion of the benzylic alcohol to a ketone would provide further opportunity to 
add substituents to this part of the molecule through Grignard chemistry. Some 
difficulty was encountered in the oxidation of the benzylic alcohol to the ketone. 
Oxidation of 105 using 2 equivalents of IBX gave a complex mixture, although the 
1H NMR spectrum of the crude sample showed the disappearance of the signal 
corresponding to the methine proton, there was no other evidence of the desired 
product being formed. Isolation of a pure compound through column 
chromatography was not possible. Oxidation with manganese dioxide also gave a 
mixture of products however the major product was isolated and was determined to 
be the trione 182 (see Scheme 28). The 1H NMR spectrum of 182 showed no signals 
in the aliphatic region apart from those associated with the propyl chain and the N-
methyl signal. However, the aromatic signals corresponding to the isoquinoline were 
still present in the spectrum but they were shifted downfield significantly. The 13C 
NMR spectrum showed four signals in the region of 150 to 180 ppm where it would 
be expected to find the carbon signals associated with the three carbonyl groups as 





Scheme 28 Attempted oxidation of the benzylic alcohol with MnO2. 
A similar reaction has been reported by Lesèche et al. in the oxidation of a similar 
isoquinoline (see Scheme 29).162 Considering all of the above data along with the 
HRMS data the structure of compound 182 can be confirmed. Lesèche et al. reported 
their attempt to oxidise 6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-ol 
(184) using a number of different oxidation methods (Scheme 29), from which they 
found that an Oppenauer oxidation was the only successful method. It was 
rationalised that Oppenauer oxidation may provide a successful method to convert 







Scheme 29 Reactions reported by Lesèche et al. 
Oppenauer oxidation involves the conversion of a secondary alcohol to a ketone 
using aluminium isopropoxide as a catalyst and excess of a ketone reagent, which 
acts as a hydride acceptor.163 The mechanism (see Scheme 30) involves one of the 
isopropoxide groups on the aluminium being replaced with the alcohol which 
generates isopropyl alcohol. Coordination of the excess ketone to the aluminium 
complex results in a six-membered transition state where the α-hydrogen on the 
alcohol shifts to the ketone, resulting in formation of the desired ketone.164,165 
    
 
 
   
Scheme 30 Mechanism of the Oppenauer oxidation. 
Following the procedure reported by Lesèche et al. isoquinoline 87 was subjected to 
Oppenauer oxidation, using excess cyclohexanone as the hydride acceptor. The 
procedure involves a distillation setup which allows for azeotropic drying of the 
solvent but more importantly allows for the removal of the isopropanol and 
cyclohexanol formed in the reaction preventing them from taking place in the 
reaction and being oxidised themselves. Initial attempts showed some of the desired 
product being formed however isolation of the product from the reaction mixture via 
column chromatography resulted in decomposition. By carefully monitoring the 
reaction via TLC and ensuring it went to completion (it was required to keep adding 
more toluene so the reaction mixture did not dry out) 85% yield (crude) of what was 
believed to be the desired product was obtained. The 1H NMR spectrum showed two 
large singlets at 3.69 and 3.30 ppm which correspond to the two methylene signals. 
Due to the methylene protons now being in more similar environments for 
isoquinolone 186 as compared to isoquinoline 87 it would be expected that these 
signals now appear as singlets. The peak for the methine proton of 87 was also no 
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longer seen in the spectrum. The 13C NMR spectrum of 186 showed a carbonyl 
signal at 194.7 ppm. Conversion of isoquinone 186 to the HCl salt gave a more stable 
product as judged by no decomposition observed by 1H NMR spectroscopy over a 








Scheme 31 Oppenauer oxidation of 87. 
Gensler et al.166 reported a method of successfully oxidising a similar isoquinoline 
using Jones reagent. Although Lesèche et al. had no success with this procedure 
another example was later reported by Domínguez et al.167 in which they were 
successful in using a modified procedure of that reported by Gensler et al. Using this 
procedure the TBDPS protected isoquinoline 152 was treated with Jones reagent at   
-20°C and stirred for 10 minutes. Upon workup some of the desired product was 
obtained however a large amount of starting material still remained. Due to the 
difficulty in purifying the product it would be ideal if all of the starting material was 
converted in the reaction. It was found that stirring the reaction mixture at -20°C and 
then allowing the reaction mixture to slowly warm to 0°C (approximately 2 hrs) gave 
a better result (see Scheme 32). However, the best result that was obtained was a 
mixture of product and starting material in a ratio of 3:2. Through workup of the 
reaction it was possible to extract the HCl salt from the reaction mixture using ethyl 
acetate, the product was obtained as a yellow solid which was quite hygroscopic 






Scheme 32 Jones oxidation of 152. 
The product of the Jones oxidation (as the mixture of ketone and starting material) 
was used in a Grignard reaction, as the starting material should not affect the 
reaction. Since the ketone was isolated as the HCl salt it was necessary to use an 
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excess of Grignard reagent to allow for the reaction with the HCl salt. Initially 
attempts using methylmagnesium iodide (MeMgI) were unsuccessful resulting in 
complex mixtures being formed. Due to the hygroscopic nature of the HCl salt it was 
found that drying it under high-vacuum before introducing the Grignard reagent 
seemed to give a better result. The methylated product was successfully synthesised 
using 10 equivalents of MeMgI (Scheme 33). Workup with a sat. ammonium 
chloride solution, to quench the excess Grignard reagent without protonating the 
tertiary amine, and subsequent chromatography gave the desired product 188 in 41% 
yield. The 1H NMR spectrum showed a new signal at 1.29 ppm corresponding to the 
new methyl group, while the signals for the methylene protons are seen as two 
doublet of doublets and two doublets showing that the methylene protons now have 
axial and equatorial arrangements. This coupled with HRMS data confirms that the 







Scheme 33 Grignard reaction using MeMgI. 
Multiple attempts of the same reaction using phenylmagnesium iodide as the 
Grignard reagent gave complex mixtures which were not purified and this reaction 
was abandoned. Further work is needed to optimise the reaction conditions and allow 
a variety of Grignard reagents to be used. It would also be useful to revisit both the 
Oppenauer and Jones oxidations in order to try and improve the synthesis of the 
ketone. Optimisation of the reaction conditions would potentially allow the ketone to 
be synthesised and isolated more effectively which would also potentially improve 
the outcome of the Grignard reactions, as well as allowing for a variety of other 
transformations of the ketone. 
3.8.1 Antitrypanosomal activity of derivative 188 
The ketone was not submitted for biological testing as a pure sample could not be 
obtained. However, the Grignard derivative 188 was evaluated for its activity against 
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T. b. rhodesiense and mammalian cells. This derivative showed some activity to T. b. 
rhodesiense (see Table 18) although there was no increased activity as compared to 
the TBDPS phenol substituted isoquinoline 152. It would be interesting to see how 
using larger substituents in a Grignard reaction would affect the anti-HAT activity of 
this type of derivative.  
Table 18 In vitro activity of derivative 188. 
No.   
IC50  










2.7 ± 0.1 22.2 ± 1.1 8.2 
     
152 
 
2.8 ± 0.1 19.1 ± 0.6 6.8 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 
Ellipticine was used as a positive control for cytotoxcicity (see appendix A). 
3.9 Summary of derivatives modified at the benzylic 
alcohol 
In summary, 15 derivatives were synthesised which were modified at the benzylic 
alcohol. Substitution at the benzylic alcohol gave mixed results with larger 
substituents, such as a biphenylmethyl and cyclohexylethyl group, showing some 
activity. Disubstitution (i.e. substitution at both the phenol and benzylic alcohol) did 
not seem to improve activity as compared to derivatives substituted only at the 
phenol. Derivatives substituted at the phenol with the benzylic alcohol removed 
showed comparable activity to derivatives substituted at the phenol with the benzylic 
alcohol still intact, suggesting the benzylic alcohol is not important for activity. 
Changing the stereochemistry of the benzylic alcohol also had no impact on activity 




4 Synthesis of analogues modified at the 
phenolic position and their antitrypanosomal 
activity 
Modification of isoquinoline 86 at the phenolic position has been explored 
thoroughly (see chapter 2), however no information has been obtained regarding 
whether the flexible ether linkage is important for activity. Derivatives synthesised 
where the aromatic ring (position 6) is directly substituted forming a new carbon-
carbon bond (see Figure 42 A) would provide more rigid derivatives and also 
potentially provide some information regarding the size and shape of the receptor 
site. Also synthesised were derivatives through the formation of diaryl ethers at the 
phenolic position (see Figure 42 B). These derivatives do not have a methylene 
carbon linking the phenolic oxygen to the aryl substituent, providing derivatives with 





Figure 42 Modification of position 6. 
4.1 Direct substitution onto the aromatic ring at the 
phenolic position 6 
Synthesis of derivatives where the aromatic ring (position 6) is directly substituted 
forming a new carbon-carbon bond, was achieved through Suzuki coupling. Since it 
was determined from previous results that the benzylic alcohol played little or no part 
in anti-HAT activity (see section 3.5 pg.77), it was decided to use the 
deoxyisoquinoline derivative 175, which corresponds to the derivative with the 
benzylic alcohol removed, for the synthesis of these derivatives. This would simplify 
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the synthesis and was not expected to affect the biological activity. The first step 
required conversion of the phenol to a triflate. The triflate being a pseudo halide 
could then be used in Suzuki coupling reactions.149 Reaction of deoxyisoquinoline 
175 with triflic anhydride gave the expected triflate in 36% yield. Confirmation of 
the triflate was obtained through NMR spectroscopy. The 1H NMR spectrum showed 
a downfield shift of the aromatic protons attributed to the de-shielding effect of the 








Scheme 34 Synthesis of the triflate of 189. 
Suzuki coupling of triflate 189, using palladium acetate and triphenylphosphine to 
generate the palladium(0) source, with the corresponding boronic acids gave the 
expected diaryl derivatives. The 1H NMR spectra showed the signals corresponding 
to the aromatic hydrogens on the isoquinoline scaffold that are closest to the new 
formed bond (positions 5 and 7) have shifted downfield slightly (0.3-0.6 ppm shift) 
caused by the attachment of the new aryl group. HRMS data also confirms the 
desired products had been formed. 
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R Reaction time % Yield 
 
190 
6 hrs 33% 
 
191 
7 hrs 52% 
 
192 
6 hrs 43% 
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4.2 Synthesis of diaryl ethers at the phenolic position 6 
Synthesis of diaryl ethers at the phenolic position was achieved through Buchwald-
Hartwig cross coupling. Buchwald-Hartwig cross-coupling is the palladium catalysed 
cross coupling of phenols and aryl halides to form diaryl ethers.168 An electron rich 
phosphine ligand is also essential in this reaction. 2-(Di-tert-
butylphosphino)biphenyl 193 was the ligand used in this case.  
 
193 
Figure 43 2-(di-tert-butylphosphino)biphenyl. 
Coupling of phenol 175 with bromobenzene gave the expected diaryl ether product 
195 in low yield (Scheme 35). The 1H NMR spectrum of 195 showed a slight 
downfield shift of the aromatic protons on the isoquinoline scaffold attributed to the 
coupling of the phenyl ring to the phenolic oxygen, as well as new signals integrating 











Scheme 35 Synthesis of diaryl ether 195 by Buchwald-Hartwig coupling. 
 Coupling of phenol 175 with 4-bromobiphenyl also gave the expected aryl ether 197 
in low yield (Scheme 36). Again a slight downfield shift of the aromatic protons on 
the isoquinoline scaffold was observed in the 1H NMR spectrum attributed to the 
attachment of the biphenyl group to the phenol, as well as new signals integrating for 













Scheme 36 Synthesis of diaryl ether 197 by Buchwald-Hartwig coupling. 
4.3 Antitrypanosomal activity of derivatives modified 
at the phenolic position 
The above diaryl and diaryl ether derivatives were evaluated for their in vitro activity 
against T. b. rhodesiense and mammalian cells. The diaryl derivatives showed good 
anti-HAT activity with the biphenyl derivative 191 being tenfold more active than 
the phenyl 190 and naphthyl 192 derivatives. Both the phenyl and biphenyl 
derivatives showed an approximate tenfold increase in activity against T. b. 
rhodesiense as compared to the phenolic substituted benzyl 87 and biphenyl methyl 
129 derivatives discussed in chapter 2, with reasonable selectivity as compared to 
mammalian cells. 
This suggests that the increased rigidity of the molecule is favourable to activity. As 
for the diaryl ether derivatives (195 and 197) both showed activity against T. b. 
rhodesiense similar to the corresponding phenolic substituted derivatives 87 and 129.  
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Table 20 In vitro activity of diaryl and diaryl ether derivatives. 
 













3.0 ± 0.1 >50 16.7 
191 
 
0.27 ± 0.01 15.6 ± 0.3 57.8 
192 
 
2.7 ± 0.1 24.1 ± 2.2 8.9 
195 
 
19.8 ± 0.6 >100 5.1 
197 
 
2.7 ± 0.1 22.3 ± 0.4 8.3 
 
87  25.6 ± 0.9 >100 >3.9 
129 
 
2.9 ± 0.1 23.0 ± 2.1 7.9 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 




5 Modification of the nitrogen atom and its 
impact on antitrypanosomal activity 
The impact of the nitrogen atom in the isoquinoline ring and its substitution were 
explored in order to see how these affected anti-HAT activity. Removal of the N-
methyl would give the secondary amine allowing us to gain information on the 
importance of the N-methyl and the effect of a secondary amine as opposed to a 
tertiary amine. It would also provide the opportunity to substitute the nitrogen atom 
with different alkyl groups (Figure 44 A) and explore the effect on anti-HAT activity 
of having something larger than a methyl group on the nitrogen atom. Substitution of 
the phenol of the secondary amine derivative (Figure 44 B) would also be possible, 
again providing information on the effect of a secondary amine. It is also possible to 
substitute the nitrogen atom and also substitute the phenol (Figure 44 C) providing 
some disubstituted derivatives which may be of interest. Finally removing the 
nitrogen atom from the ring completely (Figure 44 D) would provide information on 









Figure 44 Modification of the nitrogen atom. 
5.1 N-Demethylation of isoquinoline 86 
There are a number of different ways to achieve N-demethylation of amines.156 One 
of the most common ways of N-demethylation is the Polonovski reaction. Classical 
and non-classical Polonovski reaction conditions were used in an attempt to N-
demethylate isoquinoline 86. After multiple unsuccessful attempts to demethylate 
isoquinoline 86 it was decided that rather than demethylating the isoquinoline it 
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would be better to instead synthesise the desired de-methylated product via a Pictet-
Spengler cyclisation from nor-phenylephrine.  
5.1.1 Polonovski reaction 
The Polonovski reaction describes the reaction of a tertiary N-oxide with an 
activating agent, most commonly acetic anhydride, which results in the formation of 
an acetamide and an aldehyde (see Scheme 37). 169 The secondary amine can then be 





Scheme 37 Classical Polonovski reaction. 
The N-oxide 173 was synthesised as described previously (see Scheme 25 pg. 75). 
Treatment of the N-oxide 173 with 4 equivalents acetic anhydride under Polonovski 
reaction conditions170 was expected to give the tri-acetyl compound 198. However, 
after workup of the reaction a complex mixture was obtained. Under the same 
conditions treatment of N-oxide 173 with 10 equivalents of acetic anhydride also 
gave a complex mixture observed by 1H NMR spectroscopy, isoquinolone 174 was 










Scheme 38 Attempted Polonovski reaction of 173. 
5.1.2 Non-classical Polonovski reaction 
After little success of N-demethylation using classical Polonovski reaction conditions 
attention was turned to using non-classical conditions. A non-classical Polonovski 
reaction was reported by Scammells et al.171 where N-demethylation of an opiate 
alkaloid is achieved using an FeSO4·7H2O mediated Polonovski reaction. In this 
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example rather than using acetic anhydride as an activating agent an iron(II) salt is 
used. The proposed mechanism involves coordination of iron(II) to the protonated N-
oxide which undergoes a one electron reduction resulting in cleavage of the N-O 
bond and formation of an aminium radical cation. This radical cation then loses an α-
proton and reorganises to form a carbon centred radical which is subsequently 
oxidised by iron(III) to form an iminium ion. Hydrolysis of the iminium ion then 







      
      
Scheme 39 Proposed mechanism of the non-classical iron mediated Polonovski 
reaction. 
After treatment of N-oxide 173 with 1 equivalent of concentrated HCl to give the 
protonated N-oxide and treatment with FeSO4·7H2O, according to the procedure 
proposed by Scammells et al.,171 the N-oxide was recovered as well as some of the 
original isoquinoline 86. This was apparent by TLC which showed two spots in the 
reaction mixture corresponding to the N-oxide and a new spot corresponding to 
isoquinoline 86. Comparison of the 1H NMR spectra of the N-oxide and isoquinoline 
86 also confirmed this.  
5.1.3 Pictet-Spengler cyclisation with nor-phenylephrine 
After multiple unsuccessful attempts to demethylate isoquinoline 86 it was decided 
to instead synthesise the demethylated version. This was achieved through a Pictet-
Spengler cyclisation of nor-phenylephrine. The Pictet-Spengler cyclisation describes 
the condensation of a β-arylethylamine with a carbonyl compound followed by 
cyclisation; the cyclisation occurs through an iminium intermediate.172 Treatment of 
racemic nor-phenylephrine hydrochloride 199 with formaldehyde gave the desired 
para cyclised product 200, as well as the ortho cyclised product 201 as a mixture of 
isomers (3:1) which were separated by crystallisation.173 The 1H NMR spectra for 
96 
 
both the para and ortho products showed only 3 aromatic protons consistent with the 
cyclised product, nor-phenylephrine showed 4 aromatic protons. For the para 
product the aromatic region showed two doublets and a doublet of doublets 
consistent with the isoquinoline being substituted in the 6 position. For the ortho 
product the aromatic region showed two doublet of doublets and a multiplet 
consistent with the isoquinoline being substituted in the 8 position. Both spectra also 
showed two new signals in the region of 4.2-4.5 ppm which can be observed as two 













Scheme 40 Pictet-Spengler cyclisation of nor-phenylephrine. 
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5.2 Substitution of the nitrogen atom 
Availability of the ‘demethylated’ isoquinoline 200 now allowed for different 
substituents to be added to the nitrogen atom in order to assess the effect on anti-
HAT activity. Substituents were added to the nitrogen atom via a simple alkylation 
reaction with the appropriate alkylating agents in the presence of Hünigs base. 
Hünigs base was used to prevent disubstitution and formation of the quaternary 
ammonium salt.174 Alkylation with a range of alkyl halides gave the corresponding 
tertiary amine derivatives in moderate to good yields (Table 21). The 1H NMR 
spectra of these derivatives showed an upfield shift of the signals for both sets of 
methylene protons on the isoquinoline scaffold consistent with alkylation of the 
nitrogen atom. Derivative 204 has been reported previously as the hydrochloride 
salt.175 





R X Reaction time % Yield 
 
202 
Br 1.5 days 55% 
 
203 
Br 1.5 days 47% 
 
204 
Br 24 hrs 88% 
 
205 
Cl 24 hrs 67% 
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5.3 Substitution of the phenol 
Substitution of the phenol of the ‘demethylated’ isoquinoline 200 was the next area 
of interest. Substituting the phenol would allow for information to be gained on the 
effect of a secondary amine as opposed to a tertiary amine in the isoquinoline 
scaffold. Since the isoquinoline with an unsubstituted phenol showed no anti-HAT 
activity, substituting the phenol would allow a comparison to be made with other 
active compounds and determination of the impact of the secondary amine. 
Substitution of the phenol first required protection of the amine to prevent the 
substitution reaction taking place at the amine instead of the phenol. Reaction of 
isoquinoline 200 with BOC-anhydride176 gave the BOC protected amine 206 in 
excellent yield. The 1H NMR spectrum showed a new peak at 1.50 ppm which 
integrates for 9 protons and corresponds to the tert-butyl group of the BOC 







Scheme 41 BOC protection of isoquinoline 200. 
Substitution of the phenol of the BOC protected isoquinoline 206 with a range of 
alkylating agents as described previously then gave the desired ether derivatives in 
moderate to good yields (Table 22).  
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Br 24 hrs 83% 
 
208 
Cl 3 days 83% 
 
209 
OTs 3 days 39% 
Following this the BOC protected isoquinolines (207-209) were deprotected by 
treatment with trifluoroacetic acid148 to give the secondary amines (210-212) in 
moderate to excellent yields (Table 23). The 1H NMR spectra showed the upfield 
shift of the methylene protons adjacent to the nitrogen atom in the isoquinoline 
scaffold (position 3) consistent with removal of the BOC group. 
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Table 23 BOC deprotection of derivatives 207-209. 
   
















5.4 Substitution of the nitrogen atom and phenol  
As well as substituting both the nitrogen atom and phenol separately, substitution of 
both the nitrogen atom and phenol on the same molecule could potentially show 
some interesting biological activity. The simplest way to achieve this was to take the 
N-substituted derivative 204 and alkylate the phenol. The phenol of derivative 204 
was substituted with both a benzyl and biphenylmethyl group as described in 
Scheme 42 and Scheme 43 below to give the phenolic and nitrogen disubstituted 



















Scheme 43 Synthesis of derivative 214. 
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5.5 Antitrypanosomal activity of N-modified 
derivatives 
The synthesised N-modified derivatives were evaluated for their in vitro activity 
against T. b. rhodesiense and mammalian cells. The ‘N-demethylated’ isoquinoline 
200 showed no activity against T. b. rhodesiense. Derivatives substituted at the 
nitrogen atom with an ethyl 202 or propyl 203 group also showed no activity, 
however when the nitrogen atom was substituted with a benzyl group some activity 
was seen. N-Biphenylmethyl derivative 205 showed increased activity with and IC50 
in the low micromolar range. Derivatives with a secondary amine in the isoquinoline 
core and substituted at the phenol with a benzyl 210 and cyclohexylethyl 212 group 
showed comparable activity to their counterparts with a tertiary amine in the 
isoquinoline core (87 and 108 as reported previously). The derivative substituted at 
the phenol with a biphenyl methyl group 211 showed a tenfold increase in activity 
against T. b. rhodesiense as compared to its counterpart 129, with comparable 
cytotoxicity to mammalian cells, making it almost 80 times more selective for T. b. 
rhodesiense than mammalian cells. This increase in activity is potentially due to 
increased solubility. As for derivatives substituted at the nitrogen atom with a benzyl 
group and at the phenol, the benzyl derivative 213 showed increased activity as 
compared to the corresponding N-methyl derivative 87. The biphenyl derivative 
showed almost identical activity to its N-methyl counterpart 129. 
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Table 24 In vitro activity of N-modified derivatives. 
 
No.  R R’ 
IC50  








200 H H >100 >100  
202 H  >100 >100  
203 H  >100 >100  
204 H 
 
70.5 ± 0.5 >100 1.4 
205 H 
 
5.4 ± 0.7 >50 9.3 
210 
 
H 17.4 ± 2.3 >50 2.9 
211 
 
H 0.25 ± 0.02 20.8 ± 0.8 83.2 
212 
 
H 2.5 ±0.2 >50 20 
213 
  




2.7 ± 0.1 14.8 ± 5.5 5.5 
87 
 
Me 25.6 ± 0.9 >100 >3.9 
129 
 
Me 2.9 ± 0.1 23.0 ± 2.1 7.9 
108 
 
Me 2.5 ± 0.1 >50 >20 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 




5.6 Derivatives without a nitrogen atom 
It was suspected that the nitrogen atom in the isoquinoline scaffold was important to 
anti-HAT activity. In order to confirm this a core scaffold without a nitrogen atom 
was synthesised, giving a tetrahydronaphthalene. This was achieved following a 
literature procedure starting from commercially available 7-methoxy-1-tetralone 
215.177 This was demethylated using aluminium chloride to give the phenol 216 in 
52% yield. Reduction of the ketone 216 using sodium borohydride then gave the 











Scheme 44 Synthesis of the core scaffold without a nitrogen atom. 
5.6.1 Substitution of the phenol 
The phenol of this scaffold was then substituted with a benzyl (Scheme 45) and a 
biphenylmethyl (Scheme 46) group to allow a comparison of anti-HAT activity with 
the isoquinoline derivatives. This was achieved as described above to give the 
desired ether derivatives in good yields. This was confirmed through 1H NMR 
spectroscopy by the slight downfield shift of the signals for the aromatic protons of 





















Scheme 46 Biphenylmethyl substitution of 217. 
5.6.2 Antitrypanosomal activity 
The above derivatives were evaluated for their in vitro activity against T. b. 
rhodesiense and mammalian cells (Table 25). The core scaffold with the nitrogen 
atom removed 217 showed no anti-HAT activity, as was expected. Substitution at the 
phenol of this scaffold (218 and 219) did not improve the activity, therefore 
confirming the importance of the nitrogen atom in the scaffold for anti-HAT activity.  
Table 25 In vitro activity of naphthyl derivatives. 
 
No.  R 
IC50  








217 H >100 >100  
218 
 
65.9 ± 0.6 39.0 ± 10.4 0.6 
219 
 
>100 >100  
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 





5.7 Summary of derivatives modified at the nitrogen 
atom 
In summary, 14 derivatives were synthesised with modifications at the nitrogen 
atom. Derivatives substituted at the nitrogen atom with larger groups such as a 
benzyl group showed some activity, with the biphenylmethyl derivative showing 
activity in the low micromolar range. Substituting the phenol of N-demethylated 
derivatives gave comparable results to derivatives where the nitrogen atom was 
methylated. An exception to this was derivative 211 substituted with a 
biphenylmethyl group at the phenol, which showed a tenfold increase in activity as 
compared to the N-methyl version. Substituting both the phenol and nitrogen atom 
did not increase activity as compared to N-methyl derivatives substituted at the 
phenol. Derivatives with no nitrogen atom in the scaffold showed no activity, 
confirming the importance of the nitrogen atom for activity.
107 
 
6 Addition of substituents via Pictet-Spengler 
cyclisations and the effect on 
antitrypanosomal activity 
It is possible to add substituents to position 1 of the isoquinoline scaffold by using 
functionalised aldehydes in the place of formaldehyde in the Pictet-Spengler 
cyclisation with phenylephrine. This provides an opportunity to add substituents to 
this position without altering the rest of the molecule (Figure 45 A). Synthesis of 
these derivatives would also allow for them to be substituted at the phenol (Figure 






Figure 45 Substitution of position 1. 
6.1 Pictet-Spengler Cyclisations 
The Pictet-Spengler cyclisations were originally attempted using previously reported 
conditions,178 involving reflux of phenylephrine and the aldehyde in ethanol. The 
reaction was attempted with both benzaldehyde and acetaldehyde and in both cases 
no reaction was observed. The reaction mixture was heated at reflux for multiple 
days however still no reaction was observed. TLC and 1H NMR spectra showed only 
starting material. Heating phenylephrine hydrochloride 89 with 1 equivalent of the 
aldehyde neat at 130°C was successful in giving the desired cyclised products 
(Scheme 47). Using any aldehyde other than formaldehyde in this cyclisation has 
been reported to give only the para substituted product,173 and only formation of the 
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para cyclised product was observed. This is obvious from the substitution pattern in 
the 1H NMR spectra which showed a small doublet (J = 2.5 Hz), a large doublet (J = 
8.4 Hz), and a doublet of doublets (J = 8.4, 2.5 Hz) consistent with this 1,2,4-
substitution pattern.† However, two isomers were observed from the reaction with 
almost identical 1H NMR spectra. In most cases these two isomers were separated by 
column chromatography and represent the two diastereomers (Scheme 47), where 














Scheme 47 Pictet-Spengler cyclisation using a range of aldehydes. 
The cyclisation as described above was performed using a number of different 
aldehydes (see Table 26). Due to the reaction conditions the choice of aldehydes was 
restricted to those with high boiling points. Below is a summary of the derivatives 
synthesised. The two diastereomers were successfully separated via column 
chromatography (>90% purity by NMR) in most cases except for the pyridine and 
the undecyl derivatives. Derivative 220 has been reported in the literature, although 
the separated diastereomers were not reported.179,180 
                                                          
† Coupling constants reported here correspond to compound 220A, however the coupling 
pattern is consistent for all other derivatives (i.e. compounds 220-225). 
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Table 26 Derivatives synthesised by Pictet-Spengler cyclisation. 

























As a mixture of isomers  
A and B (66:34 by 1H NMR) 
The 1H NMR spectra of the cyclised derivatives showed a new signal between the 
region of 3.7 ppm and 4.9 ppm (depending on the particular derivative) 
corresponding to the new methine proton at position 1 of the cyclised product. In the 
case of derivative 222 a singlet is observed at ~4.3 ppm (see Figure 46) for both 
isomers A and B. Almost identical 1H NMR spectra are observed for isomers A and 
B. The signals for the proton on the benzylic alcohol and the proton next to the 
benzylic alohol (position 4) are significantly downshifted (by ~0.3 ppm in the case of 
222) for isomer B as compared to isomer A. This is consistent for all derivatives. 
Interestingly the two methylene protons at position 3 are observed as two doublets of 
doublets for isomer A and as a doublet of doublets and an apparent triplet for isomer 






Figure 46 1H NMR spectra of 222219 isomers A (top) and B (bottom). 
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6.2 Stereochemistry of cyclised products 
To assign the correct structures to isomers A and B of the above derivatives, attempts 
were made to grow a single crystal of each of the isomers in order to determine the 
structure by x-ray crystallography. However, these attempts were not successful. To 
overcome this it was decided to synthesise the dibenzoates of two of the isomers to 
create some derivatives that would potentially be more easily crystallised.  
6.2.1 Synthesis of the benzoates  
The dibenzoates of derivative 222 isomer A and isomer B were synthesised through 
an esterification reaction with benzoyl chloride to give the desired dibenzoates in 
45% and 76% yield respectively. Crystallisation of these derivatives was more 
successful, and high quality crystals were obtained for the dibenzoates of both 
isomers A and B. 
 
222 






Figure 47 Synthesis of dibenzoates. 
6.2.2 Crystal structure 
A crystal structure was obtained for the dibenzoate of isomer B. X-ray 
crystallography was carried out by Professor Chiara Massera from the University of 
Parma (details can be found in section 11.3 pg. 164). Unfortunately a crystal 
structure could not be obtained for the dibenzoate of isomer A. From the crystal 
structure (Figure 48) it can be seen that the benzylic oxygen and the nitrophenyl 
group are in a trans orientation. Therefore isomer B can be assigned to a trans 
conformation (227) and it can be assumed that isomer A will have a cis conformation 
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(226). Since the 1H NMR spectra of isomers A and B are consistent for all of the 
derivatives it can be assumed that isomer A always corresponds to the cis derivative 
and isomer B always corresponds to the trans derivative. 
 
Figure 48 Crystal structure of the dibenzoate of isomer B. 
With the stereochemistry of isomers A and B now assigned with reasonable 
confidence it is possible to relate the observed 1H NMR spectra to the structures. 
Since for isomer A two doublets of doublets were observed which represent the 
coupling pattern between the two methylene protons in position 3 and the methine 
proton in position 4. For isomer B this was observed as a doublet of doublets and a 
triplet. It can be assumed that the ring structures for isomers A and B have different 
conformations, which cause the dihedral angles between these protons to be different 
accounting for the difference in coupling patterns.  
6.2.3 Computational studies 
As a crystal structure could not be obtained for isomer A, computational studies were 
used in order to confirm the structure of isomer A, as well as to better understand the 
conformational differences between isomers A and B. Computational studies were 
undertaken to calculate the energy minimised structures for each isomer. 
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Computational studies were carried out by Professor Andrew Rohl from Curtin 
University, details can be found in experimental section 11.4. The 1H NMR spectra 
were also predicted from these energy minimised structures in order to compare them 
with the experimental NMR spectra and confirm the correct conformation. These 
calculations were also carried out by Professor Rohl, and details can be found in 
experimental section 11.4 pg. 165. The structures of both isomers were optimised, 
and the NMR chemical shifts and 1H-1H coupling constants were calculated. Figure 
49 below shows a representation of the crystal structure of 227 and the dihedral 
angles between the methine proton Hc and both of the methylene protons Ha and Hb 
of the isoquinoline scaffold. Figure 50 shows the energy optimised structure of 222 
isomer B and the same dihedral angles between the methine proton and both of the 
methylene protons of the isoquinoline scaffold. Both of these structures represent the 
trans isomer and from the images it is possible to see that both derivatives have the 
same conformation. The dihedral angles measured for the crystal structure and for 
the energy minimised structure are very similar. This is expected as both structures 
should have the same conformation. This similarity adds validity to the energy 
minimised structure for isomer B. The 1H NMR spectrum of 222 isomer B showed 
the signals for the two methylene protons as a doublet of doublets (J = 10.4, 5.5 Hz) 
and a triplet (J = 10.4 Hz), see Figure 46 pg.111. This observation can be explained 
in terms of the dihedral angles between these protons. The doublet of doublets can be 
explained by the coupling of methylene proton Hb to methylene proton Ha as well as 
to methine proton Hc. Since these two couplings would be expected to have 
significantly different coupling constants, ~9-13Hz for Ha-Hb (range for normal 
geminal coupling) and ~2-6 Hz for Hb-Hc (according to the Karplus relationship), 
observation of a well defined doublet of doublets would be expected. However, due 
to the dihedral angle between methylene proton Ha and methine proton Hc the 
coupling constant would be expected to be ~9-13 Hz (according to the Karplus 
relationship) which is the same for the coupling between Ha and Hb. This could 
cause overlap of the signals which explains why this proton is observed as a triplet. 
In the 1H NMR of the benzoate of isomer B 227 (see Figure 51) the signal 
representing Ha is seen as a doublet of doublets, not a triplet. The J values are no 
longer the same but are similar enough to cause the doublet of doublets to almost 



















Figure 51 1H NMR spectrum of 227. 
Figure 52 below shows the energy minimised structure of 222 isomer A and the 
dihedral angles between the two methylene protons Ha and Hb and the methine 
proton Hc. This is the cis isomer and from the image it can be seen that it has a 
similar conformation to isomer B above, and consequently the dihedral angles are 
also similar to that of isomer B reported above. The 1H NMR spectrum for 222 
isomer A showed the signals for the methylene protons as two doublets of doublets 
(J = 12.1, 3.9 Hz and J = 12.1, 3.5 Hz) both with very similar coupling constants. 
This observation does not fit with the structure below. If isomer A had this 
conformation, the 1H NMR spectrum should look similar to isomer B however it 






Figure 52 Dihedral angles for 222 isomer A obtained from energy minimised 
conformation 1. 
Looking at the observed 1H NMR spectrum for isomer A the dihedral angles between 
Ha and Hc are expected to be similar to that between Hc and Hb. This would give 
rise to two almost identical doublets of doublets in the spectrum. Looking at the 
structure of isomer A this would occur if the saturated isoquinoline ring was twisted 
in such a way that nitrogen atom was pointing in an upwards direction, (see Figure 
53 conformation 2) relative to the plane of the molecule rather than down, (see 
Figure 53 conformation 1) as is represented above. With this in mind another 
energy minimised structure was calculated this time starting with the ring in this 






Figure 53 Two conformations of the saturated ring of isomer A, where the bold bond 
indicate the planar part of the ring. 
Figure 54 below shows the energy minimised structure of 222 isomer A in the 
second conformation (i.e. with the nitrogen atom pointing up relative to the plane of 





protons Ha and Hc, and Hb and Hc are very similar. This fits with what would be 
expected from the signals in the 1H NMR spectrum. In this conformation the second 
dihedral angle Ha-Hc is much smaller than in the first conformation, a much smaller 
coupling constant ~2-6 Hz would therefore be expected, which is in agreement with 
the spectrum. The two signals would also be expected to be almost identical which is 
what is observed. From this information it seems reasonable to assign the 





Figure 54 Dihedral angles for 222 isomer A, obtained from energy minimised 
conformation 2. 
The energies of the two conformations were also calculated, and the second 
conformation was determined to have a lower energy than the first adding more 
evidence that this is the correct conformation. As another confirmation that isomers 
A and B had been assigned to the correct conformations the 1H NMR spectra were 
calculated and a comparison made to the experimental spectra. Table 27 shows a 
summary of the experimental and calculated 1H NMR data for the methylene and 
methine protons discussed above for both isomers A and B. The experimental spectra 
were obtained using DMSO-d6 as a solvent, while the computational spectra were 
determined for CDCl3 solutions. Looking first at the chemical shift values for isomer 
B it can be seen that they fit reasonbly well with the experimental data, giving an 
indication that this is a reasonable model. In terms of coupling constants the 




H28 is very different from H27-29 giving rise to the doublet of doublets seen in the 
experimental spectrum. Whereas the coupling between H28 and H29 is calculated to 
be very close to that of H27-28 which explains why a triplet is seen in the 1H NMR 
specrtum. Looking at the chemical shifts for isomer A, both of the sets of calculated 
data (for conformation 1 and 2 see above) seem to fit reasonably well with the 
experimental data. However, looking at the coupling constants it can be seen that 
those calculated for the first conformation do not fit so well with the experimental 
data, the coupling constants are much larger than those determined experimentally. 
The coupling constants calculated for the second conformation fit a lot better with 
the experimental data, they are a little lower than those dertermined experimentally, 
however H27-H29 and H28-29 are much more similar which would give rise to two 
more similar looking signals in the spectrum which is indeed observed. Therefore 
conformation 2 again seems to be the best fit, and can be confidently assigned as the 
correct conformation of isomer A. 





Chemical shifts (ppm) 
 Exp Calc 1 Calc 2   Exp Calc 
H27 2.65 2.41 2.78  H27 3.13 2.80 
H28 2.92 2.71 2.88  H28 2.38 2.61 
H29 4.51 4.76 4.16  H29 4.83 4.89 
Coupling constants (Hz) 
 Exp Calc 1 Calc 2   Exp Calc 
H27-28 12.1 -11.3 -11.2  H27-28 10.4 10.2 
H27-29 3.5 6.3 1.8  H27-29 5.5 5.0 
H28-29 3.9 9.5 2.6  H28-29 10.4 9.8 
Where exp is experimental data and calc is calculated data. Calc 1 represents data from 
conformation 1 of isomer A (see Figure 52) and calc 2 represents data from conformation 2 of 
isomer A (see Figure 54). All experimental NMR data was obtained using DMSO-d6 as the 
solvent. All calculated data was obtained using CDCl3 as the solvent. 
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6.3 Substitution of the phenol 
The phenol of two of the above derivatives was substituted to give the ether products 
in order to provide some information on how having substituents at both the phenolic 
position and on carbon 1 would affect anti-HAT activity. The two derivatives used 
were the nitrophenyl and the undecyl derivatives. The substitution reaction was 
carried out as described previously using either a benzyl or biphenylmethyl group as 
the alkylating agent. In the case of the nitrophenyl derivatives isomer A was used to 
give the benzyl ether in 69% yield (Scheme 48), while isomer B was used to give the 
biphenylmethyl derivative in 44% yield (Scheme 49). The reason that the benzyl and 
biphenylmethyl derivatives of only either isomer A or B, and not of both isomers, 
were synthesised was simply due to the fact that only low quantities of the starting 
material were readily available. Therefore to save time only one derivative of each 
isomer was made, with the rationale that when the biological results were obtained if 
they were interesting then the other derivatives could be synthesised. Formation of 
the ether was confirmed through 1H NMR spectroscopy by the slight downfield shift 
of the signals for the aromatic protons on the isoquinoline scaffold and the new 
























Scheme 49 Biphenylmethyl substitution of 222 isomer B. 
In the case of the undecyl derivative, as isomers A and B could not be separated, a 
mixture of the two isomers was used in the substitution reaction to give the two 
desired ethers in moderate yields (see Scheme 50 and Scheme 51). Formation of the 
ether was confirmed through 1H NMR spectroscopy by the slight downfield shift of 




















Scheme 51 Biphenylmethyl substitution of 225. 
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6.4 Antitrypanosomal activity 
The above cyclised derivatives and the phenolic substituted derivatives were 
evaluated for their activity against T. b. rhodesiense and mammalian cells in vitro 
(see Table 28 and Table 29). The cyclised derivatives 220 to 222, and 224, showed 
no activity towards T. b. rhodesiense. Interestingly however, the derivatives cyclised 
with cinnamaldehyde (223) showed some activity with no significant difference in 
activity between isomers A and B, and also no observed cytotoxicity. The undecyl 
derivative 225 showed quite good activity against T. b. rhodesiense with lower than 
expected cytotoxicity, giving a selectivity index of ~60. It would be expected that a 
derivative such as this with a long alkyl chain would show significant cytotoxicity 
due to its potential to disrupt cell walls, however derivative 225 only showed 
moderate cytotoxicity and had a good selectivity index. 
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Table 28 In vitro activity of cyclised derivatives. 
 













>100 >100  
220B 
 
>100 >100  
221A 
 
>100 >100  
221B 
 
>100 >100  
222A 
 
>50 >50  
222B 
 
>50 >50  
223A 
 
17.5 ± 1.3 >50 2.9 
223B 
 
16.9 ± 0.9 >50 3.0 
224A 
 
>100 >100  
225  0.39 ± 0.04 24.3 ± 2.9 62.3 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 
Ellipticine was used as a positive control for cytotoxcicity (see appendix A). 
The phenolic substituted derivatives 228-231 (Table 29) all showed some anti-HAT 
activity however they also showed a significant increase in cytotoxicity as compared 
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to their unsubstituted counterparts (222 and 225). For the nitrophenyl derivatives 228 
and 229, both showed almost identical activity, although from previous results it 
would have been expected that the biphenylmethyl derivative would be more active 
than the benzyl. For the phenolic substituted undecyl derivatives (230 and 231) the 
benzyl substituted derivative (230) showed almost identical activity to the 
unsubstituted derivate (225) with a significant increase in cytotoxicity. Interestingly 
the biphenylmethyl derivative, which would be expected to be more active from 
previous trends, showed less activity against T. b. rhodesiense than the unsubstituted 
version (225). 
Table 29 In vitro activity of phenolic substituted derivatives of 222 and 225. 
 
No.  R R’ 
IC50  










19.2 ± 0.6 26.8 ± 4.1 1.4 
229 
  
19.4 ± 1.0 37.6 ± 4.1 1.9 
230   0.32 ± 0.01 3.2 ± 0.2 10.0 
231 
 
 2.5 ± 0.2 3.6 ±0.7 1.4 
aIC50 on T. b. rhodesiense (STIB-900) cells. bCytotoxicity on VERO cells. cThe selectivity 
index (SI) is defined as the ratio of IC50-Vero/IC50-T. b. rhodesiense. A series of standard 
antifolates (pyrimethamine, cycloguanil, and WR99210, were used as positive controls 
Ellipticine was used as a positive control for cytotoxcicity (see appendix A). 
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7 Stereochemistry of the benzylic alcohol 
The core isoquinoline scaffold contains a chiral benzylic alcohol which is in the R 
configuration, it is synthesised from enantiopure (R)-phenylephrine. However, it 
cannot be assumed that the benzylic alcohol has retained the same stereochemistry 
throughout all the transformations of the core scaffold discussed in previous 
chapters. In order to confirm if the derivatives have retained the same 
stereochemistry, or determine if racemisation has occurred, a combination of chiral 
HPLC and optical rotation were used. Chiral HPLC chromatograms and specific 
rotations were obtained for a selection of derivatives. The derivatives selected 
include examples from each of the main transformations performed on the core 
scaffold, substitution of the phenol (129 and 101), Suzuki coupling (133), and 
substitution of the benzylic alcohol (167), as well as the two benzoates 180 and 181. 
It can be assumed that the benzylic alcohol will behave the same every time under 
any given set of reaction conditions, and hence it seemed reasonable to analyse only 
one derivative from each group. Firstly a suitable chiral HPLC method needed to be 
developed that was able to achieve separation of two enantiomers of this kind (i.e. 
the R and S configurations of the benzylic alcohol in the core scaffold). Since 
derivatives 180 and 181 have the opposite stereochemistry they provided a perfect 
means of doing this. Equal amounts of derivatives 180 and 181 were mixed together 
and showed baseline separation (see Figure 55) when analysed via chiral HPLC 
using an amylose column and an isocratic method (see experimental section for 
details). This type of column was used simply because it was on hand, and 
fortuitously gave acceptable results. The ability to obtain baseline separation of these 
two enantiomers gave evidence that using this column and method would be suitable 




Figure 55 Chiral HPLC chromatogram of an equal mixture of derivatives 180 and 
181. 
Derivatives 180 and 181 were also analysed by chiral HPLC separately, the 
chromatograms obtained can be seen in Figure 56. From the chromatograms it can 
be seen that in both cases there is one large and one small peak, hence each of the 
derivatives contains a very small amount of the other enantiomer. The enantiomeric 
excess was calculated to be 95%, and 98% for derivatives 180 and 181 respectively. 
 
 
Figure 56 Chiral HPLC chromatograms of derivatives 180 and 181. 
The specific rotation of both derivatives were also measured (see Table 30), and 
found to be approximately opposite, as is expected. 
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Table 30 Optical rotation of derivatives 180 and 181. 
Structure Specific rotation 
 
180 
[α]D +29.8°  
 
(c 1.00, CH2Cl2) 
 
181 
[α]D -37.4°  
 
(c 1.01, CH2Cl2) 
The other derivatives mentioned above were therefore analysed by chiral HPLC. A 
summary of the results can be seen in Table 31. In all but one case only one peak 
was observed, suggesting that each of the derivatives contained only one enantiomer. 
The exception to this was derivative 101 which showed two overlapping peaks in the 
HPLC chromatogram. The optical rotation of this derivative was also approximately 
zero (-0.9°), and had become negative when it is expected that it would be positive 
agreeing with all of the other derivatives. This derivative was resynthesised and the 
optical rotation of the freshly prepared sample found to be +2.9°. This result 
suggested that the benzylic alcohol may be susceptible to racemisation over long 
periods of time. Unfortunately the freshly prepared sample could not be analysed by 
chiral HPLC due to limited access to the instrument. The optical rotations of the 
other derivatives (see Table 31) were non-zero values, providing further evidence 
that racemisation had not occurred. 
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Table 31 Specific rotation and chiral HPLC for selected derivatives. 





[α]D +41.0°  
 
(c 1.00, CH3OH) 
One peak (6.68 min) 
 
129 
[α]D +11.5°  
 
(c 1.00, CH2Cl2) 
One peak (12.56 min) 
 
101 
*[α]D -0.93°  
 
(c 1.07, CH2Cl2) 
Two overlapping 
peaks (~7.19 min) 
 
133 
[α]D +7.9°  
 
(c 0.98, CH2Cl2) 
One peak (13.85 min) 
 
167 
[α]D +11.2°  
 
(c 1.05, CH2Cl2) 
One peak (11.36 min) 
 
180 
[α]D +29.8°  
 
(c 1.00, CH2Cl2) 
One peak (12.73 min) 
 
181 
[α]D -37.4°  
 
(c 1.01, CH2Cl2) 
One peak (10.21 min) 




The other derivatives analysed by chiral HPLC are significantly more polar than 
enantiomers 180 and 181 for which baseline separation was obtained. There was 
some concern if these derivatives were stereochemically pure, due to the difference 
in polarity they may not be separable via this method and only one peak would be 
observed. In order to test if this concern was valid a more polar derivative that was 
known to be racemic was analysed by chiral HPLC. Derivative 211 (see Figure 57) 
is racemic since it was synthesised initially from racemic nor-phenylephrine, it also 
contains a secondary amine making it much more polar. Figure 57 shows the chiral 
HPLC chromatogram of derivative 211. From the chromatogram it can be seen that 
there is a broad peak at about 15.5 min. Close inspection of this peak suggests two 
overlapping peaks, showing that separation of the two enantiomers in this case is not 
perfect but it is still possible to see that there are two enantiomers present. Since the 
other derivatives analysed by chiral HPLC are less polar than derivative 211 and 
some evidence of separation was obtained for enantiomers of this derivative, this 
gives more confidence that if the derivatives were in fact racemic some evidence 
would be seen in the chiral HPLC chromatogram. The specific rotation for this 
derivative was measured at +1.5°. This is a very low value and confirms the racemic 
nature of the compound. 
 
211 
[α]D 1.5 (c 1.01, CH3OH) 
 
Figure 57 Chiral HPLC chromatogram of derivative 211. 
The optical rotations of cyclised derivative 220 isomer A and B were also obtained 
as well as chiral HPLC data. Due to the fact that this derivative has two chiral centres 
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the specific rotations would not be expected to be opposite, but they would be 
expected to be significantly different. This is in agreement with the measured 
rotations (see Table 32). A summary of the chiral HPLC chromatograms for each of 
these isomers can also be seen in Table 32. Both isomers showed only one peak on 
the HPLC chromatogram, and they both elute at significantly different times. This 
provides another confirmation that these two isomers are stereochemically pure in 
addition to those discussed in section 1.1, and that the cyclisation reaction does not 
cause racemisation of the benzylic alcohol. 
Table 32 Specific rotation and chiral HPLC for derivative 220 isomers A and B. 





[α]D +174.6°  
 
(c 0.59, CH3OH) 
One peak (5.99 min) 
 
220B 
[α]D -59.7°  
 
(c 0.72, CH3OH) 
One peak (4.92 min) 
Taking the chiral HPLC and optical rotation results into account it can be concluded 
that the benzylic alcohol retains its stereochemistry when subjected to the reaction 




8 Summary of antitrypanosomal activity, and 
discussion of logD 
8.1 Summary of antitrypanosomal activity and SAR 
development 
Throughout this work 90 new compounds were synthesised based on the core 
scaffold below (see Figure 58) and evaluated in vitro for their activity against T. b. 
rhodesiense and mammalian cells. From this, a structure activity relationship was 
developed. Figure 58 shows a summary of the structure activity relationship, which 
is described in more detail below.  
 
Figure 58 SAR summary. 
Alkylation of the phenol generally resulted in increased activity against T. b. 
rhodesiense, with larger groups tending to be more active. However, this was 
generally accompanied by an increase in cytotoxicity. Having a nitrogen atom in the 
alkylating group resulted in a significant decrease in activity while oxygen seemed to 
have no effect. This suggests the possibility of a positively charged residue in the 
active site which would have unfavourable interactions with a nitrogen atom that 
would be charged at physiological pH. Derivatives substituted at the phenol with a 




significantly cytotoxic. An exception to this is derivative 132, with a p-chloro 
biphenylmethyl group on the phenol, which showed increased activity against T. b. 
rhodesiense with similar cytotoxicity resulting in a selectivity index of ~85. 
 
132 
IC50 = 0.28 ± 0.01 μM 
Cytotoxicity = 24.1 ± 4.3 μM  
SI = 86.1 
Figure 59 Derivative 132 and its biological activity. 
Alkylation at the benzylic alcohol resulted in moderate activity for larger groups 
such as cyclohexylethyl and biphenylmethyl with no observed cytotoxicity. 
Substitution of both the benzylic alcohol and the phenol did not result in any 
significant increase in activity as compared to derivatives only substituted at the 
phenol. Removing the benzylic alcohol completely did not have any significant 
effect on activity, while inverting the stereochemistry resulted in no change in 
activity. This suggests that the benzylic alcohol is not important to anti-HAT activity. 
Increasing the rigidity of the groups attached to the aromatic portion of the scaffold 
resulted in significantly increased activity. Where substitution directly onto the 
aromatic ring at position 6 resulted in derivatives with tenfold increased activity as 
compared to the same derivative substituted at the phenol, with derivative 191 
showing activity against T. b. rhodesiense in the submicromolar range (0.3 ± 0.1 
μM), and having a selectivity index of 57.8.  
 
191 
IC50 = 0.27 ± 0.01 μM 
Cytotoxicity = 15.6 ± 0.3  
SI = 57.8 
Figure 60 Derivative 191 and its biological activity. 
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Alkylation of the nitrogen atom resulted in no significant increase in activity as 
compared to N-methyl derivatives. Removing the N-methyl group to give a 
secondary amine showed comparable results to the corresponding N-methyl 
derivatives. An exception to this was derivative 211 which showed a tenfold increase 
in activity as compared to its N-methyl counterpart. This was accompanied by no 
change in the cytotoxicity resulting in good selectivity for T. b. rhodesiense over 
mammalian cells (SI=83.2). Removal of the nitrogen atom from the scaffold resulted 
in a loss of activity, confirming its importance.  
 
211 
IC50 = 0.25 ± 0.02 μM 
Cytotoxicity = 20.8 ± 0.8 μM  
SI = 83.2 
Figure 61 Derivative 211 and its biological activity. 
Adding substituents at position 1 in most cases did not have any effect. However, 
adding a cinnamyl group gave derivatives with moderate activity while adding an 
undecyl group (derivative 225) increased the activity dramatically with activity 
against T. b. rhodesiense in the sub micromolar range and lower than expected 
cytotoxicity giving a selectivity index of ~60. Substitution at the phenol and position 
1 gave conflicting results. Derivatives with a p-nitrophenyl group at position 1, when 
substituted at the phenol, resulted in an increase in activity. Substitution at the phenol 
of the derivative with an undecyl group at position 1 did not result in any increased 
activity against T. b. rhodesiense for the benzyl derivative but resulted in a decrease 





IC50 = 0.39 ± 0.04 μM 
Cytotoxicity = 24.3 ± 2.9 μM  
SI = 62.3 
Figure 62 Derivative 225 and its biological activity. 
8.2 Calculation and discussion of logD 
The logD values (where D is the distribution coefficient) of all of the derivatives 
were calculated181 at physiological pH and used as another way of analysing the 
biological data. The logD value describes the lipophilicity of a molecule and is the 
extent of the affinity for organic over aqueous phases and takes into account all 
species present at a given pH.182 The distribution coefficient was used as opposed to 
the partition coefficient (i.e. logP) as the majority of the derivatives in this work 
contain ionisable groups and so logD is a better estimate of the lipophilicity than 
logP which only takes into account the neutral form. For derivatives which do not 
contain ionisable groups, the logD value is equal to the logP value. The graph below 
(Figure 63) shows the calculated logD values plotted against the IC50 values for T. b. 
rhodesiense of all derivatives with IC50 values of less than 5 μM, logD values of all 
derivatives are given in Appendix A. The graph shows that most of the derivatives 
are clustered together with IC50 values between 2 and 3 μM and logD values between 
2 and 6. However, there is also another smaller group of derivatives which are 
circled. These are the more interesting derivatives as they all show IC50 values below 
0.5 μM and logD values less than 5. From Lipinski’s rule of 5 compounds are most 
likely to have good absorption if the logP/logD value is less than 5.183,184 See Figure 




Figure 63 Plot of calculated logD values vs IC50 of T. b. rhodesiense.  
These five derivatives (Figure 64) all show good activity against T. b. rhodesiense 
and from the calculated logD values it can be expected that they will have good 
absorption. All of the compounds below also show good selectivity and provide good 

























































IC50 = 0.25 ± 0.02 μM 
Cytotoxicity = 20.8 ± 0.8 μM 
SI = 83.2 
logD = 2.96 
 
191 
IC50 = 0.27 ± 0.01 μM 
Cytotoxicity = 15.6 ± 0.3 μM 
SI = 57.8 
logD = 3.94 
 
132 
IC50 = 0.28 ± 0.01 μM 
Cytotoxicity = 24.1 ± 4.3 μM 
SI = 86.1 
logD = 4.51 
   
 
225 
IC50 = 0.39 ± 0.04 μM 
Cytotoxicity = 24.3 ± 2.9 μM 
SI = 62.3 




IC50 = 0.24 ± 0.01 μM 
Cytotoxicity = 0.31 ± 0.01 μM 
SI = 1.3 
logD = 4.90 
 
Figure 64 Five derivatives circled in Figure 63. 
 
8.3 ADME properties 
 
The five compounds above were submitted to SwissADME,185 in order to evaluate 
their ADME properties. None of the compounds were found to show any motifs that 
are of concern in terms of metabolic stability. SwissADME analyses molecules based 
on both the PAINS186 and Brenk187 models. Additionally all of the compounds were 
predicted to be able to passively permeate through the blood-brain barrier, this was 
predicted using the BOILED-Egg model188 inside of SwissADME. These results are 
only predictions and as such not conclusive. However, the results suggest that these 
molecules will be metabolically stable and are also capable of crossing the blood-
brain barrier, making them good candidates for further optimisation and testing.
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9 Potential antimalarials 
Compounds showing activity against T. brucei are often found to show activity 
against the causative agent of Malaria, and vice versa.46,63,74,98,115,189 For this reason, 
as well as ready access to antimalarial testing, all of the compounds synthesised in 
this study were also analysed for their antimalarial activity. 
9.1 Malaria 
Malaria is a parasitic disease which is caused by infection of red blood cells by 
parasites belonging to the genus Plasmodium, which is spread from person to person 
via the bite of female mosquitoes. In 2015, it was estimated that the number of cases 
of malaria was 214 million resulting in 438,000 deaths. There are five species of 
plasmodium which cause malaria. Of these, Plasmodium falciparum, occurring 
mainly in Africa, is the most prevalent and is responsible for the most deaths.190 
Initial symptoms of malaria are nonspecific and include headache, muscle and joint 
ache fatigue, followed by fever and vomiting.191 When prompt treatment is 
administered full recovery is expected, however if treatment is delayed progression 
to severe malaria will occur which usually takes days but can occur within hours. 
Severe malaria is fatal in the majority of cases.192 Artemisinin combination therapies 
(ACTs) are used to treat Malaria. ACTs are a combination of a derivative of the 
natural product artemisinin and a quinoline or aminoalcohol partner drug. The 
artemisinin derivative clears parasites from the blood while the main role of the 
partner drug is to provide protection against development of resistance to the 
artemisinin derivatives. There are currently five ACTs recommended for the 
treatment of Malaria.192,193 Resistance in recent years to many of the current 
antimalarial drugs means new drugs are urgently needed.194 This has led to a huge 
amount of research being undertaken into new antimalarial lead compounds.193,195–197 
There are currently a number of new molecules undergoing different stage clinical 
trials for malaria treatment.198 Four of the most promising new molecules currently 
undergoing clinical trials are a novel trioxolane OZ439 232,199 spiroindolone 
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KAE609 233,200–202 imidazolopiperazine KAF156 234,203 and triazolopyrimidine 


















9.2 Antimalarial activity of derivatives substituted at 
the phenol  
All of the derivatives synthesised were also evaluated for their in vitro activity 
against two strains of P. falciparum; TM4/8.2 (a wild-type drug sensitive strain), and 
K1CB1 (a multidrug resistant strain). 
9.2.1 Benzyl substituents, cyclohexyl substituents, and N-
heterocycles 
Derivatives of isoquinoline 86 showed some activity against both strains of P. 
falciparum when substituted at the phenol. The benzyl substituted derivative 87 
showed activity in the micromolar range against both strains, with slightly better 
activity against wildtype P. falciparum. Adding an electron withdrawing nitro group 
to the benzyl ring (96) increases the activity against both strains of P. falciparum 
with IC50 values for both in the low micromolar range. Substitution of the phenol 
with a methoxy (97), bromo (98 and 99), or methyl (100 and 101) substituted benzyl 
group resulted in comparable or slightly reduced activity as compared to the 
unsubstituted benzyl derivative. Increasing the chain length between the phenolic 
oxygen and the phenyl group to two carbons in length (103) did not improve the 
activity against P. falciparum. Interestingly increasing the chain length to three 
carbons (105) improved the activity against the multidrug resistant strain by 
twentyfold as compared to benzyl substituted derivative 87, while the activity against 
the wildtype strain was unchanged. The two cyclohexyl derivatives (88 and 108) 
showed some activity, but again they were comparable or less active than the benzyl 
substituted derivative. The derivatives functionalised with an N-heterocycle (111 to 
127) were mostly inactive. Exceptions being the pyridine derivative 112, which 
showed mild activity, and nitroimidazole derivative 126, which interestingly showed 
good activity while contrastingly nitroimidazole derivative 127 was inactive. 
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>100 >100 >100 
 
87 
5.2 ± 1.0 15.1 ± 3.9 >100 
 
96 
1.6 ± 0.7 3.0 ± 0.3 >50 
 
97 
7.3 ± 1.4 14.9 ± 2.6 >50 
 
98 
14.4 ± 3.6 5.4 ± 1.2 37.0 ± 6.0 
 
99 
12.2 ± 1.6 5.2 ± 0.8 60.3 ± 34.8 
 
100 
13.7 ± 1.0 10.3 ± 2.2 >50 
 
101 
27.8 ± 3.1 11.0 ± 2.6 >100 
 
103 
23.8 ± 1.3 14.9 ±2.6 >50 
 
105 
4.3 ± 0.4 0.7 ± 0.1 >50 
 
88 
















16.9 ± 1.8 6.6 ± 1.5 >50 
 
111 
>50 >50 >50 
 
112 
25.0 ± 3.3 21.7 ± 6.4 >50 
 
118 
>100 >100 >100 
 
119 
59.0 ± 9.4 >100 >100 
 
126 
5.0 ± 1.7 13.7 ± 6.5 >50 
 
127 
>50 >50 >50 
9.2.2 Biphenyl and diphenyl ether substituents 
Derivatives of isoquinoline 86 substituted at the phenol with larger biphenyl and 
diaryl ether groups also showed some activity against both strains of P. falciparum. 
Contrastingly to the T. b. rhodesiense activities, derivative 129 substituted at the 
phenol with a biphenyl methyl group showed decreased activity as compared to the 
benzyl substituted derivative 87. All of the substituted biphenyl derivatives (130 to 
133) showed similar activity, while methoxy substituted and chloro substituted 
derivatives 136 and 132 showed slightly increased activity. The p-terphenyl 
derivative 140 showed good activity in the low micromolar range against both strains 
of P. falciparum, however it is highly cytotoxic, while the naphthyl derivative 142 
showed comparable activity to the biphenyl derivatives. Both of the diaryl ether 
derivatives 148 and 149 showed good activity against both strains. Derivative 148 
was approximately fivefold more active against the wildtype strain than the multi 
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drug resistant strain. Derivative 149 showed comparable activity for both strains with 
an IC50 of ~3 μM. 















24.5 ± 0.3 21.3 ± 2.9 23.0 ± 2.1 
 
130 
17.6 ± 1.1 17.0 ± 2.6 10.8 ± 4.2 
 
131 
17.5 ± 4.6 18.3 ± 1.4 25.5 ± 3.0 
 
132 
7.4 ± 0.5 17.6 ± 0.8 24.1 ± 4.3 
 
133 
20.9 ± 2.4 20.1 ± 0.9 33.8 ± 16.7 
 
136 
7.0 ± 0.8 6.3 ± 1.8 24.3 ± 3.8 
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3.7 ± 0.2 3.6 ± 0.9 0.28 ± 0.04 
 
142 
7.4 ± 1.1 7.5 ± 1.0 0.31 ± 0.01 
 
148 
3.6 ± 1.0 16.2 ± 5.6 3.4 ± 0.8 
 
149 
2.7 ± 1.0 2.9 ± 1.5 5.6 ± 0.1 
9.2.3 Other phenolic substituents 
In terms of other phenolic substituents, TBDPS substituted derivative 152 showed 
good activity against both strains of P. falciparum with IC50 values of ~3 μM, which 
is comparable to the activity of this derivative against T. b. rhodesiense. Dodecyl 
derivative 155 showed only mild activity against both strains, and was not selective 
for P. falciparum over mammalian cells. 
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52.2 ± 1.1 23.9 ± 2.1 >100 
 
151 
41.5 ± 5.9 43.1 ± 5.0 87.9 ± 7.1 
 
152 
2.7 ± 1.5 3.2 ± 0.5 19.1 ± 0.6 
 
153 
>50 >50 >50 
 
154 
>50 >50 >50 
 
155 
19.8 ± 1.6 19.4 ± 4.4 18.3 ± 3.7 
 
157 




9.2.4 Derivatives of isoquinoline 90 
Derivatives of isoquinoline 90 substituted at the phenol with a cyclohexylethyl 160 
or biphenylmethyl group 161 showed activity against both strains of P. falciparum. 
The cyclohexyl derivative 160 showed good activity against the multi drug resistant 
strain with an IC50 value of ~3 μM. 
















>100 >100 >100 
 
159 
72.0 ± 13.6 19.9 ± 3.2 >100 
 
160 
20.2 ± 3.2 3.2 ± 0.9 62.7 ± 9.1 
 
161 
21.2 ± 4.3 18.8 ± 6.0 >50 
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9.3 Antimalarial activity of derivatives modified at the 
benzylic alcohol 
9.3.1 Substitution of the benzylic alcohol 
Derivatives substituted at the benzylic alcohol with a methyl (162) or benzyl group 
(166) were inactive against P. falciparum. However, substitution with a 
biphenylmethyl group (167) gave a derivative with good activity against the wildtype 
strain of P. falciparum and mild activity against the multi drug resistant strain. The 
cyclohexylethyl derivative 168 showed mild activity against both strains. 
Disubstituted derivatives 169 to 172, derivatives substituted at both the phenol and 
benzylic alcohol, showed mild activity against both strains of P. falciparum, however 
they were also significantly cytotoxic. 
Table 37 In vitro activity against P. falciparum of benzylic alcohol substituted 
derivatives. 
 














162 H  >100 >100 >100 
166 H 
 
>50 >50 >50 
167 H 
 
2.2 ± 0.2 27.1 ± 8.1 >50 
168 H 
 
19.6 ± 1.6 28.7 ± 13.1 >50 
169 
  
19.4 ± 4.5 17.1 ± 4.3 23.5 ± 1.4 
147 
 
















>10 >10 >10 
172 
  
6.7 ± 1.6 12.8 ± 0.9 23.6 ± 1.5 
9.3.2 Removal of the benzylic alcohol and substitution of the 
phenol 
Derivatives substituted at the phenol with the benzylic alcohol removed showed mild 
activity. The benzyl substituted derivative 176 was significantly less active against P. 
falciparum than the corresponding derivative with the benzyl alcohol intact (87). 
However, cyclohexylethyl derivative 178 showed comparable activity to its 
corresponding derivative with the benzyl alcohol still intact (108). These conflicting 
























57.9 ± 8.4 26.7 ± 3.6 >100 
 
177 
>20 >20 16.5 ± 2.8 
 
178 
13.5 ± 2.8 14.0 ± 3.8 25.0 ± 3.9 
 
179 




9.3.3 Changing the stereochemistry and Grignard product 
Derivatives 180 and 181 showed almost identical activity against P. falciparum, 
suggesting the stereochemistry of the benzylic alcohol is not important to P. 
falciparum inhibition. However, both of these derivatives showed good activity in 
the low micromolar range against both strains of P. falciparum, although they are 
both significantly cytotoxic. Derivative 188 also showed good activity against both 
strains of P. falciparum with lower cytotoxicity.  
















3.0 ± 0.7 2.3 ± 0.6 10.5 ± 4.1 
 
181 
2.8 ± 0.5 2.8 ± 0.4 12.9 ± 2.3 
 
188 




9.4 Antimalarial activity of derivatives modified at 
position 6 
Derivatives substituted directly at the aromatic ring at position 6 (190 to 192) showed 
mild activity. Derivative 191 has improved activity as compared to the phenol 
substituted biphenylmethyl derivative 129, however it is not evident from these 
results if the increase in rigidity of these compounds is having an effect on the 
inhibition of P. falciparum. The aryl ether derivatives 195 and 197 did not show any 
significant activity against P. falciparum.  















26.5 ± 2.9 30.9 ± 13.0 >50 
 
191 
5.7 ± 1.8 10.1 ± 2.0 15.6 ± 0.3 
 
192 
21.6 ± 1.2 21.4 ± 1.4 24.1 ± 2.2 
 
195 
>100 >100 >100 
 
197 




9.5 Antimalarial activity of derivatives modified at the 
nitrogen atom 
9.5.1 Substitution of the nitrogen atom 
Derivatives substituted at the nitrogen atom with larger groups showed some activity, 
with biphenyl substituted derivative 205 showing mild activity against both strains of 
P. falciparum. However, derivatives substituted at the nitrogen atom with smaller 
groups such as ethyl and propyl derivatives 202 and 203 were inactive, while 
substitution with a somewhat larger benzyl group (204) showed very mild activity to 
the multi drug resistant strain. Derivatives of the secondary amine substituted at the 
phenol (210 to 212) showed mild activity, however there is no improvement in 
activity as compared to derivatives with an N-methyl group in the scaffold. 
Derivatives 213 and 214 which are substituted at both the phenol and the nitrogen 
atom showed good activity against both strains of P. falciparum with IC50 values of 
~4 μM and reasonable selectivity over mammalian cells. 
Table 41 In vitro activity against P. falciparum of derivatives modified at the nitrogen 
atom. 
 














200 H H >100 >100 >100 
202 H  >100 >100 >100 
203 H  >100 >100 >100 
204 H 
 
>50 40.2 ± 6.3 >100 
152 
 
















19.0 ± 2.4 13.7 ± 1.7 >50 
210 
 
H 27.9 ± 10.1 18.3 ± 3.5 >50 
211 
 
H 7.7 ± 0.4 14.4 ± 2.3 20.8 ± 0.8 
212 
 
H 19.8 ± 0.9 4.8 ± 1.7 >50 
213 
  




3.9 ± 0.4 3.4 ± 0.3 14.8 ± 5.5 
9.5.2 Derivatives without a nitrogen atom 
Derivatives without a nitrogen atom in the core scaffold showed no activity against 
P. falciparum, except derivative 217 which showed good activity against wildtype P. 
falciparum and no activity against multidrug resistant P. falciparum. This result is 
inconsistent with what has been seen from other derivatives tested against P. 



















3.3 ± 0.22 >100 >100 
 
218 
>100 >100 39.0 ± 10.4 
 
219 
>100 >100 >100 
9.6 Antimalarial activity of derivatives modified at 
position 1 
Derivatives substituted at position 1 showed similar trends in activity against P. 
falciparum as compared to activity against T. b. rhodesiense, with most derivatives 
showing no activity. However, both isomers of cinnamyl derivative 223 showed mild 
activity against both strains of P. falciparum, with good selectivity over mammalian 
cells. The undecyl derivatives 225 showed good activity against both strains of P. 
falciparum with reasonable selectivity over mammalian cells. 
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A >100 60.6 ± 25.9 >100 
B >100 73.8 ± 7.2 >100 
 
221 
A >100 >100 >100 
B >100 >100 >100 
 
222 
A >50 >50 >50 
B >50 >50 >50 
 
223 
A 24.2 ± 0.7 19.7 ± 2.0 >50 
B 12.0 ± 1.4 19.7 ± 1.8 >50 
 
224 
A >100 >100 >100 
 
225 




9.6.1 Substitution of the phenol 
Derivatives with a nitrophenyl group at position 1 and substituted at the phenol (228 
and 229) showed activity against both strains of P. falciparum with better activity 
against the wildtype strain than the multi drug resistant strain. Derivatives substituted 
at position 1 with an undecyl group and substituted at the phenol (230 and 231) 
showed good activity against both strains of P. falciparum, however there was no 
selectivity over mammalian cells. 
Table 44 In vitro activity against P. falciparum of derivatives substituted at position 1 
and the phenol. 
 














A   





9.9 ± 1.3 22.1 ± 3.7 37.6 ± 4.1 
230 
A+B  




 16.6 ± 4.9 2.9 ± 0.8 3.6 ±0.7 
 
In conclusion, the derivatives above show potential to be developed into antimalarial 
compounds, with many derivatives showing good inhibition of both wildtype and 
multidrug resistant P. falciparum in the low micromolar range and with good 
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selectivity over mammalian cells. The most promising derivatives are p-nitrobenzyl 
substituted phenol derivative 96 which showed activity against wildtype P. 
falciparum and multidrug resistant P. falciparum with IC50 values of 1.6 ± 0.7 μM 
and 3.0 ± 0.3 μM respectively, and phenylpropyl phenol substituted derivative 105 
which showed activity against wildtype P. falciparum and multidrug resistant P. 
falciparum with IC50 values of 4.3 ±0.4 μM and 0.7 ± 0.1 μM respectively. From this 
study there is insufficient data to develop an accurate SAR for this scaffold against P. 




10 Future work and conclusion 
10.1 Future work 
The five derivatives mentioned above (Figure 64) provide good leads for further 
optimisation of this scaffold. Looking at these derivatives, the most obvious path is 
to start by synthesising derivatives of compounds 191, 132, 225, and 142 without the 
N-methyl group to give a secondary amine similar to compound 211, which would 
give derivatives 236 to 239 (see Figure 66). From the activities of the above 
derivatives and looking at the SAR it would be expected that doing this would give 









Figure 66 Four most obvious derivatives to synthesise in the future. 
From this study a number of areas that could be advantageous to explore in the future 
have been identified. These are discussed below. It was reported previously that 
phenolic substituents containing nitrogen atoms were generally not tolerated, 
however oxygen atoms were tolerated. This suggests the possibility of an 
unfavourable interaction between the nitrogen atom which would be charged at 
physiological pH and a positively charged residue in the active site. Therefore 
exploration of derivatives with a negatively charged residue, such as a carboxylic 
158 
 
acid, attached to the scaffold at the phenolic position could prove to be interesting. 
Another area to be explored more thoroughly in the future is the oxidation of the 
benzylic alcohol. Oxidation of the benzylic alcohol to give the ketone was achieved, 
although isolation of a pure product was not. The ketone would provide access to 
many different ways of functionalising the core scaffold, and indeed it was shown 
that Grignard chemistry is possible. Optimisation of reaction conditions as well as 
isolation and purification methods are needed to satisfactorily synthesise the ketone 
and isolate it with reasonable purity. Both the Oppenauer and Jones oxidation 
methods showed potential and should be revisited. Inversion of the stereochemistry 
of the benzylic alcohol has been described, synthesis of both the R and S benzoates 
was achieved. It was shown that the benzylic alcohol plays little or no part in anti-
HAT activity and there was no difference in activity between the R and S benzoates 
suggesting that the stereochemistry of the benzylic alcohol was not important. 
However, hydrolysis of both of the benzoates to give the R and S benzylic alcohols 
would provide another confirmation of the lack of importance of the stereochemistry 
of the benzylic alcohol. Of the derivatives substituted at position 1 of the 
isoquinoline scaffold only those substituted with larger groups, such as a cinnamyl 
and undecyl group, showed any anti-HAT activity. It would be interesting to explore 
the addition of different derivatives at this position and evaluate if addition of some 
larger aromatic groups for example would improve the anti-HAT activity. 
Substitution of the phenol of the cinnamyl derivative would also be interesting to 
explore. Establishing collaborations in order to try and determine the target of these 
types of molecules and how they work in a mechanistic sense would also be very 
valuable to the progression of this work in the future. 
10.2 Testing at other labs 
All of the biological results reported in this thesis were obtained by the BIOTEC 
Medical Molecular Biology Research Unit in Thailand. However, biological testing 
of some compounds was also carried out by two other labs. Details and results can be 




In conclusion, over 90 compounds were synthesised based around a phenylephrine 
derived tetrahydroisoquinoline scaffold. These compounds were evaluated for their 
activity against T. b. rhodesiense and two strains of P. falciparum, as well as their 
cytotoxicity to mammalian cells. From this study a structure activity relationship was 
developed between T. b. rhodesiense and this tetrahydroisoquinoline scaffold. Five 
derivatives, with sub micromolar activity against T. b. rhodesiense and good 
selectivity against mammalian cells, were identified as being promising leads for 
further optimisation. This scaffold was also shown to have potential to be explored as 
an antimalarial compound, with two derivatives identified with good activity against 





11.1 General methods 
All reactions were conducted under a positive pressure of nitrogen. (4R)-4,6-
Dihydroxy-N-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride (86) was obtained 
from Epichem Pty Ltd. All other materials were obtained from commercial sources 
unless otherwise stated. Dry solvents were prepared according to Armarego and 
Chai.205 Compounds were purified via column chromatography on Davisil silica gel 
40-63 μm. Melting points were determined using an Electrothermal 1A9100 digital 
melting point apparatus. NMR spectra were recorded on a Bruker AVANCEIII 400 
MHz spectrometer (1H NMR 400 MHz, 13C NMR 100 MHz). All NMR spectra were 
referenced to residual proton solvent signal. Multiplicity was assigned as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, qu = quintet m = multiplet. High 
resolution mass spectrometry (HRMS) ESI measurements were recorded in positive 
ionisation mode on a LQT orbitrap XL instrument at Curtin University. Elemental 
analysis was carried out at Curtin University. Optical rotations were measured using 
a Rudolph research analytical autopol I polarimeter. Chiral HPLC was performed on 
a Phenomenex Lux Amylose-2 column, 150mm x 4.6mm, 5 micron, and the flow 
rate was 0.6mL/min with a 5uL injection. The conditions were isocratic, run with 
30% isopropyl alcohol containing 0.1% diethylamine and 70% hexane. Microwave 
reactions were carried out using a Biotage Initiator EXP machine. All exact masses 
were calculated using chemdraw, the exact mass is calculated bases on the most 
common isotope for each element. 
 
Workup Method 1: The reaction mixture was concentrated under reduced pressure, 
diluted with 5% sodium bicarbonate solution, and extracted three times with ethyl 
acetate. The ethyl acetate fractions were combined, dried over magnesium sulfate, 
and concentrated under reduced pressure to afford the crude product.  
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Workup Method 2: The reaction mixture was concentrated under reduced pressure, 
diluted with 5% sodium bicarbonate solution, and extracted three times with 10% 
isopropyl alcohol in ethyl acetate.  
Workup Method 3: The reaction mixture was diluted with ethyl acetate and washed 
with water. The ethyl acetate fraction was dried over magnesium sulfate, and 
concentrated under reduced pressure to afford the crude product. 
11.2 Biological Methods 
Biological testing was carried out by Sumalee Kamchonwongpaisan, Jutharat 
Pengon, and Roonglawan Rattanajak from BIOTEC Medical Molecular Biology 
Research Unit, National Science and Technology Development Agency, 113 
Thailand Science Park, Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum 
Thani 12120, Thailand. A series of standard antifolates (pyrimethamine, cycloguanil, 
and WR99210, were used as positive controls for T. b. rhodesiense and P. falciparum 
testing. Ellipticine was used as a positive control for cytotoxicity. 
11.2.1 Trypanosome culture and testing compounds in vitro 
Trypanosome brucei rhodesiense (STB900) was maintained continuously in 
MEM/EBSS medium supplemented with 3 g/L sodium bicarbonate, 4.5 g/L glucose, 
25 mM HEPES, pH 7.3, 0.05 mM bathocuproinedisulfonic acid disodium salt, 1.5 
mM L-cysteine, 1 mM hypoxanthine, 0.16 mM thymidine, 1 mM sodium pyruvate, 
0.2 mM 2-mercaptoethanol, 1% MEM non-essential amino acid, and 15% heated 
fetal bovine serum, in a 5% CO2 incubator. To assay anti-T. b. rhodesiense activity, a 
modified reported protocol206 was used. Briefly, 2 x 104 trypanosome cells in 175 μL 
culture media /well were incubated with 25 μL of varying concentrations of each 
compound in a 96-well plate under the same culture condition. The compounds were 
dissolved in DMSO and the final concentration of DMSO in each well was 0.1% 
which causes no effect on parasite viability. Following 72-hour incubation, 20 µL 
Alamar Blue (a resazurin solution) was added in each well. The reaction was further 
incubated at 37°C, 5% CO2 for 3 hours to allow irreversible reduction of resazurin 
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(violet colour) to resorufin (pink colour) by viable trypanosome cells. The 
fluorescence signals were measured by a spectrofluorometer at ex530/em585 nm. 
The results were read as concentration of each compound that exhibit 50% growth 
inhibition (IC50) from the dose-response curve established from the fluorescence 
signals at each concentration of compounds.  
11.2.2 Parasite Culture and Antimalarial Testing in Vitro. 
Two P. falciparum strains, TM4/8.2 (wild-type drug sensitive strain) and K1CB1 
(multidrug resistant strain) were used in this study. These were generous gifts from 
S. Thaithong, Department of Biology, Faculty of Science, Chulalongkorn University. 
The parasites were maintained continuously in human erythrocytes at 37°C under 3% 
CO2 in RPMI 1640 culture media (Gibco, USA) supplemented with 25 mM HEPES 
(Sigma), pH 7.4, 2 g/L NaHCO3 and 10% human serum. In vitro antimalarial activity 
was determined by using the [3H] hypoxanthine incorporation method. 1.5% cell 
suspension of parasitised erythrocytes with 1% parasitemia (200 µL) in each well 
was incubated with varying concentration of compound (25 µL) under the same 
culture conditions for 24 h. Parasite survival was determined by [3H] hypoxanthine 
incorporation assay. Briefly, 25 µL of 0.5 µCi [3H] hypoxanthine was added to each 
well, and the mixture was further incubated for 18-20 h. Then the cells were lysed 
with water and the parasite DNA was harvested onto 96-well microplates with built-
in glass fiber filters (Unifilter TM plates, Packard, USA). The filters in the plates 
were air-dried, and then 22 µL of liquid scintillation fluid (Microscint, Packard) was 
added. The radioactivity on the filters was then measured using a microplate 
scintillation counter (TopCount, Packard, USA). The IC50 of each compound was 
determined from dose-response curve.207  
11.2.3 Cytotoxicity testing by sulforhodamine B (SRB) 
colorimetric assay. 
African green monkey kidney fibroblast (Vero cells) and human epidermoid 
carcinoma (KB) cells were obtained from the bioassay laboratory, BIOTEC, 
NSTDA. Vero cells were maintained continuously in MEM/EBSS medium 
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supplemented with 10% heated fetal bovine serum, 2.2 g/L sodium bicarbonate, and 
100 mM sodium pyruvate. KB cells were maintained continuously in DMEM/low 
glucose medium supplemented with 10% heated fetal bovine serum, 3.7 g/L sodium 
bicarbonate, and 1% non-essential amino acid. Cytotoxicity was determined by 
sulforhodamine B (SRB) assay. Briefly, 1.9 x 104 cells were incubated with test 
compounds at 37°C, 5% CO2 for 72 hours. Then, the cells were fixed with 10% 
trichloroacetic acid at 4°C for 45 minutes, washed with water and dried at room 
temperature overnight. Then the plate was stained with 0.057% (W/V) 
sulforhodamine B, washed 4 times with 1% (V/V) acetic acid, and left dry at room 
temperature overnight. Finally, 10X tris-base was added to each well to dissolve 
protein-bound dye. The optical density was determined by spectrophotometer at 
wavelength 510 nm. The IC50 value of each compound was determined from the 
dose-response curve.208 
11.3 X-ray Crystallography 
The crystal structure of compound 227 was determined by X-ray diffraction 
methods. Intensity data and cell parameters were recorded at 100(2) K at the 
ELETTRA Synchrotron Light Source (CNR Trieste, strada statale 14, Area Science 
Park, 34149, Basovizza, Trieste, Italy). The raw frame data were processed using the 
program package CrysAlisPro 1.171.38.41.209 The structure was solved by Direct 
Methods using the SIR97 program210 and refined on Fo
2 by full-matrix least-squares 
procedures, using the SHELXL-2014/7 program 211 in the WinGX suite 
v.2014.1.212,213 All non-hydrogen atoms were refined with anisotropic atomic 
displacements. The hydrogen atoms were included in the refinement at idealized 
geometry (C-H 0.95 Å) and refined “riding” on the corresponding parent atoms. The 
weighting scheme used in the last cycle of refinement was w = 1/ [σ2Fo
2 + (0.1020P)2 
+ 0.0528P], where P = (Fo
2 + 2Fc
2)/3. Crystal data and experimental details for data 
collection and structure refinement are reported in Appendix C.  
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11.4 Computational methods 
Computational studies were carried out by Professor Andrew Rohl at Curtin 
University. The NMR chemical shifts and 1H-1H coupling constants were computed 
using the Gaussian 09 software,214 utilising the recommended procedure of Bally and 
Rablen.215 Each structure/conformation was optimised at the B3LYP/6-31G(d) level 
in the gas phase. The isotropic magnetic shieldings, m, were calculated at this 
geometry at the WP04/cc-pVDZ level using the Gauge-Independent Atomic Orbital 
(GIAO) method in a chloroform implicit solvent. Chemical shifts were calculated by:
 δ = (31.844 – m) / 1.0205  
1H-1H Fermi contact terms were calculated at the B3LYP/6-31G(d,p)u+1s[H] level 
and these were multiplied by 0.9155 to yield the proton-proton coupling constants. 
11.5 Substitution of the phenol 
11.5.1 (R)-6-(Benzyloxy)-2-methyl-1,2,3,4-tetrahydroisoquinolin-
4-ol (87)  
 
87 
The isoquinoline hydrochloride 86 (0.502 g, 2.30 mmol) was added to a suspension 
of sodium hydride (60% dispersion in mineral oil, 0.204 g, 5.10 mmol) in anhydrous 
dimethylformamide and the mixture stirred at room temperature for 30 minutes. 
Benzyl bromide (305 μL, 2.60 mmol) was added and the reaction mixture stirred at 
room temperature for a further 24 hrs. The reaction was quenched with methanol (2 
mL) and then subjected to workup method 1. The resulting brown gummy solid was 
purified by column chromatography (5% methanol in dichloromethane) to afford the 
desired product as a pale orange gummy solid (0.363 g, 56%). 1H NMR (CDCl3) δ 
7.46-7.43 (2 H, m), 7.41-7.36 (2 H, m), 7.34-7.30 (1 H, m), 7.04 (1 H, d, J = 2.8 Hz), 
6.87 (1 H, dd, J = 8.4, 2.8 Hz), 6.80 (1 H, d, J = 8.4), 5.08 (2 H, s), 4.52 (1 H, t, J = 
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2.8 Hz), 3.12 (1 H, d, J = 14.4 Hz), 3.02 (1 H, d, J = 14.4), 2.93 (1 H, ddd, J = 11.8, 
2.8, 1.0 Hz), 2.44 (1 H, dd, J = 11.8, 2.8 Hz), 2.29 (3 H, s); 13C NMR (CDCl3) δ 
157.7, 137.4, 137.2, 128.7, 128.1, 127.6, 127.5, 127.2, 115.6, 114.4, 70.2, 67.3, 60.5, 
57.1, 46.1; HRMS m/z: [M+H]+ Calcd for C17H20NO2 270.1489; Found 270.1489. 
Also isolated was the disubstituted product (169) as a pale orange gummy solid 
(0.140 g, 18%). 1H NMR (CDCl3) δ 7.46 -7.27 (10 H, m), 7.01 (1 H, d, J = 2.6 Hz), 
6.98 (1 H, d, J = 8.4 Hz), 6.87 (1 H, dd, J = 8.4, 2.6 Hz), 5.08- 4.95 (2 H, m), 4.78- 
4.57 (3 H, m), 3.60 (1 H, d, J = 14.6 Hz), 3.48 (1 H, d, J = 14.6 Hz), 2.89 (1 H, ddd, 
J = 11.6, 4.7, 0.9 Hz), 2.79 (1 H, dd, J = 11.6, 6.0 Hz), 2.48 (3 H, s); 13C NMR 
(CDCl3) δ 157.4, 138.7, 137.1, 135.4, 128.6, 128.4, 127.9, 127.9, 127.6, 127.5, 
127.1, 115.1, 113.9, 73.6, 70.9, 70.1, 57.4, 57.2, 46.2 (note some peaks coincident); 
HRMS m/z: [M+H]+ Calcd for C24H26NO2 360.1958; Found 360.1951. 
11.5.2 (R)-2-Methyl-6-((4-nitrobenzyl)oxy)-1,2,3,4-
tetrahydroisoquinolin-4-ol (96)  
 
96 
The isoquinoline hydrochloride 86 (0.505 g, 2.34 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.247 g, 6.18 mmol) and 4-nitrobenzyl 
bromide (0.553 g, 2.56 mmol) as described for 87 and then subjected to workup 
method 1. The resulting orange solid was purified by column chromatography (15% 
methanol in ethyl acetate) to afford the desired product as a pale yellow solid (0.425 
g, 58%). m.p. 155.0 - 160°C; 1H NMR (CDCl3) δ 8.25-8.22 (2 H, m), 7.62-7.58 (2 H, 
m), 7.01 (1 H, d, J = 2.8 Hz), 6.91 (1 H, d, J = 8.4 Hz), 8.86 (1 H, dd, J = 8.4, 2.8 
Hz), 5.17 (2 H, s), 4.54 (1 H, t, J = 2.8 Hz), 3.41 (1 H, d, J = 14.8 Hz), 3.15 (1 H, d, 
J = 14.8 Hz), 2.94 (1 H, ddd, J = 11.6, 2.8, 1.0 Hz), 2.52 (1 H, dd, J = 11.6, 2.8), 
2.37 (3 H, s); 13C NMR (CDCl3) δ 157.1, 147.7, 144.7, 137.7, 127.72, 127.69, 124.0, 
115.6, 114.4, 68.9, 67.3, 60.4, 57.2, 46.1 (note some peaks coincident); HRMS m/z: 




tetrahydroisoquinolin-4-ol (97)  
 
97 
The isoquinoline hydrochloride 86 (0.430 g, 2.73 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.240 g, 6.08 mol) and 1-(chloromethyl)-4-
methoxybenzene 240 (0.500 g, 2.31 mmol) as described for 87 and then subjected to 
workup method 1. The resulting orange gummy solid was purified by column 
chromatography (40% methanol in ethyl acetate) to afford the desired product as an 
orange gummy solid (0.20 g, 29%). 1H NMR (CDCl3) δ 7.37-7.34 (2 H, m), 7.02 (1 
H, d, J = 2.4 Hz), 6.93-6.89 (2 H, m), 6.85 (1 H, dd, J = 8.4, 2.4 Hz), 6.77 (1 H, d, J 
= 8.4 Hz), 4.99 (2 H, s), 4.52 (1 H, t, J = 2.6 Hz), 3.80 (3 H, s), 3.05 (1 H, d, J = 
14.6 Hz), 2.99 (1 H, d, J = 14.6 Hz), 2.93 (1 H, dd, J = 11.8, 2.6 Hz), 2.43 (1 H, dd, 
J = 12.0, 2.6 Hz), 2.28 (3 H, s); 13C NMR (CDCl3) δ 159.5, 157.5, 137.2, 129.2, 
129.1, 127.6, 127.0, 115.6, 114.2, 114.1, 69.9, 67.0, 60.5, 56.7, 55.4, 46.1; HRMS 
m/z: [M+H]+ Calcd for C18H22NO3 300.1594; Found 300.1595. See pg. 240 for 
details on the synthesis of 1-(chloromethyl)-4-methoxybenzene 240. 
11.5.4 (R)-6-((4-Bromobenzyl)oxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-4-ol (98)  
 
98 
The isoquinoline hydrochloride 86 (1.04 g, 4.83 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.430 g, 10.6 mmol) and 4-bromobenzyl 
bromide (1.33 g, 5.31 mmol) as described for 87 and then subjected to workup 
method 1. The resulting brown gummy solid was purified by column 
chromatography (10% methanol in dichloromethane) to afford the desired product as 
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a brown solid (1.01 g, 60%). m.p. 127 - 129°C; 1H NMR (CDCl3) δ 7.52-7.49 (2 H, 
m), 7.32-7.29 (2 H, m), 7.00 (1 H, d, J = 2.6 Hz), 6.88 (1 H, d, J = 8.5 Hz), 6.84 (1 
H, dd, J = 8.5, 2.6 Hz), 5.02 (2 H, s), 4.54 (1 H, t, J = 2.8 Hz), 3.43 (1 H, d, J = 14.5 
Hz), 3.15 (1 H, d, J = 14.5 Hz), 2.93 (1 H, ddd, J = 11.7, 2.8, 1.2 Hz), 2.51 (1 H, dd, 
J = 11.7, 2.8 Hz), 2.38 (3 H, s); 13C NMR (CDCl3) δ 157.4, 137.6, 136.2, 131.9, 
129.2, 127.6, 127.6, 122.0, 115.6, 114.4, 69.4, 67.4, 60.5, 57.2, 46.2; Anal. Calcd for 





The isoquinoline hydrochloride 86 (1.00 g, 4.64 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.420 g, 10.4 mmol) and 3-bromobenzyl 
bromide (1.260 g, 5.100 mmol) as described for 87 and then subjected to workup 
method 1. The resulting orange gummy solid was purified by column 
chromatography (2% methanol, 1% triethylamine in dichloromethane) to afford the 
desired product as a waxy orange solid (1.07 g, 66%). m.p. 64 - 75°C; 1H NMR 
(CDCl3) δ 7.60 (1 H, t, J = 1.5 Hz), 7.49-7.47 (1 H, m), 7.35 (1 H, dd, J = 7.8, 0.5 
Hz), 7.23 (1 H, d, J = 7.8 Hz), 7.00 (1 H, d, J = 2.6 Hz), 6.85 (1 H, dd, J = 8.4, 2.6 
Hz), 6.79 (1 H, d, J = 8.4 Hz), 5.04 (2 H, s), 4.50 (1 H, t, J = 2.7 Hz), 3.06 (1 H, d, J 
= 14.7 Hz), 3.00 (1 H, d, J = 14.7 Hz), 2.92 (1 H, dd, J = 11.8, 1.8 Hz), 2.42 (1 H, 
dd, J = 11.8, 2.7 Hz), 2.27 (3 H, s); 13C NMR (CDCl3) δ 157.3, 139.6, 137.5, 131.1, 
130.4, 130.3, 127.7, 127.6, 126.0, 122.8, 115.6, 114.3, 69.2, 67.2, 60.5, 57.0, 46.1; 




tetrahydroisoquinolin-4-ol (100)  
 
100 
The isoquinoline hydrochloride 86 (0.505 g, 2.34 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.230 g, 5.80 mmol) and 3-methylbenzyl 
chloride 241 (0.372 g, 2.65 mmol) as described for 87 and then subjected to workup 
method 1. The resulting brown gummy solid was purified by column 
chromatography (10% methanol in ethyl acetate) to afford the desired product as a 
colourless gummy solid (0.285 g, 43%). 1H NMR (CDCl3) δ 7.29-7.22 (3 H, m), 
7.15-7.12 (1 H, m), 7.05 (1 H, d, J = 2.8 Hz), 6.87 (1 H, dd, J = 8.4, 2.8 Hz), 6.75 (1 
H, d, J = 8.4 Hz), 5.04 (2 H, s), 4.51 (1 H, t, J = 3.0 Hz), 2.95 (2 H, s), 2.92 (1 H, dd, 
J = 12.0, 3.0 Hz), 2.40 (1 H, dd, J = 12.0, 3.0 Hz), 2.38 (3 H, s), 2.24 (3 H, s); 13C 
NMR (CDCl3) δ 157.5, 138.3, 137.2, 137.0, 128.8, 128.5, 128.2, 127.6, 127.0, 124.6, 
115.5, 114.2, 70.1, 66.9, 60.5, 56.6, 46.0, 21.5; HRMS m/z: [M+H]+ Calcd for 
C18H22NO2 284.1645; Found 284.1637. See pg. 241 for details on the synthesis of 3-
methylbenzyl chloride 241. 
11.5.7 (R)-2-Methyl-6-((2-methylbenzyl)oxy)-1,2,3,4-
tetrahydroisoquinolin-4-ol (101)  
 
101 
The isoquinoline hydrochloride 86 (0.101 g, 0.460 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.040 g, 1.0 mmol) and 2-methylbenzyl 
chloride (67 μL, 0.51 mmol) as described for 87 and then subjected to workup 
method 1. The resulting brown gummy solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford the desired product as a 
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colourless gummy solid which slowly crystallised (0.085 g, 65%). m.p. 122 - 124°C; 
1H NMR (CDCl3) δ 7.43-7.41 (1 H, m), 7.28-7.20 (3 H, m), 7.09 (1 H, d, J = 2.4 
Hz), 6.72 (1 H, dd, J = 8.4, 2.4), 6.88 (1 H, d, J = 8.4), 5.07 (2 H, s), 4.58 (1 H, t, J = 
2.4 Hz), 3.31 (1 H, d, J = 14.6 Hz), 3.12 (1 H, d, J = 14.6 Hz), 2.98 (1 H, dd, J = 
11.8, 2.4 Hz), 2.51 (1 H, dd, J = 11.8, 2.4 Hz), 2.41 (3 H, s), 2.38 (3 H, s); 13C NMR 
(CDCl3) δ 157.8, 137.4, 136.8, 135.0, 130.5, 128.7, 128.4, 127.6, 127.1, 126.1, 
115.6, 114.2, 68.8, 67.3, 60.5, 57.0, 46.1, 19.0; Anal. Calcd for C18H21NO2: C, 76.29; 
H, 7.47; N 4.94. Found: C, 76.20; H, 7.35; N, 4.76; [α]D +2.9°(c 1.03, CH2Cl2). 
 
11.5.8 (R)-2-Methyl-6-phenethoxy-1,2,3,4-tetrahydroisoquinolin-
4-ol (103)  
 
103 
The isoquinoline hydrochloride 86 (0.506 g, 2.34 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.245 g, 6.35 mmol) and phenylethyl tosylate 
102 (0.722 g, 2.61 mmol) as described for 87 and then subjected to workup method 
1. The resulting pale orange solid was then recrystallised from petroleum spirits 60-
80 to afford the desired product as a white solid (0.268 g, 40%). m.p. 90 - 91°C; 1H 
NMR (CDCl3) δ 7.34-7.21 (5 H, m), 6.95 (1 H, d, J = 2.4 Hz), 6.88 (1 H, d, J = 8.4 
Hz), 6.80 (1 H, dd, J = 8.4, 2.4 Hz), 4.54 (1 H, t, J = 2.8 Hz), 4.21-4.15 (2 H, m), 
3.44 (1 H, d, J = 14.4), 3.17 (1 H, d, J = 14.4 Hz), 3.10 (2 H, t, J = 7.0 Hz), 2.96 (1 
H, ddd, J = 12.4, 2.8, 1.2 Hz), 2.53 (1 H, dd, J = 12.4, 2.8 Hz), 2.40 (3 H, s); 13C 
NMR (CDCl3) δ 157.8, 138.4, 137.3, 129.1, 128.6, 127.5, 126.7, 126.6, 115.4, 114.1, 
68.9, 67.3, 60.5, 57.1, 46.1, 35.9; Anal. Calcd for C18H21NO3: C, 76.29; H, 7.47; N 
4.94. Found: C, 76.14; H, 7.57; N, 4.86. See pg. 43 for details on the synthesis of 




tetrahydroisoquinolin-4-ol (105)  
 
105 
The isoquinoline hydrochloride 86 (0.102 g, 0.470 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.041 g, 0.47 mmol) and 3-
bromopropylbenzene (76 μL, 0.51 mmol) as described for 87 and then subjected to 
workup method 1. The resulting orange gummy solid was purified by column 
chromatography 5% methanol in dichloromethane) to afford the desired product as a 
pale orange gummy solid (0.081 g, 58%). 1H NMR (CDCl3) δ 7.32-7.28 (2 H, m), 
7.24-7.18 (3 H, m), 6.95 (1 H, d, J = 2.0 Hz), 6.83 (1 H, d, J = 8.4 Hz), 6.80 (1 H, 
dd, J = 8.4, 2.4 Hz), 4.53 (1 H, t, J = 2.8 Hz), 3.97 (2 H, t, J = 6.2 Hz), 3.16 (1 H, d, 
J = 14.4 Hz), 3.05 (1 H, d, J = 14.4), 2.94 (1 H, dd, J = 12.0, 2.8 Hz), 2.82 (2 H, t, J 
= 7.6 Hz), 2.46 (1 H, dd, J = 12.0, 2.8 Hz), 2.32 (3 H, s), 2.15-2.08 (2 H, m); 13C 
NMR (CDCl3) δ 157.9, 141.6, 137.3, 128.6, 128.5, 127.5, 126.8, 126.0, 115.3, 113.9, 
67.2, 67.1, 60.5, 56.9, 46.1, 32.2, 30.9; HRMS m/z: [M+H]+ Calcd for C19H24NO2 
298.1807; Found 298.1800. 
11.5.10 (R)-6-(Cyclohexylmethoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-4-ol (88)  
 
88 
The isoquinoline hydrochloride 86 (0.215 g, 1.00 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.088 g, 2.2 mmol) and cyclohexylmethyl 
bromide (0.15 mL, 1.1 mmol) as described for 87 and then subjected to workup 
method 1. The resulting brown gummy solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford the desired product as a 
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colourless gummy solid which slowly crystallised to give a white solid (0.135 g, 
49%). m.p. 94 - 96 °C; 1H NMR (CDCl3) δ 6.93 (1 H, d, J = 2.6 Hz), 6.90 (1 H, d, J 
= 8.4 Hz), 6.79 (1 H, dd, J = 8.4, 2.6 Hz), 4.55 (1 H, t, J = 2.8 Hz), 3.78-3.72 (2 H, 
m), 3.49 (1 H, d, J = 14.5 Hz), 3.17 (1 H, d, J = 14.5 Hz), 2.93 (1 H, ddd, J = 11.7, 
2.8, 1.3 Hz), 2.52 (1 H, dd, J = 11.7, 2.8 Hz), 2.40 (3 H, s), 1.89-1.83 (2 H, m), 1.79-
1.66 (4 H, m), 1.35-1.18 (3 H, m), 1.09-0.99 (2 H, m); 13C NMR (CDCl3) δ 158.3, 
137.4, 127.4, 126.8, 115.4, 113.9, 73.8, 67.6, 60.6, 57.3, 46.2, 37.9, 30.1, 26.7, 26.0; 
HRMS m/z: [M+H]+ Calcd for C17H26NO2 276.1958; Found 276.1955. 
11.5.11 (R)-6-(2-Cyclohexylethoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-4-ol (108)  
 
108 
The isoquinoline hydrochloride 86 (0.202 g, 0.940 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.092 g, 2.3 mmol) and 2-cyclohexylethyl 
tosylate 107 (0.289 g, 1.02 mmol) as described for 87 and then subjected to workup 
method 1. The resulting white solid was purified by recrystallisation (petroleum 
spirits 60-80) to afford the desired product as a white crystalline solid (0.157 g, 
58%). m.p. 108 - 110°C; 1H NMR (CDCl3) δ 6.95 (1 H, d, J = 2.8 Hz), 6.87 (1 H, d, 
J = 8.6 Hz), 6.79 (1 H, dd, J = 8.6, 2.8 Hz), 4.55 (1 H, t, J = 2.8 Hz), 3.99 (2 H, t, J 
= 6.8 Hz), 3.39 (1 H, d, J = 14.4 Hz), 3.15 (1 H, d, J = 14.4 Hz), 2.97 (1 H, ddd, J = 
11.8, 2.8, 1.1 Hz), 2.52 (1 H, dd, J = 11.8, 2.8 Hz), 2.39 (3 H, s), 1.79-1.65 (7 H, m), 
1.55-1.45 (1 H, m), 1.23-1.11 (3 H, m), 1.02-0.92 (2 H, m); 13C NMR (CDCl3) δ 
158.1, 137.2, 127.5, 126.4, 115.4, 113.9, 67.3, 66.2, 60.5, 57.1, 46.1, 36.8, 34.7, 33.5, 
33.4, 26.7; Anal. Calcd for C18H27NO2: C, 74.70; H, 9.40; N 4.84. Found: C, 74.74; 






carboxylate (109)  
 
109 
The isoquinoline hydrochloride 86 (0.500 g, 2.54 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.204 g, 5.10 mmol) and tert-butyl 4-
(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate 243 (0.746 g, 2.54 mmol) as 
described for 87 and then subjected to workup method 2. The resulting brown 
gummy solid was purified by column chromatography (5% methanol in 
dichloromethane) to afford the desired product as an orange gummy solid (0.276 g, 
32%). 1H NMR (CDCl3) δ 6.94 (1 H, d, J = 2.6 Hz), 6.90 (1 H, d, J = 8.4 Hz), 6.78 
(1 H, dd, J = 8.4, 2.6 Hz), 4.58 (1 H, br. s.), 4.26 - 4.01 (2 H, m), 3.79 (2 H, dd, J = 
6.5, 2.1 Hz), 3.54 (1 H, d, J = 14.5 Hz), 3.23 (1 H, d, J = 14.5 Hz), 2.99 (1 H, dd, J 
= 11.8, 2.4 Hz), 2.74 (2 H, t, J = 12.2 Hz), 2.58 (1 H, dd, J = 11.8, 2.4 Hz), 2.43 (3 
H, s), 2.01 - 1.87 (1 H, m), 1.83-1.78 (2 H, m), 1.46 (9 H, s), 1.32 - 1.17 (2 H, m); 
13C NMR (CDCl3) δ 158.1, 155.0, 137.2, 127.4, 126.0, 115.5, 114.0, 79.5, 72.6, 67.1, 
60.4, 57.1, 45.9, 36.3, 29.8, 29.0, 28.6; HRMS m/z: [M+H]+ Calcd for C21H33N2O4 






carboxylate (110)  
 
110 
The isoquinoline hydrochloride 86 (0.502 g, 5.10 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.204 g, 5.10 mmol) and tert-butyl 4-(3-
chloropropyl)piperazine-1-carboxylate 115 (0.670 g, 2.55 mmol) as described for 87 
and then subjected to workup method 2. The resulting brown gummy solid was 
purified by column chromatography (10% methanol, 1% triethylamine in 
dichloromethane) to afford the desired product as an orange gummy solid (0.724 g, 
76%). 1H NMR (CDCl3) δ 6.93 (1 H, d, J = 2.6 Hz), 6.84 (1 H, d, J = 8.6 Hz), 6.77 
(1 H, dd, J = 8.6, 2.6 Hz), 4.52 (1 H, t, J = 2.8 Hz), 4.00 (2 H, t, J = 6.4 Hz), 3.46 -
3.36 (4 H, m), 3.28 (1 H, d, J = 14.5 Hz), 3.09 (1 H, d, J = 14.5 Hz), 2.91 (1 H, dd, J 
= 11.7, 2.1 Hz), 2.56 - 2.44 (3 H, m), 2.39 (4 H, t, J = 5.1 Hz), 2.34 (3 H, s), 2.04 - 
1.88 (2 H, m), 1.45 (9 H, s); 13C NMR (CDCl3) δ 157.9, 154.9, 137.4, 127.4, 126.9, 
115.3, 113.9, 79.7, 67.4, 66.3, 66.0, 60.5, 57.2, 55.3, 53.2, 46.1, 28.6, 26.8. See pg. 
239 for details on the synthesis of tert-butyl 4-(3-chloropropyl)piperazine-1-
carboxylate 115. 
11.5.14 (R)-2-Methyl-6-(3-morpholinopropoxy)-1,2,3,4-
tetrahydroisoquinolin-4-ol (111)  
 
111 
The isoquinoline hydrochloride 86 (0.203 g, 0.940 mmol) was treated with potassium 
tert-butoxide (0.217 g, 1.95 mmol), sodium iodide (0.300 g, 2.00 mmol), and 4-(3-
chloropropyl)morpholine 117 (0.168 g, 1.03 mmol) as described for 87 and then 
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subjected to workup method 2. Attempted purification by column chromatography 
was unsuccessful. The resulting orange gummy solid was purified by dissolving in a 
mixture of hot ethyl acetate and petroleum spirits 40-60, decanting off the solvent 
and concentrating under reduced pressure to afford a pale yellow gummy solid 
(0.049 g, 17%). 1H NMR (CDCl3) δ 6.95 (1 H, d, J = 2.6 Hz), 6.89 (1 H, d, J = 8.4 
Hz), 6.79 (1 H, dd, J = 8.4, 2.6 Hz), 4.56 (1 H, t, J = 2.6 Hz), 4.03-3.99 (2 H, m), 
3.73-3.70 (4 H, m), 3.47 (1 H, d, J = 14.7 Hz), 3.19 (1 H, d, J = 14.7 Hz), 2.97 (1 H, 
ddd, J = 11.7, 3.1, 1.0 Hz), 2.54-2.50 (3 H, m), 2.47-2.44 (4 H, m), 2.42 (3 H, s), 
1.99-1.92 (2 H, m); 13C NMR (CDCl3) δ 157.9, 137.4, 127.4, 127.0, 115.4, 114.0, 
67.5, 67.1, 66.4, 60.5, 57.3, 55.7, 53.9, 46.2, 26.6; HRMS m/z: [M+H]+ Calcd for 






2-(Chloromethyl)pyridine hydrochloride (0.168 g, 1.02 mmol) was added to a 
suspension of sodium hydride (60% dispersion in mineral oil, 0.120 g, 2.98 mmol) in 
anhydrous dimethylformamide and the mixture stirred at room temperature for 10 
minutes. The isoquinoline hydrochloride 86 (0.202 g, 0.930 mmol) was added and 
the reaction mixture was stirred at room temperature for 2 days. The reaction was 
quenched with methanol (2 mL) and then subjected to workup method 1. The 
resulting brown gummy solid was purified by column chromatography (5% 
methanol, 0.5% sat. ammonia solution, in dichloromethane) to afford the desired 
product as a colourless gummy solid (0.146 g, 58%). 1H NMR (CDCl3) δ 8.65 (1 H, 
dt, J = 1.6, 0.8 Hz), 8.55 (1 H, dd, J = 4.9, 1.7 Hz), 7.78 - 7.73 (1 H, m), 7.30 (1 H, 
ddd, J = 7.8, 4.9, 1.0 Hz), 7.06 - 7.03 (1 H, m), 6.89 - 6.82 (2 H, m), 5.06 (2 H, s), 
4.60 - 4.55 (1 H, m), 3.41 (1 H, d, J = 14.6 Hz), 3.21 (1 H, d, J = 14.6 Hz), 2.97 (1 
H, ddd, J = 11.8, 3.3, 1.3 Hz), 2.58 (1 H, dd, J = 11.8, 3.2 Hz), 2.42 - 2.37 (3 H, m); 
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13C NMR (CDCl3) δ 157.6, 149.5, 149.1, 137.1, 135.5, 132.6, 127.6, 125.8, 123.7, 
115.9, 114.4, 67.8, 66.5, 60.1, 56.7, 45.6; HRMS m/z: [M+H]+ Calcd for C16H19N2O2 
271.1441; Found 271.1443. 
11.5.16 (R)-2-Methyl-6-(piperidin-4-ylmethoxy)-1,2,3,4-
tetrahydroisoquinolin-4-ol (118)  
 
118 
The BOC protected amine 109 (0.485 g, 1.29 mmol) was dissolved in a mixture of 
anhydrous dichloromethane and trifluoroacetic acid (2:1), stirred at room 
temperature for 15 minutes, and subjected to workup method 2. The resulting orange 
gummy solid was purified by column chromatography (15% methanol, 2% 
sat.ammonia, in dichloromethane) to afford the desired product as a colourless 
gummy solid (0.323 g, 83%). 1H NMR (D2O) δ 7.25 (1 H, d, J = 8.4 Hz), 7.14 - 7.08 
(2 H, m), 5.13 - 5.05 (1 H, m), 4.59 (1 H, d, J = 15.4 Hz), 4.28 (1 H, d, J = 15.4 Hz), 
4.04 (2 H, d, J = 6.3 Hz), 3.78 - 3.70 (1 H, m), 3.64 - 3.56 (1 H, m), 3.56 - 3.43 (2 H, 
m), 3.13-3.04 (5 H, m), 2.29 - 2.17 (1 H, m), 2.17 - 2.05 (2 H, m), 1.71 - 1.52 (2 H, 
m); 13C NMR (D2O) δ 163.1, 162.8, 158.3, 127.9, 117.8, 114.9, 71.9, 63.5, 54.4, 
43.6, 43.3, 33.0, 25.1 (note some peaks coincident); HRMS m/z: [M+H]+ Calcd for 





carboxylate (119)  
 
119 
The BOC protected amine 110 (0.100 g, 0.250 mmol) was deprotected as described 
for 118, and subjected to workup method 2. The resulting orange gummy solid was 
purified by column chromatography (15% methanol 1% triethylamine in 
dichloromethane) to afford the desired product as a pale orange gummy solid (0.033 
g, 44%). 1H NMR (CDCl3) δ 6.96 - 6.89 (2 H, m), 6.78 (1 H, dd, J = 8.4, 2.6 Hz), 
4.61 (1 H, t, J = 3.0 Hz), 3.99 (2 H, td, J = 6.1, 2.6 Hz), 3.61 (1 H, d, J = 14.7 Hz), 
3.26 (1 H, d, J = 14.7 Hz), 3.14 - 3.06 (4 H, m), 2.99 (1 H, dd, J = 11.8, 2.2 Hz), 
2.72 - 2.62 (4 H, m), 2.62 - 2.52 (3 H, m), 2.45 (3 H, s), 1.91 (2 H, quin, J = 6.6 Hz); 
13C NMR (CDCl3) δ 157.9, 137.4, 127.4, 127.0, 115.3, 114.0, 67.4, 66.4, 60.5, 57.4, 
55.6, 53.6, 46.2, 45.6, 26.7; HRMS m/z: [M+H]+ Calcd for C17H28N3O2 306.2176; 
Found 306.2176. 
11.5.18 (R)-2-Methyl-6-(3-(2-nitro-1H-imidazol-1-yl)propoxy)-
1,2,3,4-tetrahydroisoquinolin-4-ol (126)  
 
126 
The isoquinoline hydrochloride 86 (0.086 g, 0.400 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.035 g, 0.880 mmol), and 1-(3-
chloropropyl)-2-nitro-1H-imidazole 122 (0.095 g, 0.500 mmol) as described for 87 
and then subjected to workup method 2. The resulting orange gummy solid was 
purified by column chromatography (5% methanol, 0.5% sat. ammonia solution, in 
dichloromethane) to afford the desired product as a yellow gummy solid (0.014 g, 
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11%). 1H NMR (DMSO-d6) δ 7.65 (1 H, d, J = 1.0 Hz), 7.17 (1 H, d, J = 1.0 Hz), 
6.98 - 6.90 (2 H, m), 6.71 (1 H, s), 5.22 (1 H, d, J = 6.9 Hz), 4.57 (3 H, t, J = 6.9 
Hz), 3.99 - 3.88 (2 H, m), 3.48 (1 H, s), 3.27 (1 H, s), 2.89 - 2.79 (1 H, m), 2.31 (3 H, 
s), 2.28 - 2.20 (3 H, m); 13C NMR (DMSO-d6) δ 156.7, 139.5, 127.9, 127.8, 127.1, 
126.5, 113.5, 112.4, 65.7, 64.6, 60.5, 57.1, 46.9, 45.7, 29.3 (note some signals 
coincident); HRMS m/z: [M+H]+ Calcd for C16H21N4O4 333.1557; Found 333.1573. 
See pg. 242 for details on the synthesis of 1-(3-chloropropyl)-2-nitro-1H-
imidazole122. 
11.5.19 (R)-2-Methyl-6-(3-(4-nitro-1H-imidazol-1-yl)propoxy)-
1,2,3,4-tetrahydroisoquinolin-4-ol (127)  
 
127 
The isoquinoline hydrochloride 86 (0.151 g, 0.700 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.061 g, 1.5 mmol), 1-(3-chloropropyl)-4-
nitro-1H-imidazole 125 (0.155 g, 0.820 mmol), and sodium iodide (0.251 g, 1.67 
mmol) as described for 87 and then subjected to workup method 2. The resulting 
brown gummy solid was purified by column chromatography (5% methanol, 0.5% 
sat. ammonia solution, in dichloromethane) to afford the desired product as a 
colourless gummy solid (0.085 g, 37%). 1H NMR (DMSO-d6) δ 8.46 (1 H, d, J = 1.5 
Hz), 7.88 (1 H, d, J = 1.5 Hz), 6.98 (1 H, d, J = 2.6 Hz), 6.95 (1 H, d, J = 8.4 Hz), 
6.72 (1 H, dd, J = 8.4, 2.6 Hz), 5.25 (1 H, d, J = 6.9 Hz), 4.63 - 4.52 (1 H, m), 4.25 
(2 H, t, J = 7.0 Hz), 3.96 - 3.86 (2 H, m), 3.52 (1 H, d, J = 14.7 Hz), 3.32 - 3.28 (1 
H, m), 2.86 (1 H, ddt, J = 11.1, 5.4, 0.6 Hz), 2.35 - 2.31 (3 H, m), 2.30 - 2.18 (3 H, 
m); 13C NMR (DMSO-d6) δ 156.7, 147.0, 139.4, 137.5, 127.0, 126.6, 121.7, 113.7, 
112.5, 65.7, 64.5, 60.4, 57.0, 45.6, 44.8, 29.6; HRMS m/z: [M+H]+ Calcd for 





tetrahydroisoquinolin-4-ol (129)  
 
129 
The isoquinoline hydrochloride 86 (0.201 g, 0.930 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.091 g, 2.3 mmol) and 4-(chloromethyl)-
1,1'-biphenyl 128 (0.205 g, 1.01 mmol) as described for 87 and then subjected to 
workup method 1. The resulting brown solid was purified by column 
chromatography (50:50 ethyl acetate: petroleum spirits 40-60 then 25% methanol in 
ethyl acetate) to afford the desired product as a white solid (0.173 g, 54%). m.p. 159 
- 161°C; 1H NMR (CDCl3) δ 7.63-7.58 (4 H, m), 7.51-7.49 (2 H, m), 7.46-7.42 (2 H, 
m), 7.37-7.33 (1 H, m), 7.08 (1 H, d, J = 2.4 Hz), 6.94 (1 H, d, J = 8.4 Hz), 6.91 (1 
H, dd, J = 8.4, 2.4 Hz), 5.11 (2 H, s), 4.62 (1 H, t, J = 2.8 Hz), 3.66 (1 H, d, J = 14.4 
Hz), 3.30 (1 H, d, J = 14.4 Hz), 3.06 (1 H, ddd, J = 12.0, 2.8, 1.0 Hz), 2.65 (1 H, dd, 
J = 12.0, 2.8 Hz), 2.49 (3 H, s); 13C NMR (CDCl3) δ 157.9, 141.1, 140.9, 137.1, 
136.1, 128.9, 128.1, 127.5, 127.3, 126.2, 115.9, 114.5, 70.0, 67.0, 60.4, 57.0, 45.8 
(note some signals coincident); Anal. Calcd for C23H23NO2: C, 79.97; H, 6.71; N 
4.05. Found: C, 79.62; H, 6.58; N, 3.91; [α]D +11.5° (c 1.00, CH2Cl2). See pg. 240 
for details on the synthesis of 4-(chloromethyl)-1,1'-biphenyl 128. 
11.5.21 (R)-6-((3'-Methoxy-[1,1'-biphenyl]-4-yl)methoxy)-2-
methyl-1,2,3,4-tetrahydroisoquinolin-4-ol (130)  
 
130 
Bromophenyl ether 98 (0.103 g, 0.300 mmol) was combined with 3-
methoxyphenylboronic acid (0.037 g, 0.42 mmol), potassium carbonate (0.169 g, 
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1.20 mmol), dioxane (0.8 mL), and water (0.8 mL). This mixture was degassed by 
bubbling with nitrogen gas for 10 minutes. Tetrakis(triphenylphosphine)palladium(0) 
(0.0027 g, 0.0023 mmol) was added and the reaction mixture was heated to 160°C 
for 13 minutes in a microwave reactor, and subjected to workup method 3. The 
resulting orange gummy solid was purified by column chromatography (0-10% 
methanol in dichloromethane) to afford the desired product as a colourless gummy 
solid (0.021 g, 19%). 1H NMR (CDCl3) δ 7.62-7.59 (2 H, m), 7.50 (2 H, d, J = 8.0 
Hz), 7.36 (1 H, t, J = 8.0 Hz), 7.19-7.17 (1 H, m), 7.13-7.12 (1 H, m), 7.06 (1 H, d, J 
= 2.5 Hz), 6.95-6.88 (3 H, m), 5.11 (2 H, s), 4.57 (1 H, t, J = 3.0 Hz), 3.87 (3 H, s), 
3.54 (1 H, d, J = 14.6 Hz), 3.19 (1 H, d, J = 14.6 Hz), 2.95 (1 H, ddd, J = 11.7, 3.0, 
1.2 Hz), 2.54 (1 H, dd, J = 11.7, 3.0 Hz), 2.41 (3 H, s); 13C NMR (CDCl3) δ 160.1, 
157.7, 142.5, 141.0, 137.5, 136.4, 129.9, 128.1, 127.6, 127.5, 127.4, 119.8, 115.7, 
114.4, 113.1, 112.9, 70.0, 67.5, 60.5, 57.3, 55.5, 46.2; HRMS m/z: [M+H]+ Calcd for 
C24H26NO3 376.1907; Found 376.1898. 
11.5.22 (R)-6-((3'-Chloro-[1,1'-biphenyl]-4-yl)methoxy)-2-methyl-
1,2,3,4-tetrahydroisoquinolin-4-ol (131)  
 
131 
Bromophenyl ether 98 (0.102 g, 0.290 mmol) was treated with 3-
chlorophenylboronic acid (0.054 g, 0.34 mmol), potassium carbonate (0.160 g, 1.15 
mmol), dioxane (4 mL), and water (2 mL). The mixture was degassed by bubbling 
with nitrogen for 15 minutes. 
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.0035 g, 0.0043 mmol) 
was added and the reaction mixture heated at reflux for 6 hrs, then subjected to 
workup method 3. The resulting brown gummy solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford the desired product as a 
pale yellow solid (0.093 g, 84 %). m.p. 108.5 - 110.1°C; 1H NMR (CDCl3) δ 7.61 - 
7.56 (3 H, m), 7.53 - 7.49 (2 H, m), 7.46 (1 H, dt, J = 7.5, 1.5 Hz), 7.40 - 7.34 (1 H, 
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m), 7.34 - 7.30 (1 H, m), 7.05 (1 H, d, J = 2.4 Hz), 6.93 (1 H, d, J = 8.6 Hz), 6.89 (1 
H, dd, J = 8.6, 2.4 Hz), 5.11 (2 H, s), 4.59 - 4.54 (1 H, m), 3.51 (1 H, d, J = 14.7 
Hz), 3.18 (1 H, d, J = 14.7 Hz), 2.99 - 2.89 (1 H, m), 2.53 (1 H, dd, J = 11.7, 3.0 
Hz), 2.41 (3 H, s); 13C NMR (CDCl3) δ 157.6, 142.8, 139.6, 137.5, 136.9, 134.8, 
130.2, 128.2, 127.6, 127.5, 127.5, 127.4, 125.4, 115.7, 114.4, 69.8, 67.5, 60.5, 57.3, 
46.2 (note some signals coincident); HRMS m/z: [M+H]+ Calcd for C23H23ClNO2 
380.1412; Found 380.1412. 
11.5.23 (R)-6-((4'-Chloro-[1,1'-biphenyl]-4-yl)methoxy)-2-methyl-
1,2,3,4-tetrahydroisoquinolin-4-ol (132)  
 
132 
Bromophenyl ether 98 (0.103 g, 0.300 mmol) was combined with 4-
chlorophenylboronic acid (0.054 g, 0.340 mmol), potassium carbonate (0.170 g, 1.23 
mmol), dioxane (1.0 mL), and water (1.0 mL). This mixture was degassed by 
bubbling with nitrogen gas for 10 minutes. [1,1′-Bis(diphenylphosphino)ferrocene]- 
dichloropalladium(II) (0.0031 g, 0.0043 mmol) was added and the reaction mixture 
was heated to 140°C for 30 minutes in a microwave reactor, and subjected to workup 
method 3. The resulting orange gummy solid was purified by column 
chromatography (0-10% methanol in dichloromethane) to afford the desired product 
as an orange solid (0.072 g, 64%). m.p. 138 - 146°C; 1H NMR (CDCl3) δ 7.58 - 7.55 
(2 H, m), 7.53 - 7.49 (4 H, m), 7.42 - 7.40 (2 H, m), 7.05 (1 H, d, J = 2.6 Hz), 6.95 (1 
H, d, J = 8.4 Hz), 6.89 (1 H, dd, J = 8.4, 2.6 Hz), 5.11 (2 H, s), 4.57 (1 H, br. s.), 
3.58 (1 H, d, J = 14.7 Hz), 3.21 (1 H, d, J = 14.7 Hz), 2.95 (1 H, ddd, J = 11.8, 3.0, 
1.0 Hz), 2.55 (1 H, dd, J = 11.8, 3.0 Hz), 2.42 (3 H, s); 13C NMR (CDCl3) δ 157.6, 
139.8, 139.4, 137.6, 136.6, 133.7, 129.1, 128.5, 128.2, 127.6, 127.5, 127.3, 115.7, 
114.4, 69.9, 67.5, 60.5, 57.3, 46.2; HRMS m/z: [M+H]+ Calcd for C23H23NO2Cl 




1,2,3,4-tetrahydroisoquinolin-4-ol (133)  
 
133 
Bromophenyl ether 98 (0.098 g, 0.29 mmol) was treated with 4-fluorophenylboronic 
acid (0.049 g, 0.34 mmol), potassium carbonate (0.158 g, 1.15 mmol), and 
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.0040 g, 0.0049 mmol) as 
described for 131136, and subjected to workup method 3. The resulting orange 
gummy solid was purified by column chromatography (5% methanol in 
dichloromethane) to afford the desired product as a brown solid (0.079 g, 75 %). m.p. 
117.9 - 120.9 °C; 1H NMR (CDCl3) δ 7.60 - 7.45 (6 H, m), 7.17 - 7.05 (3 H, m), 6.95 
- 6.86 (2 H, m), 5.15 - 5.01 (2 H, m), 4.63 (1 H, t, J = 2.8 Hz), 3.62 (1 H, d, J = 14.6 
Hz), 3.31 (1 H, d, J = 14.6 Hz), 3.08 (1 H, dd, J = 11.8, 2.1 Hz), 2.67 (1 H, dd, J = 
11.8, 2.8 Hz), 2.49 (3 H, s); 13C NMR (CDCl3) δ 162.6 (d, 
1JCF = 245.1 Hz), 157.7, 
140.0, 137.0, 136.9 (d, 4JCF = 3.1 Hz), 136.0, 128.7 (d, 
3JCF = 8.0 Hz), 128.0, 127.4, 
127.2, 126.1, 115.73, 115.67 (d, 2JCF = 21.4 Hz), 114.3, 69.8, 66.7, 60.2, 56.7, 45.7; 
HRMS m/z: [M+H]+ Calcd for C23H23FNO2 364.1707; Found 364.1707; [α]D +7.9° 





Bromophenyl ether 99 (0.105 g, 0.300 mmol) was treated with 3-
methoxyphenylboronic acid (0.054 g, 0.36 mmol), potassium carbonate (0.173 g, 
1.25 mmol) and, bis(diphenylphosphino)ferrocene]-dichloropalladium (II) (0.0038 g, 
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0.0047 mmol) as described for 131. The resulting brown gummy solid was purified 
by column chromatography (5% methanol in dichloromethane) to afford the desired 
product as an orange gummy solid (0.055 g, 49%). 1H NMR (CDCl3) δ 7.66 (1 H, s), 
7.55 (1 H, dt, J = 7.2, 2.0 Hz), 7.46 (1 H, d, J = 7.2 Hz), 7.44 - 7.40 (1 H, m), 7.36 (1 
H, t, J = 8.1 Hz), 7.21 - 7.17 (1 H, m), 7.15 - 7.11 (1 H, m), 7.07 (1 H, d, J = 2.0 
Hz), 6.93 - 6.84 (3 H, m), 5.13 (2 H, s), 4.55 (1 H, t, J = 2.8 Hz), 3.87 (3 H, s), 3.39 
(1 H, d, J = 14.5 Hz), 3.12 (1 H, d, J = 14.5 Hz), 2.95 (1 H, dd, J = 11.8, 2.8 Hz), 
2.50 (1 H, dd, J = 11.8, 2.8 Hz), 2.37 (3 H, s); 13C NMR (CDCl3) δ 160.0, 157.9, 
142.4, 141.5, 137.4, 136.8, 129.8, 129.0, 127.3, 126.9, 126.6, 126.3, 119.7, 115.9, 
114.4, 112.9, 112.9, 70.1, 66.6, 60.1, 56.7, 55.3, 45.4 (note some signals coincident); 
HRMS m/z: [M+H]+ Calcd for C24H27NO3 376.1907; Found 376.1908.  
11.5.26 (R)-6-((4'-Chloro-[1,1'-biphenyl]-3-yl)methoxy)-2-methyl-
1,2,3,4-tetrahydroisoquinolin-4-ol (138)  
 
138 
Bromophenyl ether 99 (0.099 g, 0.28 mmol) was combined with 4-
chlorophenylboronic acid (0.055 g, 0.35 mmol), potassium carbonate (0.159 g, 1.15 
mmol, and bis(diphenylphosphino)ferrocene]dichloropalladium (II) (0.0036 g, 
0.0044 mmol) as described for 131, and subjected to workup method 3. The resulting 
orange gummy solid was purified by column chromatography (0-10% methanol in 
dichloromethane) to afford the desired product as an orange gummy solid (0.070 g, 
66%). 1H NMR (CDCl3) δ 7.62 (1 H, s), 7.55 - 7.38 (7 H, m), 7.06 (1 H, d, J = 2.1 
Hz), 6.95 - 6.87 (2 H, m), 5.12 (2 H, s), 4.56 (1 H, t, J = 2.9 Hz), 3.51 (1 H, d, J = 
14.5 Hz), 3.18 (1 H, d, J = 14.5 Hz), 2.95 (1 H, ddd, J = 11.8, 2.9, 1.0 Hz), 2.54 (1 
H, dd, J = 11.8, 2.9 Hz), 2.40 (3 H, s); 13C NMR (CDCl3) δ 157.6, 140.5, 139.5, 
137.9, 137.5, 133.7, 129.3, 129.1, 128.6, 127.6, 127.4, 126.8, 126.7, 126.2, 115.6, 
114.4, 70.1, 67.4, 60.5, 57.2, 46.1; HRMS m/z: [M+H]+ Calcd for C23H23NO2Cl 




1,2,3,4-tetrahydroisoquinolin-4-ol (140)  
 
140 
Bromophenyl ether 98 (0.100 g, 0.290 mmol) was combined with 4-biphenylboronic 
acid (0.071 g, 0.35 mmol), potassium carbonate (0.164 g, 1.19 mmol), 
triphenylphosphine (0.0057 g, 0.020 mmol), dioxane (4.0 mL), and water (4.0 mL). 
This mixture was degassed by bubbling with nitrogen for 15 minutes. Palladium 
acetate (0.005 g, 0.02 mmol) was added and the reaction mixture heated to reflux for 
6 hrs, and subjected to workup method 3. The resulting cream coloured solid was 
purified by column chromatography (5% methanol in dichloromethane) to afford the 
desired product as a cream coloured solid (0.45 g, 37%). m.p.182 - 184.5 °C; 1H 
NMR (CDCl3) δ 7.69 - 7.62 (8 H, m), 7.55 - 7.50 (2 H, m), 7.49 - 7.43 (2 H, m), 7.41 
- 7.37 (1 H, m), 7.07 (1 H, d, J = 2.6 Hz), 6.98 (1 H, d, J = 8.4 Hz), 6.91 (1 H, dd, J 
= 8.4, 2.6 Hz), 5.12 (2 H, dd, J = 1.6, 0.5 Hz), 4.59 (1 H, br. s.), 3.70 (1 H, d, J = 
14.5 Hz), 3.26 (1 H, d, J = 14.5 Hz), 2.96 (1 H, ddd, J = 11.8, 3.3, 1.2 Hz), 2.58 (1 
H, dd, J = 11.8, 2.6 Hz), 2.46 (3 H, s); 13C NMR (CDCl3) δ 157.7, 140.8, 140.6, 
140.4, 139.8, 137.6, 136.3, 129.0, 128.2, 127.7, 127.6, 127.52, 127.50, 127.47, 127.4, 
127.20 115.7, 114.4, 70.0, 67.6, 60.5, 57.5, 46.2; HRMS m/z: [M+H]+ Calcd for 




tetrahydroisoquinolin-4-ol (142)  
 
142 
Bromophenyl ether 98 (0.100 g, 0.290 mmol) was treated with 2-napthylboronic acid 
(0.060 g, 0.35 mmol), potassium carbonate (0.160 g, 1.16 mmol), triphenylphosphine 
(0.0056 g, 0.020 mmol), and palladium acetate (0.0053 g, 0.020 mmol) as described 
for 140, and subjected to workup method 3. The resulting orange solid was purified 
by column chromatography (5% methanol in dichloromethane) to afford the desired 
product as a white solid (0.084 g, 73%). m.p. 160.5 - 163 °C; 1H NMR (CDCl3) δ 
8.07 - 8.02 (1 H, m), 7.95 - 7.83 (3 H, m), 7.78 - 7.72 (3 H, m), 7.58 - 7.45 (4 H, m), 
7.08 (1 H, d, J = 2.3 Hz), 6.97 - 6.89 (2 H, m), 5.19 - 5.08 (2 H, m), 4.58 (1 H, t, J = 
3.0 Hz), 3.56 (1 H, d, J = 14.7 Hz), 3.21 (1 H, d, J = 14.7 Hz), 2.96 (1 H, ddd, J = 
11.8, 3.1, 1.3 Hz), 2.55 (1 H, dd, J = 11.8, 2.9 Hz), 2.43 - 2.38 (3 H, m); 13C NMR 
(CDCl3) δ 157.7, 141.0, 138.3, 137.5, 136.3, 133.8, 132.8, 128.6, 128.4, 128.2, 
127.79, 127.76, 127.5, 127.4, 126.5, 126.1, 125.9, 125.6, 115.7, 114.4, 70.0, 67.5, 
60.5, 57.3, 46.2; HRMS m/z: [M+H]+ Calcd for C27H26NO2 396.1964; Found 
396.1959. 
11.5.29 4-Phenoxybenzaldehyde (145a) 
 
145a 
4-Hydroxybenzaldehyde (0.501 g, 4.10 mmol), phenylboronic acid (0.447 g, 3.67 
mmol), copper(II) acetate monohydrate (0.732 g, 3.67 mmol), and triethylamine 
(2.60 mL, 18.4 mol) were dissolved in anhydrous dichloromethane. 4Å molecular 
sieves were added and the reaction mixture stirred at room temperature open to the 
air for 24 hrs. The reaction mixture was filtered and concentrated under reduced 
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pressure. The resulting black gummy solid was purified by column chromatography 
(10% ethyl acetate in petroleum spirit 40-60) to afford the desired product as a pale 
yellow gummy solid (0.194 g, 27%). 1H NMR (CDCl3) δ 9.93 (1 H, s), 7.89 - 7.82 (2 
H, m), 7.46 - 7.40 (2 H, m), 7.26 - 7.21 (1 H, m), 7.12 - 7.05 (4 H, m). 
11.5.30 4-(4-Fluorophenoxy)benzaldehyde (145b)  
 
145b 
4-Hydroxybenzaldehyde (0.500 g, 4.10 mmol) was treated with 4-
fluorophenylboronic acid (0.515 g, 4.10 mmol), copper(II) acetate monohydrate 
(0.820 g, 4.10 mmol), and triethylamine (2.90 mL, 20.5 mol) as described for 145a. 
The resulting green gummy solid was purified by column chromatography (10% 
ethyl acetate in petroleum spirit 40-60) to afford the desired product as a colourless 
gummy solid which slowly crystallised (0.161 g, 18%). 1H NMR (CDCl3) δ 9.93 (1 
H, s), 7.89 - 7.82 (2 H, m), 7.16 - 7.01 (6 H, m). 
11.5.31 (4-Phenoxyphenyl)methanol (146a)  
 
146a 
Aldehyde 145a (0.194 g, 0.920 mmol) was dissolved in methanol. Sodium 
borohydride (0.040 g, 1.1 mmol) was added and the reaction mixture stirred at room 
temperature for 30 minutes. The reaction mixture was concentrated under reduced 
pressure, diluted with water, and extracted three times with ethyl acetate. The ethyl 
acetate fractions were combined, dried over magnesium sulfate, and concentrated 
under reduced pressure. The resulting colourless oil (0.180 g, 92%) was used without 
further purification. 1H NMR (CDCl3) δ 7.38 - 7.31 (4 H, m), 7.15 - 7.09 (1 H, m), 
7.05 - 6.99 (4 H, m), 4.68 (2 H, s). 
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11.5.32 (4-(4-Fluorophenoxy)phenyl)methanol (146b)  
 
146b 
Aldehyde 145b (0.160 g, 0.740 mmol) was treated with sodium borohydride (0.029 
g, 0.77 mmol) as described for 146a. The resulting colourless oil (0.180 g, >95%) 
was used without further purification. 1H NMR (CDCl3) δ 7.37 - 7.31 (2 H, m), 7.07 
- 6.94 (6 H, m), 4.67 (2 H, s). 
11.5.33 1-(Chloromethyl)-4-phenoxybenzene (147a)  
 
147a 
Alcohol 146a (0.180 g, 0.850 mmol) was treated with methanesulfonyl chloride (79 
μL, 1.0 mmol), and triethylamine (181 μL, 1.30 mmol) as described for 243. The 
resulting colourless oil (0.190 g, >95%) was determined to be the alkyl chloride and 
was used without further purification. 1H NMR (CDCl3) δ 7.39 - 7.33 (4 H, m), 7.17 
- 7.10 (1 H, m), 7.06 - 6.96 (4 H, m), 4.60 (2 H, s). 
11.5.34 1-(Chloromethyl)-4-(4-fluorophenoxy)benzene (147b)  
 
147b 
Alcohol 146b (0.166 g, 0.760 mmol) was treated with methanesulfonyl chloride (70 
μL, 0.91 mmol), and triethylamine (159 μL, 1.14 mmol) as described for 243. The 
resulting pale yellow oil (0.152 g, 85%) was determined to be the alkyl chloride and 
was used without further purification. 1H NMR (CDCl3) δ 7.36 - 7.32 (2 H, m), 7.07 




tetrahydroisoquinolin-4-ol (148)  
 
148 
The isoquinoline hydrochloride 86 (0.170 g, 0.790 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.071 g, 1.7 mmol), diphenyl ether 147a 
(0.190 g, 0.870 mmol), and sodium iodide (0.244 g, 1.63 mmol) as described for 87 
and then subjected to workup method 1. The resulting brown gummy solid was 
purified by column chromatography (5% methanol in dichloromethane) to afford the 
desired product as a pale pink gummy solid (0.106 g, 37%). 1H NMR (CDCl3) δ 7.44 
- 7.30 (4 H, m), 7.19 - 7.09 (1 H, m), 7.06 - 6.99 (4 H, m), 6.98 - 6.94 (1 H, m), 6.94 
- 6.91 (1 H, m), 6.90 - 6.87 (1 H, m), 5.08 - 4.99 (2 H, m), 4.60 - 4.53 (1 H, m), 3.48 
(1 H, dd, J = 14.6, 0.4 Hz), 3.18 (1 H, d, J = 14.6 Hz), 3.00 - 2.92 (1 H, m), 2.50 - 
2.56 (1 H, m), 2.41 (3 H, s); 13C NMR (CDCl3) δ 157.7, 157.3, 157.2, 137.5, 131.9, 
129.9, 129.4, 127.6, 127.4, 123.5, 119.1, 119.0, 115.7, 114.3, 69.8, 67.5, 60.5, 57.2, 
46.2; HRMS m/z: [M+H]+ Calcd for C23H24NO3 362.1751; Found 362.1752. 
11.5.36 (R)-6-((4-(4-Fluorophenoxy)benzyl)oxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-4-ol (149)  
 
149 
The isoquinoline hydrochloride 86 (0.114 g, 0.530 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.048 g, 1.2 mmol), diphenyl ether 147b 
(0.137 g, 0.580 mmol), and sodium iodide (0.160 g, 1.06 mmol) as described for 87 
and then subjected to workup method 1. The resulting brown gummy solid was 
purified by column chromatography (5% methanol in dichloromethane) to afford the 
desired product as a colourless gummy solid (0.133 g, 66%). 1H NMR (CDCl3) δ 
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7.42 - 7.37 (2 H, m), 7.07 - 6.96 (7 H, m), 6.89 (2 H, t, J = 1.6 Hz), 5.03 (2 H, s), 
4.60 - 4.53 (1 H, m), 3.41 (1 H, dt, J = 14.6, 0.6 Hz), 3.19 - 3.12 (1 H, m), 2.98 (1 H, 
ddd, J = 11.8, 3.0, 1.0 Hz), 2.53 (1 H, dd, J = 11.8, 3.1 Hz), 2.43 - 2.37 (3 H, m); 13C 
NMR (CDCl3) δ 159.0 (d, 
1JCF = 240.6 Hz), 157.7, 157.6, 152.8 (d, 
4JCF = 2.6 Hz), 
137.4, 131.8, 129.4, 127.6, 127.3, 120.8 (d, 3JCF = 8.1 Hz), 118.4, 116.4 (d, 
2JCF = 
23.0 Hz), 115.7, 114.3, 69.8, 67.3, 60.5, 57.2, 46.1; HRMS m/z: [M+H]+ Calcd for 
C23H23FNO3 380.1656; Found 380.1659. 
11.5.37 (R)-2-Methyl-6-(2-phenoxyethoxy)-1,2,3,4-
tetrahydroisoquinolin-4-ol (150)  
 
150 
The isoquinoline hydrochloride 86 (0.495 g, 2.30 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.230 g, 5.80 mmol) and 2-phenoxyethyl 
tosylate 245 (0.753 g, 2.58 mmol) as described for 87 and then subjected to workup 
method 1. The resulting light brown solid was purified by column chromatography 
(10% methanol in ethyl acetate) to afford the desired product as an off-white solid 
(0.444 g, 65%) which was further purified by recrystallisation (ethyl acetate: 
petroleum spirits 60-80) to afford a white solid (0.352 g, 51%). m.p. 123 - 125°C; 1H 
NMR (CDCl3) δ 7.32 - 7.26 (2 H, m), 7.01 (1 H, d, J = 2.4 Hz), 6.99 - 6.94 (3 H, m), 
6.91 (1 H, d, J = 8.4 Hz), 6.86 (1 H, dd, J = 8.4, 2.4 Hz), 4.57 (1 H, t, J = 2.8 Hz), 
4.33 (4 H, s), 3.44 (1 H, d, J = 14.6 Hz), 3.18 (1 H, d, J = 14.6), 2.96 (1 H, dd, J = 
11.8, 2.8 Hz), 2.54 (1 H, dd, J = 11.8, 2.8 Hz), 2.40 (3 H, s); 13C NMR (CDCl3) δ 
158.8, 157.6, 137.4, 129.6, 127.6, 127.2, 121.3, 115.7, 114.9, 114.2, 67.3, 66.9, 66.6, 
60.5, 57.1, 46.1; Anal. Calcd for C18H21NO3: C, 72.22; H, 7.07; N 4.68. Found: C, 





ol (151)  
 
151 
The isoquinoline hydrochloride 86 (0.286 g, 1.33 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.117 g, 2.90 mmol) and trityl chloride 
(0.408 g, 1.46 mmol) as described for 87 and then subjected to workup method 1. 
The resulting orange gummy solid was purified by column chromatography (5% 
methanol, 1% triethylamine in ethyl acetate) to afford the desired product as a 
colourless gummy solid (0.242 g, 46%). This was then recrystallised from petroleum 
spirits 60-80 to afford a white solid (0.111 g, 21%). m.p. 84 - 89 °C; 1H NMR 
(CDCl3) δ 7.46 - 7.43 (6 H, m), 7.30 - 7.18 (9 H, m), 6.73 (1 H, br.s), 6.54 - 6.53 (2 
H, m), 4.32 (1 H, br. s.), 3.27 (1 H, d, J = 14.8 Hz), 3.01 (1 H, d, J = 14.8 Hz), 2.81 
(1 H, ddd, J = 11.8, 3.1, 1.0 Hz), 2.40 (1 H, dd, J = 11.8, 2.9 Hz), 2.33 (3 H, s); 13C 
NMR (CDCl3) δ 155.0, 144.3, 136.4, 129.1, 127.9, 127.7, 127.3, 126.3, 121.3, 120.6, 
90.5, 67.1, 60.4, 57.3, 46.2; HRMS m/z: [M+H]+ Calcd for C29H28NO2 422.2115; 
Found 422.2112. 
11.5.39 (R)-6-((tert-Butyldiphenylsilyl)oxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-4-ol (152)  
 
152 
The isoquinoline hydrochloride 86 (1.01 g, 4.67 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.410 g, 10.2 mmol) and tert-
butylchlorodiphenylsilane (1.33 mL, 5.10 mmol) as described for 87 and then 
subjected to workup method 1. The resulting brown gummy solid was purified by 
column chromatography (5% methanol in dichloromethane) to afford the desired 
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product as a pale yellow solid (1.56 g, 80%). m.p. 115 - 120°C; 1H NMR (CDCl3) δ 
7.76 - 7.65 (4 H, m), 7.46 - 7.30 (6 H, m), 6.89 (1 H, d, J = 2.1 Hz), 6.59 - 6.51 (2 H, 
m), 4.43 - 4.34 (1 H, m), 3.19 (1 H, d, J = 14.7 Hz), 3.00 (1 H, d, J = 14.7 Hz), 2.88 
- 2.84 (1 H, m), 2.41 (1 H, dd, J = 12.0, 2.8 Hz), 2.30 (3 H, s), 1.07 - 1.15 (9 H, s); 
13C NMR (CDCl3) δ 154.3, 137.2, 135.7, 135.7, 130.0, 127.9, 127.4, 127.1, 120.0, 
119.4, 67.1, 60.4, 57.1, 46.2, 26.7, 19.6; HRMS m/z: [M+H]+ Calcd for C26H32SiNO2 
418.2197; Found 418.2198. 
11.5.40 (R)-6-((2-Methoxyethoxy)methoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-4-ol (153)  
 
153 
The isoquinoline hydrochloride 86 (1.00 g, 4.64 mmol) as treated with sodium 
hydride (60% dispersion in mineral oil, 0.410 g, 10.3 mmol) and 2-
methoxyethoxymethyl chloride (585 μL, 5.12 mmol) as described for 87 and then 
subjected to workup method 1. The resulting brown gummy solid was purified by 
column chromatography (5% methanol in dichloromethane) to afford the desired 
product as a brown oil (0.756 g, 61%). 1H NMR (CDCl3) δ 7.13 (1 H, d, J = 2.5 Hz), 
6.95 (1 H, dd, J = 8.5, 2.5 Hz), 6.90 (1 H, d, J = 8.5 Hz), 5.30 - 5.21 (2 H, m), 4.62 - 
4.55 (1 H, m), 3.85 - 3.79 (2 H, m), 3.59 - 3.54 (2 H, m), 3.53 - 3.46 (1 H, m), 3.40 - 
3.34 (3 H, m), 3.23 (1 H, d, J = 14.7 Hz), 3.06 - 2.97 (1 H, m), 2.64 - 2.55 (1 H, m), 




tetrahydroisoquinolin-4-ol (154)  
 
154 
The isoquinoline hydrochloride 86 (0.202 g, 0.93 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.119 g, 2.98 mmol) and 2-chloro-N,N-
dimethylethylamine hydrochloride (0.149 g, 1.02 mmol) as described for 112 and 
then subjected to workup method 1. The resulting brown gummy solid was purified 
by column chromatography (5% methanol, 0.5% sat. ammonia solution, in 
dichloromethane) to afford the desired product as a yellow gummy solid (0.120 g, 
52%). 1H NMR (CDCl3) δ 6.95 (1 H, d, J = 2.5 Hz), 6.89 (1 H, d, J = 8.3 Hz), 6.82 
(1 H, dd, J = 8.3, 2.5 Hz), 4.55 (1 H, t, J = 3.2 Hz), 4.08 (2 H, t, J = 5.6 Hz), 3.46 (1 
H, d, J = 14.6 Hz), 3.17 (1 H, d, J = 14.6 Hz), 2.93 (1 H, dd, J = 11.6, 3.0 Hz), 2.77 
(2 H, t, J = 5.6 Hz), 2.53 (1 H, dd, J = 11.6, 3.0 Hz), 2.39 (3 H, s), 2.38 - 2.35 (6 H, 
m); 13C NMR (CDCl3) δ 157.7, 137.4, 127.4, 127.1, 115.5, 113.9, 67.4, 66.0, 60.5, 
58.4, 57.2, 46.1, 45.9; HRMS m/z: [M+H]+ Calcd for C14H23N2O2 251.1754; Found 
271.1756. 
11.5.42 (R)-6-(Dodecyloxy)-2-methyl-1,2,3,4-tetrahydroisoquinolin-
4-ol (155)  
 
155 
The isoquinoline hydrochloride 86 (0.200 g, 0.930 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.082 g, 2.05 mmol) and 1-bromododecane 
(212 μL, 0.880 mmol) as described for 87 and then subjected to workup method 1. 
The resulting brown gummy solid was purified by column chromatography (5% 
methanol in dichloromethane) to afford the desired product as a brown solid (0.215 
g, 74%) m.p. 52.5 - 53.9°C; 1H NMR (CDCl3) δ 6.94 (1 H, d, J = 2.6 Hz), 6.91 (1 H, 
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d, J = 8.4 Hz), 6.80 (1 H, dd, J = 8.4, 2.6 Hz), 4.58 - 4.54 (1 H, m), 3.98 - 3.90 (2 H, 
m), 3.55 (1 H, d, J = 14.5 Hz), 3.20 (1 H, d, J = 14.5 Hz), 2.96 (1 H, ddd, J = 11.5, 
3.1, 1.3 Hz), 2.57 - 2.51 (1 H, m), 2.42 (3 H, s), 1.82 - 1.71 (2 H, m), 1.50 - 1.39 (2 
H, m), 1.31 - 1.23 (16 H, m), 0.93 - 0.80 (3 H, m); 13C NMR (CDCl3) δ 158.0, 137.3, 
127.5, 126.7, 115.4, 113.8, 68.3, 67.4, 60.6, 57.1, 46.2, 32.1, 29.8, 29.8, 29.7, 29.7, 
29.54, 29.49, 29.4, 26.2, 22.8, 14.3; HRMS m/z: [M+H]+ Calcd for C22H38NO2 
348.2897; Found 348.2902. 
11.5.43 (4R,4'R)-6,6'-((Oxybis(ethane-2,1-diyl))bis(oxy))bis(2-
methyl-1,2,3,4-tetrahydroisoquinolin-4-ol) (157)  
 
157 
Isoquinoline hydrochloride 86 (0.202 g, 0.940 mmol) was added to a suspension of 
sodium hydride (60% dispersion in mineral oil, 0.076 g, 1.9 mmol) in anhydrous 
dimethylformamide (20 mL), and the reaction mixture stirred at room temperature 
for 30 minutes. Diethylene glycol bis(p-toluenesulfonate) (0.182 g, 0.440 mmol) was 
added and the reaction mixture stirred for a further 2 weeks at room temperature. The 
reaction was quenched with methanol (2 mL), and subjected to workup method 1. 
The resulting brown gummy solid was purified by column chromatography (10% 
methanol in dichloromethane) to afford the desired product as a white solid (0.090 g, 
48%). m.p. 111 - 112.8 °C; 1H NMR (CDCl3) δ 6.89 (2 H, d, J = 2.5 Hz), 6.87 - 6.84 
(2 H, m), 6.82 - 6.78 (2 H, m), 4.52 (2 H, t, J = 3.1 Hz), 4.20 - 4.09 (4 H, m), 3.98 - 
3.88 (4 H, m), 3.40 (2 H, d, J = 14.5 Hz), 3.17 (2 H, d, J = 14.5 Hz), 2.91 (2 H, ddd, 
J = 11.8, 3.1, 0.8 Hz), 2.54 (2 H, dd, J = 11.8, 3.1 Hz), 2.39 (6 H, s); 13C NMR 
(CDCl3) δ 157.7, 137.3, 127.4, 126.9, 115.4, 114.3, 70.1, 67.8, 67.0, 60.6, 57.2, 46.0; 







Isoquinoline hydrochloride 90 (0.200 g, 0.930 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.085 g, 2.1 mmol) and iodomethane (64 µL, 
1.0 mmol) as described for 87, and subjected to workup method 2. The resulting 
yellow gummy solid was purified by column chromatography (5% methanol in 
dichloromethane) to afford the desired product as a colourless gummy solid which 
slowly crystallised (0.051 g, 30%). m.p. 115.5 - 117.6 °C; 1H NMR (CDCl3) δ 7.23 
(1 H, t, J = 7.9 Hz), 7.05 (1 H, d, J = 7.4 Hz), 6.77 (1 H, dd, J = 8.1, 0.7 Hz), 4.62 (1 
H, t, J = 2.9 Hz), 3.87 (1 H, d, J = 16.0 Hz), 3.82 (3 H, s), 3.16 (1 H, d, J = 16.0 Hz), 
3.01 (1 H, ddd, J = 11.7, 2.9, 1.2 Hz), 2.61 (1 H, dd, J = 11.7, 2.9 Hz), 2.52 (3 H, s); 
13C NMR (CDCl3) δ 155.6, 137.1, 127.8, 122.5, 121.4, 109.1, 66.8, 59.7, 55.5, 52.7, 





Isoquinoline 90 hydrochloride (0.202 g, 0.940 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.084 g, 2.1 mmol) and benzyl bromide (122 
µL, 1.02 mmol) as described for 87, and subjected to workup method 1. The 
resulting yellow gummy solid was purified by column chromatography (5% 
methanol in dichloromethane) to afford the desired product as a pale yellow gummy 
solid (0.171 g, 68%). 1H NMR (CDCl3) δ 7.40 - 7.39 (4 H, m), 7.36 - 7.31 (1 H, m), 
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7.20 (1 H, t, J = 7.9 Hz), 7.07 (1 H, d, J = 7.4 Hz), 6.80 (1 H, dd, J = 8.1, 0.7 Hz), 
5.05 (2 H, s), 4.62 (1 H, t, J = 3.0 Hz), 3.86 (1 H, d, J = 16.2 Hz), 3.18 (1 H, d, J = 
16.2 Hz), 2.98 (1 H, ddd, J = 11.7, 3.0, 1.1 Hz), 2.59 (1 H, dd, J = 11.7, 3.0 Hz), 
2.49 (3 H, s); 13C NMR (CDCl3) δ 154.7, 137.6, 137.2, 128.7, 128.0, 127.5, 127.3, 
123.7, 121.7, 110.3, 69.9, 67.0, 59.9, 52.9, 46.1; HRMS m/z: [M+H]+ Calcd for 
C17H20NO2 270.1489; Found 270.1489. 
11.5.46 (R)-8-(2-Cyclohexylethoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-4-ol (160)  
 
160 
Isoquinoline hydrochloride 90 (0.198 g, 0.920 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.084 g, 2.1 mmol) and 2-cyclohexylethyl 
tosylate 107 (0.291 g, 1.03 mmol) as described for 87, and subjected to workup 
method 1. The resulting yellow solid was purified by column chromatography (5% 
methanol in dichloromethane) to afford the desired product as a white solid (0.131 g, 
50%). m.p. 85.5 - 86.8 °C; 1H NMR (CDCl3) δ 7.22 - 7.16 (1 H, m), 7.02 (1 H, d, J = 
7.8 Hz), 6.74 (1 H, dd, J = 7.8, 0.7 Hz), 4.61 (1 H, t, J = 2.8 Hz), 3.99 (2 H, t, J = 
6.7 Hz), 3.84 (1 H, d, J = 16.2 Hz), 3.13 (1 H, d, J = 16.2 Hz), 2.99 (1 H, ddd, J = 
11.7, 2.8, 1.2 Hz), 2.59 (1 H, dd, J = 11.7, 2.8 Hz), 2.54 - 2.49 (3 H, m), 1.81- 1.60 
(7 H, m), 1.48 (1 H, s), 1.33 - 1.10 (3 H, m), 1.05 - 0. 91 (2 H, m); 13C NMR (CDCl3) 
δ 155.1, 137.3, 127.5, 123.3, 121.1, 109.8, 67.1, 66.2, 59.9, 52.9, 46.1, 36.7, 34.9, 
33.5, 26.7, 26.4; HRMS m/z: [M+H]+ Calcd for C18H28NO2 290.2115; Found 




tetrahydroisoquinolin-4-ol (161)  
 
161 
Isoquinoline hydrochloride 90 (0.201 m, 0.930 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.084 g, 2.1 mmol) and 4-(chloromethyl)-
1,1'-biphenyl 128 (0.207 g, 1.02 mmol) as described for 87, and subjected to workup 
method 1. The resulting brown solid was purified by column chromatography (2% 
methanol in dichloromethane) to afford the desired product as a white solid (0.145 g, 
45%). m.p. 177 - 179 °C; 1H NMR (CDCl3) δ 7.66 - 7.58 (4 H, m), 7.52 - 7.43 (4 H, 
m), 7.40 - 7.34 (1 H, m), 7.26 - 7.20 (1 H, m), 7.08 (1 H, d, J = 7.8 Hz), 6.86 (1 H, 
dd, J = 7.8, 0.7 Hz), 5.14 (2 H, s), 4.63 (1 H, t, J = 2.8 Hz), 4.00 (1 H, d, J = 16.2 
Hz), 3.23 (1 H, d, J = 16.2 Hz), 2.99 (1 H, ddd, J = 11.6, 2.8, 1.0 Hz), 2.60 (1 H, dd, 
J = 11.6, 2.8 Hz), 2.53 (3 H, s); 13C NMR (CDCl3) δ 154.8, 141.1, 140.9, 137.8, 
136.2, 129.0, 127.8, 127.6, 127.5, 127.4, 127.3, 124.1, 121.7, 110.3, 69.8, 67.3, 59.9, 
53.1, 46.3; HRMS m/z: [M+H]+ Calcd for C23H24NO2 346.1802; Found 346.1800. 
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 Alcohol 152 (0.200 g, 0.480 mmol) was added to a suspension of sodium hydride 
(60% dispersion in mineral oil, 0.105 g, 2.63 mmol) in anhydrous tetrahydrofuran (5 
mL) and the reaction mixture stirred at room temperature for 30 minutes. 
Iodomethane (33 µL, 0.53 mmol) was added and the reaction mixture stirred for a 
further 2 days at room temperature. The reaction was quenched with methanol (2 
mL), and subjected to workup method 2. The resulting brown gummy solid was 
purified by column chromatography (5% methanol in dichloromethane) to afford an 
orange gummy solid (0.046 g, 50%) which was determined to be the deprotected 
phenol of the desired product. 1H NMR (CDCl3) δ 6.86 (1 H, d, J = 8.2 Hz), 6.79 (1 
H, d, J = 2.6 Hz), 6.65 (1 H, dd, J = 8.2, 2.6 Hz), 4.33 (1 H, t, J = 4.9 Hz), 3.61 (1 
H, d, J = 14.4 Hz), 3.49 - 3.40 (4 H, m), 2.87 - 2.73 (2 H, m), 2.47 (3 H, s); 13C 
NMR (CDCl3) δ 155.0, 134.9, 127.4, 126.4, 115.8, 115.2, 75.6, 57.3, 56.9, 56.5, 
46.1; HRMS m/z: [M+H]+ Calcd for C11H16NO2 194.1181.; Found 194.1175. 
11.6.2 (R)-4-(Benzyloxy)-6-((2-methoxyethoxy)methoxy)-2-
methyl-1,2,3,4-tetrahydroisoquinoline (163)  
 
163 
The MEM protected phenol 153 (0.152 g, 0.560 mmol) was added to a suspension of 
sodium hydride (60% dispersion in mineral oil, 0.045 g, 1.1 mmol) in anhydrous 
dimethylformamide and the mixture stirred at room temperature for 30 minutes. 
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Benzyl bromide (74 μL, 0.62 mmol) was added and the reaction mixture stirred at 
room temperature for 1.5 hrs, quenched with methanol (2 mL), then subjected to 
workup method 1. The resulting yellow gummy solid was purified by column 
chromatography (2% methanol in dichloromethane) to afford the desired product as a 
yellow gummy solid (0.072 g, 36%). 1H NMR (DMSO-d6) δ 7.43 - 7.33 (4 H, m), 
7.32 - 7.25 (1 H, m), 7.06 - 6.98 (2 H, m), 6.91 - 6.86 (1 H, m), 5.22 - 5.16 (2 H, m), 
4.69 - 4.62 (2 H, m), 4.59 - 4.51 (1 H, m), 3.72 - 3.67 (2 H, m), 3.47 - 3.43 (2 H, m), 
3.41 (2 H, s), 3.21 (3 H, s), 2.94 - 2.84 (1 H, m), 2.62 - 2.54 (1 H, m), 2.34 (3 H, s). 
11.6.3 (R)-4-([1,1'-Biphenyl]-4-ylmethoxy)-6-((2-
methoxyethoxy)methoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinoline (164)  
 
164 
The MEM protected phenol 153 (0.200 g, 0.750 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.063 g, 1.6 mmol), 4-(chloromethyl)-1,1'-
biphenyl 128 (0.170 g, 0.830 mmol) and sodium iodide (0.225 g, 1.50 mmol) as 
described for 163, then subjected to workup method 1. The resulting brown gummy 
solid was purified by column chromatography (2% methanol in dichloromethane) to 
afford the desired product as an orange gummy solid (0.270 g, 83%). 1H NMR 
(DMSO-d6) δ 7.70 - 7.60 (4 H, m), 7.51 - 7.43 (4 H, m), 7.36 (1 H, s), 7.07 (1 H, d, J 
= 2.6 Hz), 7.02 (1 H, d, J = 8.4 Hz), 6.90 (1 H, dd, J = 8.3, 2.6 Hz), 5.20 (2 H, d, J = 
1.3 Hz), 4.71 (2 H, d, J = 3.8 Hz), 4.62 - 4.56 (1 H, m), 3.72 - 3.67 (2 H, m), 3.47 - 
3.40 (4 H, m), 3.21 - 3.17 (3 H, m), 2.92 (1 H, dd, J = 11.5, 4.8 Hz), 2.61 (1 H, dd, J 





tetrahydroisoquinoline (165)  
 
165 
The MEM protected phenol 153 (0.200 g, 0.750 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.060 g, 1.5 mmol), and 2-cyclohexylethyl 
methanesulfonate 242 (0.170 g, 0.830 mmol) as described for 163, then subjected to 
workup method 1. The resulting brown gummy solid was purified by column 
chromatography (2% methanol in dichloromethane) to afford the desired product as 
an orange gummy solid (0.130 g, 46%). 1H NMR (DMSO-d6) δ 7.00 (2 H, s), 6.90 - 
6.85 (1 H, m), 5.20 (2 H, s), 4.45 - 4.36 (1 H, m), 3.74 - 3.67 (2 H, m), 3.66 - 3.51 (2 
H, m), 3.49 - 3.42 (2 H, m), 3.41 - 3.35 (2 H, m), 3.22 (3 H, s), 2.91 - 2.80 (1 H, m), 
2.46 - 2.39 (1 H, m), 2.32 (3 H, s), 1.76 - 1.56 (5 H, m), 1.48 - 1.34 (3 H, m), 1.27 - 
1.06 (3 H, m), 0.95 - 0.82 (2 H, m). See pg. 241 for details on the synthesis of 2-
cyclohexylethyl methanesulfonate 242. 
11.6.5 (R)-4-(Benzyloxy)-2-methyl-1,2,3,4-tetrahydroisoquinolin-
6-ol (166)  
 
166 
The MEM protected phenol 163 (0.072 g, 0.20 mmol) was dissolved in a mixture of 
anhydrous dichloromethane and trifluoroacetic acid (1:1), and the reaction mixture 
stirred at room temperature for 45 minutes, then subjected to workup method 1. The 
resulting orange gummy solid was purified by column chromatography (5% 
methanol in dichloromethane) to afford the desired product as an orange gummy 
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solid (0.027 g, 50%). 1H NMR (DMSO-d6) δ 9.18 (1 H, s), 7.42 - 7.34 (4 H, m), 7.33 
- 7.26 (1 H, m), 6.87 (1 H, d, J = 8.3 Hz), 6.82 (1 H, d, J = 2.6 Hz), 6.61 (1 H, dd, J 
= 8.3, 2.6 Hz), 4.70 - 4.59 (2 H, m), 4.53 (1 H, t, J = 5.8 Hz), 3.36 (2 H, m), 2.90 (1 
H, dd, J = 11.5, 5.0 Hz), 2.59 - 2.47 (1 H, m), 2.33 (3 H, s); 13C NMR (DMSO-d6) δ 
155.6, 139.0, 135.7, 128.3, 127.7, 127.5, 126.8, 125.7, 114.9, 114.1, 73.3, 70.0, 57.0, 
56.7, 45.7; HRMS m/z: [M+H]+ Calcd for C17H20NO2 270.1489; Found 270.1490. 
11.6.6 (R)-4-([1,1'-Biphenyl]-4-ylmethoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-6-ol (167)  
 
167 
The MEM protected phenol 164 (0.270 g, 0.620 mmol) was deprotected as described 
for 166 and subjected to workup method 1. The resulting brown gummy solid was 
purified by column chromatography (5% methanol in dichloromethane) to afford the 
desired product as a cream coloured solid (0.068 g, 32%). m.p. 72 - 75°C; 1H NMR 
(DMSO-d6) δ 9.20 (1 H, s), 7.70 - 7.63 (4 H, m), 7.51 - 7.43 (4 H, m), 7.40 - 7.32 (1 
H, m), 6.92 - 6.84 (2 H, m), 6.63 (1 H, dd, J = 8.2, 2.6 Hz), 4.74 - 4.64 (2 H, m), 
4.57 (1 H, t, J = 5.6 Hz), 3.40 3.36 - (2 H, m), 2.92 (1 H, dd, J = 11.4, 4.8 Hz), 2.57 
(1 H, dd, J = 11.4, 6.4 Hz), 2.35 (3 H, s); 13C NMR (DMSO-d6) δ 155.5, 139.9, 
138.2, 135.7, 128.9, 128.2, 127.4, 126.6, 126.5, 114.8, 114.0, 73.4, 69.6, 57.0, 56.7, 
45.7 (note some signals conincident); HRMS m/z: [M+H]+ Calcd for C23H24NO2 




tetrahydroisoquinolin-6-ol (168)  
 
168 
The MEM protected phenol 165 (0.130 g, 0.340 mmol) was deprotected as described 
for 166 and subjected to workup method 1. The resulting brown gummy solid was 
purified by column chromatography (5% methanol in dichloromethane) to afford the 
desired product as a gummy orange solid (0.052 g, 53%). 1H NMR (DMSO-d6) δ 
9.16 (1 H, s), 6.85 (1 H, d, J = 8.2 Hz), 6.76 (1 H, d, J = 2.6 Hz), 6.60 (1 H, dd, J = 
8.2, 2.6 Hz), 4.40 - 4.32 (1 H, m), 3.66 - 3.48 (2 H, m), 3.40 - 3.25 (2 H + H2O, m), 
2.89 - 2.79 (1 H, m), 2.40 (1 H, dd, J = 11.2, 6.8 Hz), 2.30 (3 H, s), 1.74 - 1.56 (5 H, 
m), 1.47 - 1.32 (3 H, m), 1.27 - 1.06 (3 H, m), 0.95 - 0.81 (2 H, m); 13C NMR 
(DMSO-d6) δ 155.5, 136.0, 126.5, 125.6, 114.6, 113.9, 73.7, 66.0, 57.0, 56.9, 45.7, 
37.2, 33.9, 32.8, 32.8, 26.1, 25.8; HRMS m/z: [M+H]+ Calcd for C18H28NO2 





See section 11.5.1 pg, 165 for details. 1H NMR (CDCl3) δ 7.46 - 7.27 (10 H, m), 7.01 
(1 H, d, J = 2.6 Hz), 6.98 (1 H, d, J = 8.4 Hz), 6.87 (1 H, dd, J = 8.4, 2.6 Hz), 5.08 - 
4.95 (2 H, m), 4.78 - 4.57 (3 H, m), 3.60 (1 H, d, J = 14.6 Hz), 3.48 (1 H, d, J = 14.6 
Hz), 2.89 (1 H, ddd, J = 11.6, 4.7, 0.9 Hz), 2.79 (1 H, dd, J = 11.6, 6.0 Hz), 2.48 (3 
H, s); 13C NMR (CDCl3) δ 157.4, 138.7, 137.1, 135.4, 128.6, 128.4, 127.9, 127.9, 
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127.6, 127.5, 127.1, 115.1, 113.9, 73.6, 70.9, 70.1, 57.4, 57.2, 46.2 (note some peaks 
coincident); HRMS m/z: [M+H]+ Calcd for C24H26NO2 360.1958; Found 360.1951. 
11.6.9 (R)-4,6-Bis([1,1'-biphenyl]-4-ylmethoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinoline (170)  
 
170 
The isoquinoline hydrochloride 86 (0.100 g, 0.460 mmol) was added to a suspension 
of sodium hydride (60% dispersion in mineral oil, 0.058 g, 1.5 mmol) in anhydrous 
dimethylformamide and the mixture stirred at room temperature for 30 minutes. 4-
(Chloromethyl)-1,1'-biphenyl 128 (0.206 g, 1.02 mmol) was added and the reaction 
mixture stirred at room temperature for 24 hrs, quenched with methanol (2 mL) and 
then subjected to workup method 1. The resulting orange gummy solid was purified 
by column chromatography (1% methanol in dichloromethane) to afford the desired 
product as a white solid (0.017 g, 7%). m.p. 162 - 164.5 °C; 1H NMR (CDCl3) δ 7.63 
- 7.56 (8 H, m), 7.50 - 7.41 (8 H, m), 7.40 - 7.32 (2 H, m), 7.05 (1 H, d, J = 2.5 Hz), 
7.01 (1 H, d, J = 8.4 Hz), 6.90 (1 H, dd, J = 8.4, 2.5 Hz), 5.13 - 5.04 (2 H, m), 4.78 - 
4.69 (2 H, m), 4.68 (1 H, t, J = 5.2 Hz), 3.63 (1 H, d, J = 14.4 Hz), 3.49 (1 H, d, J = 
14.4 Hz), 2.91 (1 H, dd, J = 11.6, 4.7 Hz), 2.83 (1 H, dd, J = 11.6, 5.9 Hz), 2.50 (3 
H, s); 13C NMR (CDCl3) δ 157.6, 141.02, 140.96, 140.7, 137.9, 136.3, 135.6, 128.9, 
128.9, 128.5, 128.1, 127.5, 127.4, 127.30, 127.27, 127.2, 115.3, 114.0, 73.8, 70.7, 
70.0, 57.6, 57.4, 46.4 (note some signals coincident); HRMS m/z: [M+H]+ Calcd for 




tetrahydroisoquinoline (172)  
 
172 
The isoquinoline hydrochloride 86 (0.100 g, 0.460 mmol) was treated with sodium 
hydride (60% dispersion in mineral oil, 0.060 g, 1.5 mmol) and 2-cyclohexylethyl 
methanesulfonate 242 (0.210 g, 1.02 mmol) as described for 170 and then subjected 
to workup method 1. The resulting orange gummy solid was purified by column 
chromatography (1% methanol in dichloromethane) to afford the desired product as a 
pale yellow gummy solid (0.026 g, 14%). 1H NMR (CDCl3) δ 6.96 (1 H, d, J = 2.7 
Hz), 6.94 (1 H, d, J = 8.4 Hz), 6.77 (1 H, dd, J = 8.4, 2.7 Hz), 4.50 (1 H, t, J = 5.7 
Hz), 4.03 - 3.94 (2 H, m), 3.78 - 3.67 (1 H, m), 3.63 (1 H, dt, J = 9.2, 6.7 Hz), 3.55 - 
3.45 (2 H, m), 2.91 (1 H, dd, J = 11.3, 4.9 Hz), 2.64 (1 H, dd, J = 11.3, 6.4 Hz), 2.48 
- 2.42 (3 H, m), 1.85 - 1.62 (12 H, m), 1.61 - 1.42 (4 H, m), 1.34 - 1.11 (6 H, m), 1.04 
- 0.78 (4 H, m); 13C NMR (CDCl3) δ 157.9, 136.0, 127.3, 127.0, 114.8, 113.1, 74.7, 
67.3, 66.1, 57.6, 57.5, 46.4, 37.7, 36.9, 34.7, 34.7, 33.7, 33.5, 33.5, 33.4, 26.8, 26.7, 
26.53, 26.51, 26.4 (note some signals coincident); HRMS m/z: [M+H]+ Calcd for 
C26H42NO2 400.3216; Found 400.3206. See pg. 241 for details on the synthesis of 2-
cyclohexylethyl methanesulfonate 242. 
11.6.11 (4R)-4,6-Dihydroxy-2-methyl-1,2,3,4-
tetrahydroisoquinoline N-oxide (173)  
 
173 
Hydrogen peroxide (30%, 7.0 mL, 62 mmol) was added to a solution of isoquinoline 
86 as the free base (1.05 g, 5.86 mmol) in methanol (30 mL) and this was stirred at 
room temperature for 18 hrs. Excess peroxide was decomposed with manganese 
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dioxide. The manganese dioxide was removed by filtration, and the filtrate was 
concentrated under reduced pressure to afford a yellow solid as a mixture of 
diastereomers A and B (70:30) which were not separated (1.14 g, >99%). m.p. 180°C 
decomp.; 1H NMR (D2O, selected peaks of isomer A) δ 7.12 (1 H, d, J = 8.4 Hz), 
7.04 (1 H, d, J = 2.4 Hz), 6.93 (1 H, dd, J = 8.4, 2.4 Hz), 4.51 (1 H, d, J = 15.2 Hz), 
3.93 (1 H, dd, J = 12.8, 4.8 Hz), 3.73 (1 H, d, J = 12.8 Hz), 3.36 (3 H, s); 1H NMR 
(D2O, selected peaks of isomer B) δ 7.08 (1 H,d, J = 3.2 Hz), 5.20 (1 H, t, J = 6.8 
Hz), 4.62 (1 H, d, J = 14.8 Hz), 4.38 (1 H, d, J = 14.8 Hz), 3.86 (1 H, dd, J = 12.4, 
6.4), 3.57 (1 H, dd, J = 12.4, 7.6 Hz), 3.38 (3 H, s); 13C NMR (D2O, mixture of 
isomers A and B) δ 155.7, 155.6, 134.7, 134.3, 128.2, 128.1, 119.9, 119.4, 116.5, 
116.1, 114.9, 113.6, 67.9, 67.8, 67.6, 65.1, 63.8, 58.3, 57.5 (2 isomers some signals 
coincident). 
11.6.12 2-Methylisoquinolin-6(2H)-one (174)  
 
174 
Acetic anhydride (6.0 mL, 64 mmol) was added to a suspension of N-oxide 173 (1.14 
g, 5.84 mmol) in ethyl acetate (50 mL), and stirred at room temperature for 2.5 days. 
The reaction mixture was concentrated under reduced pressure, diluted with water 
(20 mL) and neutralised with solid sodium bicarbonate. This mixture was then 
concentrated under reduced pressure, adsorbed onto silica and purified by column 
chromatography (15% methanol, 2% sat. ammonia, in dichloromethane) to afford the 
desired product as a yellow gummy solid which slowly crystallised (0.59 g, 64%). 
m.p. 95 - 100°C; 1H NMR (DMSO-d6) δ 8.44 (1 H, s), 7.57 - 7.47 (2 H, m), 7.05 (1 
H, d, J = 7.1 Hz), 6.65 (1 H, dd, J = 9.2, 2.1 Hz), 6.17 (1 H, d, J = 1.8 Hz), 6.19 - 
6.13 (1 H, m), 3.86 (3 H, s); 13C NMR (D2O) δ 176.7, 144.7, 140.1, 132.9, 131.8, 




11.6.13 2-Methyl-1,2,3,4-tetrahydroisoquinolin-6-ol (175)  
 
175 
Sodium borohydride (0.333 g, 8.68 mmol) was added to a solution of isoquinolone 
174 (0.690 g, 4.34 mmol) in methanol (40 mL). This was stirred at room temperature 
for 40 minutes. The reaction mixture was concentrated under reduced pressure, 
diluted with water (50 mL), and extracted with ethyl acetate (3×50 mL) The ethyl 
acetate fractions were combined, dried over magnesium sulfate, and concentrated 
under reduced pressure to afford a cream coloured solid (0.530 g, 75%) which was 
used without further purification. m.p. 176 - 178°C (185°C lit158); 1H NMR (CDCl3) 
δ 6.84 (1 H, d, J = 8.2 Hz), 6.55 (1 H, dd, J = 8.2, 2.6 Hz), 6.39 (1 H, d, J = 2.6 Hz), 
3.52 (2 H, s), 2.77 (2 H, t, J = 6.0 Hz), 2.66 (2 H, t, J = 6.0 Hz), 2.44 (3 H, s); 13C 





The isoquinoline 175 (0.100 g, 0.610 mmol) was added to a suspension of sodium 
hydride (60% dispersion in mineral oil, 0.034 g, 0.85 mmol) in anhydrous 
dimethylformamide and the mixture stirred at room temperature for 30 minutes. 
Benzyl bromide (80 µL, 0.67 mmol) was added and the reaction mixture stirred at 
room temperature for 2 days. The reaction was quenched with methanol (2 mL) and 
then subjected to workup method 1. The resulting yellow gummy solid was purified 
by column chromatography (5% methanol in dichloromethane) to afford the desired 
product as a colourless gummy solid (0.107 g, 69%). m.p. 51 - 54°C; 1H NMR 
(CDCl3) δ 7.45 - 7.28 (5 H, m), 6.93 (1 H, d, J = 8.4 Hz), 6.79 - 6.74 (1 H, m), 6.73 
(1 H, d, J = 2.5 Hz), 5.03 (2 H, s), 3.53 (2 H, s), 2.90 (2 H, t, J = 5.9 Hz), 2.73 - 2.62 
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(2 H, m), 2.46 (3 H, s); 13C NMR (CDCl3) δ 157.5, 137.1, 134.2, 128.6, 127.9, 127.5, 
127.5, 125.3, 114.4, 113.3, 70.1, 56.7, 52.3, 45.1, 28.4; HRMS m/z: [M+H]+ Calcd 
for C17H20NO 254.1539; Found 254.1538. 
11.6.15 6-([1,1'-Biphenyl]-4-ylmethoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinoline (177)  
 
177 
The isoquinoline 175 (0.101 g, 0.620 mmol) was treated with sodium hydride (60% 
dispersion in mineral oil, 0.031 g, 0.78 mmol) and 4-(chloromethyl)-1,1'-biphenyl 
128 (0.136 g, 0.670 mmol) as described for 176 and then subjected to workup 
method 1. The resulting cream coloured solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford the desired product as a 
white solid (0.060 g, 30%). m.p. 132 - 136°C; 1H NMR (CDCl3) δ 7.64 - 7.56 (4 H, 
m), 7.52- 7.41 (4 H, m), 7.39 - 7.31 (1 H, m), 6.96 (1 H, d, J = 8.4 Hz), 6.81 (1 H, 
dd, J = 8.4, 2.4 Hz), 6.76 (1 H, d, J = 2.4 Hz), 5.08 (2 H, s), 3.63 (2 H, s), 3.03 - 2.90 
(2 H, m), 2.81 - 2.73 (2 H, m), 2.52 (3 H, s); 13C NMR (CDCl3) δ 157.4, 141.0, 
141.0, 136.4, 135.01, 128.9, 128.1, 127.6, 127.5, 127.3, 127.2, 114.5, 113.1, 69.9, 
57.5, 52.9, 46.1, 29.5 (note some signals coincident); HRMS m/z: [M+H]+ Calcd for 
C23H24NO 330.1852; Found 330.1853. 
11.6.16 6-(2-Cyclohexylethoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinoline (178)  
 
178 
The isoquinoline 175 (0.100 g, 0.610 mmol) was treated with sodium hydride (60% 
dispersion in mineral oil, 0.030 g, 0.73 mmol) and 2-cyclohexylethyl tosylate 107 
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(0.190 g, 0.670 mmol) as described for 176 and then subjected to workup method 1. 
The resulting brown gummy solid was purified by column chromatography (5% 
methanol in dichloromethane) to afford the desired product as a colourless gummy 
solid (0.137 g, 82%). 1H NMR (CDCl3) δ 6.92 (1 H, d, J = 8.4 Hz), 6.69 (1 H, dd, J 
= 8.4, 2.4 Hz), 6.64 (1 H, d, J = 2.4 Hz), 3.95 (2 H, t, J = 6.8 Hz), 3.58 (2 H, s), 2.92 
(2 H, t, J = 5.9 Hz), 2.73 (2 H, t, J = 5.9 Hz), 2.49 (3 H, s), 1.80 - 1.58 (7 H, m), 1.54 
- 1.43 (1 H, m), 1.32 - 1.08 (3 H, m), 1.01 - 0.91 (2 H, m); 13C NMR (CDCl3) δ 
157.8, 134.2, 127.4, 125.2, 113.9, 112.9, 66.0, 56.8, 52.5, 45.3, 36.7, 34.6, 33.3, 28.7, 
26.5, 26.3; HRMS m/z: [M+H]+ Calcd for C18H28NO 274.2165; Found 274.2161. See 
pg. 238 for details on the synthesis of 2-cyclohexylethyl tosylate 107. 
11.6.17 4-(3-((2-Methyl-1,2,3,4-tetrahydroisoquinolin-6-
yl)oxy)propyl)morpholine (179)  
 
179 
The isoquinoline 175 (0.101 g, 0.620 mmol) was treated with sodium hydride (60% 
dispersion in mineral oil, 0.037 g, 0.93 mmol) and  4-(3-chloropropyl)morpholine 
117 (0.111 g, 0.680 mmol) as described for 176 and then subjected to workup 
method 1. The resulting brown gummy solid was purified by column 
chromatography (10% methanol, 0.5% sat. ammonia in dichloromethane) to afford 
the desired product as a colourless gummy solid (0.103 g, 57%). 1H NMR (CDCl3) δ 
6.91 (1 H, d, J = 8.4 Hz), 6.68 (1 H, dd, J = 8.4, 2.5 Hz), 6.63 (1 H, d, J = 2.5 Hz), 
3.97 (2 H, t, J = 6.4 Hz), 3.74 - 3.66 (4 H, m), 3.53 (2 H, s), 2.92 - 2.85 (2 H, m), 
2.68 (2 H, t, J = 5.9 Hz), 2.53 - 2.47 (2 H, m), 2.47 - 2.41 (7 H, m), 1.98 - 1.88 (2 H, 
m); 13C NMR (CDCl3) δ 157.8, 134.4, 127.6, 125.5, 114.1, 113.1, 67.1, 66.2, 57.0, 
55.7, 53.9, 52.6, 45.5, 28.8, 26.6; HRMS m/z: [M+H]+ Calcd for C17H27N2O2 




tetrahydroisoquinolin-4-yl benzoate (180)  
 
180 
Isoquinoline 129 (0.102 g, 0.290 mmol) was dissolved in anhydrous dichloromethane 
(10 mL). Triethylamine (80 μL, 0.58 mmol) was added followed by benzoyl chloride 
(51 μL, 0.44 mmol). The reaction mixture was stirred at room temperature for 1 hour. 
The reaction mixture was diluted with water (10 mL) and the organic phase 
separated, dried over magnesium sulfate, and concentrated under reduced pressure to 
afford a cream coloured solid which was purified by column chromatography (2% 
methanol in dicloromethane) to give the desired product as a colourless gummy solid 
which slowly crystallised (0.106 g, 81%). m.p. 132.5 - 136.5 °C; 1H NMR (CDCl3) δ 
8.11 - 8.05 (2 H, m), 7.59 - 7.50 (5 H, m), 7.49 - 7.32 (7 H, m), 7.07 (1 H, d, J = 8.5 
Hz), 7.03 (1 H, d, J = 2.8 Hz), 6.96 (1 H, dd, J = 8.5, 2.8 Hz), 6.23 (1 H, t, J = 4.5 
Hz), 5.08 (2 H, s), 3.76 (1 H, d, J = 14.7 Hz), 3.47 (1 H, d, J = 14.7 Hz), 2.98 (2 H, 
d, J = 4.6 Hz), 2.50 (3 H, s); 13C NMR (CDCl3) δ 166.8, 157.7, 141.0, 140.9, 136.0, 
133.3, 133.2, 130.3, 130.1, 128.9, 128.7, 128.5, 128.1, 127.6, 127.5, 127.4, 127.3, 
116.1, 114.3, 70.0, 69.5, 57.7, 57.4, 46.0; HRMS m/z: [M+H]+ Calcd for C30H28NO3 
450.2064; Found 450.2070; [α]D +29.8° (c 1.00, CH2Cl2). 
11.6.19 (S)-6-([1,1'-Biphenyl]-4-ylmethoxy)-2-methyl-1,2,3,4-
tetrahydroisoquinolin-4-yl benzoate (181)  
 
181 
Isoquinoline 129 (0.020 g, 0.58 mmol) and triphenylphosphine (0.186 g, 0.710 
mmol) were dissolved in anhydrous tetrahydrofuran (10 mL) and cooled to -10°C. 
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Diisopropyl azodicarboxylate (138 μL, 0.700 mmol) was added and the reaction 
mixture stirred at -10°C for a further 10 minutes. Benzoic acid (0.072 g, 0.58 mmol) 
was dissolved in anhydrous tetrahydrofuran (2 mL) and added to the reaction mixture 
which was then allowed to warm to room temperature and stirred for a further 3.5 
hrs. The reaction mixture was concentrated under reduced pressure to afford an 
orange gummy solid which was purified by column chromatography (50:50, 
ethylacetate:petroleum spirits 40-60) to give the desired product as a pale orange 
solid (0.110 g, 42%). m.p. 136.5 - 138.5 °C; 1H NMR (CDCl3) δ 8.09 - 8.04 (2 H, 
m), 7.57 - 7.49 (5 H, m), 7.48 - 7.31 (7 H, m), 7.06 (1 H, d, J = 8.6 Hz), 7.02 (1 H, d, 
J = 2.6 Hz), 6.95 (1 H, dd, J = 8.6, 2.6 Hz), 6.22 (1 H, t, J = 4.6 Hz), 5.07 (2 H, s), 
3.72 (1 H, d, J = 14.4 Hz), 3.45 (1 H, d, J = 14.4 Hz), 3.01 - 2.88 (2 H, m), 2.53 - 
2.39 (3 H, m); 13C NMR (CDCl3) δ 166.8, 157.7, 141.0, 140.9, 136.0, 133.3, 133.2, 
130.4, 130.1, 128.9, 128.8, 128.45, 128.1, 127.6, 127.5, 127.4, 127.3, 116.0, 114.3, 
70.0, 69.6, 57.8, 57.4, 46.0; HRMS m/z: [M+H]+ Calcd for C30H28NO3 450.2064; 
Found 450.2072; [α]D -37.4° (c 1.01, CH2Cl2). 
11.6.20 2-Methyl-6-(3-phenylpropoxy)isoquinoline-1,3,4(2H)-
trione (182)  
 
182 
Isoquinoline 105 (0.101 g, 0.340 mmol) was dissolved in anhydrous dichloromethane 
(6 mL). Activated manganese dioxide (0.307 g, 3.50 mmol) was added and the 
reaction mixture stirred at room temperature for 24 hrs. The reaction mixture was 
filtered through a 1 cm bed of celite, the filter cake was washed with 
dichloromethane (100 mL). The resulting filtrate was concentrated under reduced 
pressure to afford an orange gummy solid. This was purified by column 
chromatography (20% ethyl acetate in petroleum spirits 40-60) to give the title 
compound as a yellow solid (0.013 g, 12%). 1H NMR(CDCl3) δ 8.26 (1 H, d, J = 8.7 
Hz), 7.58 (1 H, d, J = 2.6 Hz), 7.36 (1 H, dd, J = 8.7, 2.6 Hz), 7.34 - 7.28 (2 H, m), 
7.25 - 7.19 (3 H, m), 4.13 (2 H, t, J = 6.2 Hz), 3.47 (3 H, s), 2.84 (2 H, t, J = 7.5 Hz), 
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2.24 - 2.13 (2 H, m); 13C NMR (101 MHz, CDCl3) δ 174.9, 163.9, 162.3, 157.7, 
140.9, 132.6, 132.0, 128.7, 128.6, 126.3, 123.8, 122.8, 110.9, 68.2, 32.1, 30.5, 27.5; 
HRMS m/z: [M+H]+ Calcd for C19H18NO4 324.1230; Found 324.1230. 
11.6.21 6-((tert-Butyldiphenylsilyl)oxy)-2-methyl-2,3-
dihydroisoquinolin-4(1H)-one hydrochloride (187) 
 
187 
TBDPS protected phenol 152 (0.800 g, 1.92 mmol) was dissolved in acetone (60 
mL) and cooled to -20°C. Jones reagent (1.3 M, 3.70 mL, 4.80 mmol) was added, 
and the reaction mixture was allowed to warm to 0°C. The reaction mixture was 
diluted with methanol (80 mL) and stirred at room temperature for 20 minutes. The 
resulting green suspension was separated by filtration and the filtrate was 
concentrated under reduced pressure to afford a green oil. This was diluted with HCl 
(1 M, 20 mL) and extracted with ethyl acetate (3×70 mL). The ethyl acetate fractions 
were combined, dried over magnesium sulfate, and concentrated under reduced 
pressure to afford a yellow gummy solid. This was dissolved in dichloromethane 
(100 mL) and concentrated under reduced pressure to afford a pale yellow solid 
(0.897 g), which contained a mixture of the desired product as the hydrochloride salt 
and starting material (60:40) which were not seperated due to poor stability of the 
free base. 1H NMR (CDCl3) δ 7.74 - 7.67 (4 H + starting material, m), 7.51 (1 H, d, J 
= 2.6 Hz), 7.46 - 7.33 (6 H + starting material, m), 6.92 (1 H, d, J = 8.4 Hz), 6.82 (1 
H, dd, J = 8.4, 2.6 Hz), 3.62 (2 H, s), 3.25 (1 H, s), 2.46 (3 H, s), 1.13 - 1.08 (9 H + 




tetrahydroisoquinolin-4-ol (188)  
 
188 
Methylmagnesium iodide (1 M, 1.5 mL, 1.5 mmol) was added to a solution of ketone 
187 (0.100 g, 0.220 mmol) in anhydrous tetrahydrofuran (20 mL), and heated at 
45°C for 18 hrs. The reaction mixture was concentrated under reduced pressure, 
diluted with sat. chloride solution (20 mL) and water (10 mL), and extracted with 
ethyl acetate (3×20 mL). The ethyl acetate fractions were combined, dried over 
magnesium sulfate and concentrated under reduced pressure to afford an orange 
gummy solid. This was purified by column chromatography (5% methanol, 1% sat. 
ammonia in dichloromethane) to afford the desired compound as a pale orange 
gummy solid (0.039 g, 41%). 1H NMR (CDCl3) δ 7.75 - 7.65 (4 H, m), 7.45 - 7.30 (6 
H, m), 6.94 (1 H, d, J = 2.6 Hz), 6.69 (1 H, d, J = 8.2 Hz), 6.59 (1 H, dd, J = 8.2, 2.6 
Hz), 3.54 (1 H, d, J = 14.4 Hz), 3.21 (1 H, d, J = 14.4 Hz), 2.75 (1 H, dd, J = 11.5, 
1.4 Hz), 2.44 - 2.33 (4 H, m), 1.29 (3 H, s), 1.13 - 1.07 (9 H, m); 13C NMR (CDCl3) δ 
154.8, 140.6, 135.7, 135.7, 130.0, 130.0, 127.9, 127.9, 127.8, 127.0, 119.4, 117.1, 
68.6, 66.5, 57.8, 45.7, 26.7, 25.5, 19.6; HRMS m/z: [M+H]+ Calcd for C27H34NO2Si 
432.2353; Found 432.2355. 
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Phenol 175 (0.160 g, 0.980 mol) was dissolved in anhydrous dichloromethane (20 
mL). Triethylamine (265 μL, 1.96 mmol) was added and the reaction mixture cooled 
to -78°C. Triflic anhydride (330 μL, 1.96 mmol) was added and the reaction mixture 
stirred for 2 hrs keeping the temperature below -10°C. Water (20 mL) was added, the 
organic phase separated, dried over magnesium sulfate, and concentrated under 
reduced pressure to afford an orange solid. This was purified by column 
chromatography (3% methanol in dichloromethane) to afford the desired product as a 
pale yellow gummy solid (0.103 g, 36%). 1H NMR (CDCl3) δ 7.10 7.05 - (1 H, m), 
7.04 - 6.99 (2 H, m), 3.56 (2 H, s), 2.94 (2 H, t, J = 6.0 Hz), 2.68 (2 H, t, J = 5.9 Hz), 
2.48 - 2.42 (3 H, m); 13C NMR (CDCl3) δ 149.3, 132.9, 129.1, 127.3, 121.8, 120.8, 
119.6 (q, JFC = 160 Hz), 54.5, 51.3, 43.1, 25.2. 
11.7.2 2-Methyl-6-phenyl-1,2,3,4-tetrahydroisoquinoline (190)  
 
190 
Triflate 189 (0.102 g, 0.340 mmol) was combined with phenylboronic acid (0.050 g, 
0.41 mmol), triphenylphosphine (0.007 g, 0.03 mmol), potassium carbonate (0.195 g, 
1.41 mmol), dioxane (4.0 mL), and water (4.0 mL). This mixture was degassed by 
bubbling with nitrogen for 15 minutes. Palladium acetate (0.0052 g, 0.020 mmol) 
was added and the reaction mixture heated to reflux for 6 hrs and subjected to 
workup method 3. The resulting brown gummy solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford the desired product as a 
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pale brown solid (0.025 g, 33%). m.p. 63 - 66.5 °C; 1H NMR (CDCl3) δ 7.60 - 7.54 
(2 H, m), 7.45 - 7.30 (5 H, m), 7.10 (1 H, d, J = 7.9 Hz), 3.70 (2 H, s), 3.02 (2 H, t, J 
= 6.1 Hz), 2.80 (2 H, t, J = 5.9 Hz), 2.53 (3 H, s); 13C NMR (CDCl3) δ 141.2, 139.6, 
134.0, 133.3, 128.9, 127.5, 127.3, 127.2, 127.0, 124.8, 57.6, 52.9, 45.9, 29.1; HRMS 
m/z: [M+H]+ Calcd for C16H18N 224.1439; Found 224.1434. 
11.7.3 6-([1,1'-Biphenyl]-4-yl)-2-methyl-1,2,3,4-
tetrahydroisoquinoline (191)  
 
191 
Triflate 189 (0.100 g, 0.340 mmol) was treated with 4-biphenylboronic acid (0.084 g, 
0.42 mmol), triphenylphosphine (0.0069 g, 0.030 mmol), potassium carbonate (0.193 
g, 1.40 mmol), and palladium acetate (0.0056 g, 0.020 mmol), as described for 190 
and subjected to workup method 3. The resulting brown solid was purified by 
column chromatography (5% methanol in dichloromethane) to afford the desired 
product as a cream coloured solid (0.053 g, 52%). m.p. 161 - 163.5 °C; 1H NMR 
(CDCl3) δ 7.68 - 7.60 (6 H, m), 7.49 - 7.33 (5 H, m), 7.14 - 7.09 (1 H, m), 3.65 (2 H, 
s), 3.01 (2 H, t, J = 5.9 Hz), 2.75 (2 H, t, J = 5.9 Hz), 2.50 (3 H, s); 13C NMR 
(CDCl3) δ 140.9, 140.2, 140.1, 138.8, 134.4, 134.1, 128.9, 127.6, 127.5, 127.4, 
127.3, 127.2, 127.1, 124.6, 57.9, 53.1, 46.2, 29.5; HRMS m/z: [M+H]+ Calcd for 







Triflate 189 (0.100 g, 0.340 mmol) was treated with 2-napthylboronic acid (0.072 g, 
0.41 mmol), triphenylphosphine (0.0072 g, 0.030 mmol), potassium carbonate (0.191 
g, 1.38 mmol), and palladium acetate (0.0052 g, 0.020 mmol), as decribed for 190 
and subjected to workup method 3. The resulting orange gummy solid was purified 
by column chromatography (5% methanol in dichloromethane) to afford the desired 
product as an orange solid (0.040 g, 43%). m.p. 92 - 95.5 °C; 1H NMR (CDCl3) δ 
8.04 - 7.99 (1 H, m), 7.92 - 7.82 (3 H, m), 7.73 (1 H, dd, J = 8.6, 1.8 Hz), 7.53 - 7.43 
(4 H, m), 7.14 (1 H, d, J = 8.1 Hz), 3.68 (2 H, s), 3.04 (2 H, t, J = 5.9 Hz), 2.78 (2 H, 
t, J = 5.9 Hz), 2.52 (3 H, s); 13C NMR (CDCl3) δ 139.3, 138.6, 134.3, 133.9, 132.7, 
128.5, 128.3, 127.8, 127.7, 127.1, 126.4, 125.9, 125.69, 125.66, 125.0, 57.8, 53.0, 
46.1, 29.4 (note some signals conincident); HRMS m/z: [M+H]+ Calcd for C20H20N 
274.1596; Found 274.1591. 
11.7.5 2-Methyl-6-phenoxy-1,2,3,4-tetrahydroisoquinoline (195)  
 
195 
Isoquinoline 175 (0.101 g, 0.610 mmol), bromobenzene (54 μL, 0.51 mmol), 2-(di-
tert-butyphosphino)biphenyl (0.0051 g, 0.017 mmol), tripotassium phosphate (0.219 
g, 1.03 mmol) and anhydrous toluene were combined and degassed by bubbling with 
nitrogen for 15 minutes. Palladium acetate (0.0024 g, 0.010 mmol) was added and 
the reaction mixture heated at reflux for 24 hrs, and subjected to workup method 1. 
The resulting brown gummy solid was purified by column chromatography (5% 
methanol in dichloromethane) to afford the desired product as a pale orange gummy 
solid (0.032 g, 22%). 1H NMR (CDCl3) δ 7.35 - 7.28 (2 H, m), 7.11 - 7.06 (1 H, m), 
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7.02 - 6.96 (3 H, m), 6.84 - 6.80 (1 H, m), 6.79 6.76 - (1 H, m), 3.71 (2 H, s), 3.00 - 
2.90 (2 H, m), 2.87 - 2.79 (2 H, m), 2.56 (3 H, s) ;13C NMR (CDCl3) δ 157.5, 155.9, 
134.9, 129.9, 127.9, 123.2, 118.9, 118.8, 117.3, 56.9, 52.4, 45.4, 28.5 (note some 






Isoquinoline 175 (0.102 g, 0.620 mmol) was treated with 4-bromobiphenyl (0.120 g, 
0.510 mmol), 2(di-tert-butyphosphino)biphenyl (0.0049 g, 0.016 mmol), 
tripotassium phosphate (0.220 g, 1.04 mmol), and palladium acetate (0.0025 g, 0.010 
mmol) as described for 195, and subjected to workup method 1. The resulting orange 
gummy solid was purified by column chromatography (5% methanol in 
dichloromethane) to afford the desired product as a brown gummy solid which 
slowly crystallised (0.072 g, 37%). m.p. 91 - 94.5 °C; 1H NMR (CDCl3) δ 7.59 - 7.53 
(4 H, m), 7.47 - 7.41 (2 H, m), 7.36 - 7.31 (1 H, m), 7.08 - 7.04 (2 H, m), 7.03 (1 H, 
d, J = 7.8 Hz), 6.89 - 6.85 (1 H, m), 6.84 6.83 - (1 H, m), 3.64 (2 H, s), 2.95 (2 H, t, J 
= 6.1 Hz), 2.76 (2 H, t, J = 6.1 Hz), 2.52 (3 H, s); 13C NMR (CDCl3) δ 157.3, 155.5, 
140.7, 136.2, 135.4, 128.9, 128.5, 127.9, 127.1, 127.0, 119.1, 118.8, 117.2, 57.4, 
52.6, 45.8, 29.0 (some signals coincident); HRMS m/z: [M+H]+ Calcd for C22H22NO 
316.1701; Found 316.1699. 
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11.8 Modification of the Nitrogen 
11.8.1 1,2,3,4-Tetrahydroisoquinoline-4,6-diol (200) and 1,2,3,4-





Formaldehyde (37%, 3.0 mL, 36 mmol) was added to a mixture of norphenylephrine 
hydrochloride (3.00 g, 15.8 mmol) in ethanol (30 mL). The resulting colourless 
solution was stirred at room temperature for 5 days. Filtration of the reaction mixture 
afforded a white powder which was recrystallised from ethanol to give the ortho 
substituted product 201 as colourless needles (0.39 g, 12%). Decomp. 210 °C; 1H 
NMR (D2O)  7.38 - 7.33 (1 H, m), 7.08 (1 H, dd, J = 7.6, 0.4 Hz), 6.98 (1 H, dd, J 
= 8.4, 0.8 Hz), 5.07 (1 H, t, J = 3.1 Hz), 4.47 (1 H, d, J = 16.5 Hz), 4.23 (1 H, d, J = 
16.5 Hz), 3.63 (1 H, ddd, J = 13.5, 3.1, 1.0 Hz), 3.51 (1 H, dd, J = 13.5, 3.1 Hz); 13C 
NMR (D2O)  152.5, 134.1, 129.3, 120.8, 115.2, 115.1, 62.2, 47.2, 40.4. The ethanol 
mother liquor was concentrated under reduced pressure to afford a pale yellow 
gummy solid which was recrystallised from an ethanol ether mixture to afford the 
para substituted product (200) as a white solid (1.05 g, 33%). m.p. 210 - 211.2 °C; 
1H NMR (D2O)  7.20 (1 H, d, J = 8.4 Hz), 7.01 (1 H, d, J = 2.5 Hz), 6.97 (1 H, dd, 
J = 8.4, 2.5 Hz), 5.04 (1 H, t, J = 3.6 Hz), 4.42 (1 H, d, J = 16.5 Hz), 4.32 (1 H, d, J 
= 16.5 Hz), 3.61 (1 H, ddd, J = 13.5, 3.6, 0.8 Hz), 3.54 (1 H, dd, J = 13.5, 3.6 Hz); 
13C NMR (D2O)  155.5, 134.3, 128.2, 119.3, 116.8, 115.3, 62.4, 47.6, 43.9. 
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11.8.2 2-Ethyl-1,2,3,4-tetrahydroisoquinoline-4,6-diol (202) 
 
202 
Isoquinoline hydrochloride 200 (0.088 g, 0.44 mmol) was added to a solution of N,N-
diisopropylethylamine (380 µL, 2.20 mmol) in anhydrous dimethylformamide. 1-
Bromoethane (36 µL, 0.48 mmol) was added and the reaction mixture stirred for a 
further 1.5 days, and subjected to workup method 1. The resulting orange gummy 
solid was purified by column chromatography (10% methanol in dichloromethane) to 
afford the desired product as a white solid (0.047 g, 55%). m.p. 125.5 - 128.5 °C; 1H 
NMR (CDCl3) δ 6.85 (1 H, d, J = 8.4 Hz), 6.79 (1 H, d, J = 2.6 Hz), 6.67 (1 H, dd, J 
= 8.4, 2.6 Hz), 4.53 (1 H, t, J = 3.3 Hz), 3.72 (1 H, d, J = 14.5 Hz), 3.31 (1 H, d, J = 
14.5 Hz), 2.97 (1 H, dd, J = 11.8, 3.3 Hz), 2.67 - 2.54 (3 H, m), 1.22 - 1.08 (3 H, m); 
13C NMR (CDCl3) δ 155.3, 137.2, 127.6, 125.8, 116.1, 115.6, 66.9, 57.9, 55.0, 52.1, 
11.9; HRMS m/z: [M+H]+ Calcd for C11H16NO2 194.1176; Found 194.1172. 
11.8.3 2-Propyl-1,2,3,4-tetrahydroisoquinoline-4,6-diol (203) 
 
203 
Isoquinoline hydrochloride 200 (0.082 g, 0.41 mmol) was treated with N,N-
diisopropylethylamine (354 µL, 2.03 mmol) and 1-bromopropane (41 µL, 0.45 
mmol) as described for 202 and then subjected to workup method 1. The resulting 
orange gummy solid was purified by column chromatography (5% methanol in 
dichloromethane) to afford the desired product as a white solid (0.040 g, 47%). m.p. 
140 - 143.2 °C; 1H NMR (CDCl3) δ 6.93 - 6.82 (2 H, m), 6.70 (1 H, d, J = 8.4 Hz), 
4.53 (1 H, br. s.), 3.84 - 3.69 (1 H, m), 3.37- 3.24 (1 H, m), 3.02 (1 H, d, J = 11.7 
Hz), 2.64 - 2.40 (3 H, m), 1.73 - 1.53 (2 H, m), 1.10 - 0.83 (3 H, m); 13C NMR 
(CDCl3) δ 155.2, 137.4, 127.7, 126.3, 116.0, 115.6, 67.2, 60.1, 58.3, 55.6, 20.1, 12.0; 
HRMS m/z: [M+H]+ Calcd for C12H18NO2 208.1332; Found 208.1331.  
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11.8.4 2-Benzyl-1,2,3,4-tetrahydroisoquinoline-4,6-diol (204)  
 
204 
Isoquinoline hydrochloride 200 (0.187 g, 0.930 mmol) was treated with N,N-
diisopropylethylamine (860 µL, 4.95 mmol) and benzyl bromide (125 µL, 1.05 
mmol) as described for 202 and then subjected to workup method 1. The resulting 
yellow gummy solid was purified by column chromatography (5% methanol in 
dichloromethane) to afford the desired product as a colourless gummy solid which 
slowly crystallised (0.210 g, 88%). m.p. 50 - 52.5 °C; 1H NMR (CDCl3) δ 7.39 - 7.27 
(5 H, m), 6.90 (1 H, d, J = 2.6 Hz), 6.85 (1 H, d, J = 8.4 Hz), 6.70 (1 H, dd, J = 8.4, 
2.6 Hz), 4.53 (1 H, t, J = 2.9 Hz), 3.78 - 3.68 (3 H, m), 3.32 (1 H, d, J = 14.5 Hz), 
3.04 (1 H, dt, J = 11.7, 1.6 Hz), 2.63 (1 H, dd, J = 11.7, 2.6 Hz); 13C NMR (CDCl3) 
δ 155.4, 137.0, 136.6, 129.6, 128.7, 127.8, 127.7, 125.5, 116.1, 115.6, 67.0, 62.5, 





Isoquinoline hydrochloride 200 (0.100 g, 0.500 mmol) was treated with N,N-
diisopropylethylamine (435 µL, 2.50 mmol) and 4-(chloromethyl)-1,1'-biphenyl 128 
(0.111 g, 0.550 mmol) as described for 202 and then subjected to workup method 1. 
The resulting yellow gummy solid was purified by column chromatography (5% 
methanol in dichloromethane) to afford the desired product as a colourless gummy 
solid which slowly crystallised (0.111 g, 67%). m.p. 59 - 63.5 °C; 1H NMR (CDCl3) 
δ 7.62 - 7.53 (4 H, m), 7.48 - 7.40 (4 H, m), 7.38 - 7.32 (1 H, m), 6.90 (1 H, d, J = 
2.5 Hz), 6.85 (1 H, d, J = 8.3 Hz), 6.71 (1 H, dd, J = 8.3, 2.5 Hz), 4.55 (1 H, t, J = 
3.1 Hz), 3.81 - 3.68 (3 H, m), 3.41 - 3.31 (1 H, m), 3.05 (1 H, dd, J = 11.7, 3.1 Hz), 
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2.66 (1 H, dd, J = 11.7, 2.9 Hz); 13C NMR (CDCl3) δ 155.3, 140.9, 140.5, 137.3, 
136.5, 129.8, 128.9, 127.7, 127.4, 127.3, 127.2, 126.1, 116.0, 115.6, 67.3, 62.3, 58.1, 
55.4; HRMS m/z: [M+H]+ Calcd for C22H22NO2 332.1651; Found 332.1644. 
11.8.6 tert-Butyl 4,6-dihydroxy-3,4-dihydroisoquinoline-2(1H)-
carboxylate (206)  
 
206 
Isoquinoline hydrochloride 200 (0.500 g, 2.48 mmol) was dissolved in methanol (10 
mL). Triethylamine (1.2 mL, 8.6 mmol) was added and the reaction mixture stirred at 
room temperature for 10 minutes. Di-tert-butyl dicarbonate (0.820 g, 3.76 mmol) 
was added and the reaction mixture stirred at room temperature for a further 2 hrs. 
The reaction mixture was concentrated under reduced pressure, diluted with 10% 
isopropyl alcohol in ethyl acetate (20 mL) and washed with 1M hydrochloric acid 
(20 mL), followed by 5% sodium bicarbonate solution (20 mL). The ethyl acetate 
fraction was dried over magnesium sulfate, and concentrated under reduced pressure 
to afford a white solid (0.64 g, >95%). This was used without further purification. 1H 
NMR (CDCl3)  6.98 (1 H, d, J = 8.4 Hz), 6.94 (1 H, d, J = 2.7 Hz), 6.78 (1 H, dd, J 
= 8.4, 2.7 Hz), 4.70 - 4.59 (2 H, m), 4.40 (1 H, s), 3.87 - 3.75 (1 H, m), 3.66 - 3.58 (1 
H, m), 1.50 (9 H, s).  
11.8.7 tert-Butyl 6-(benzyloxy)-4-hydroxy-3,4-
dihydroisoquinoline-2(1H)-carboxylate (207)  
 
207 
N-Protected phenol 206 (0.200 g, 0.750 mmol) was added to a suspension of sodium 
hydride (60% dispersion in mineral oil, 0.037 g, 0.91 mmol) in anhydrous 
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dimethylformamide and the mixture stirred at room temperature for 30 minutes. 
Benzyl bromide (100 μL, 0.84 mmol) was added and the reaction mixture stirred at 
room temperature for 24 hrs. The reaction was quenched with methanol (2 mL) and 
subjected to workup method 1. The resulting orange gummy solid was purified by 
column chromatography (5% methanol in dichloromethane) to afford the desired 
product as an orange gummy solid (0.222 g, 83%). 1H NMR (CDCl3) δ 7.47 - 7.31 (5 
H, m), 7.11 (1 H, d, J = 2.6 Hz), 7.06 (1 H, d, J = 8.4 Hz), 6.93 (1 H, dd, J = 8.4, 2.6 
Hz), 5.11 - 5.07 (2 H, m), 4.75 - 4.63 (2 H, m), 4.42 (1 H, d, J = 16.7 Hz), 3.83 (1 H, 
dd, J = 13.3, 5.4 Hz), 3.66 (1 H, dd, J = 13.3, 3.7 Hz), 1.54 - 1.46 (9 H, m). 
11.8.8 tert-Butyl 6-([1,1'-biphenyl]-4-ylmethoxy)-4-hydroxy-3,4-
dihydroisoquinoline-2(1H)-carboxylate (208)  
 
208 
N-Protected phenol 206 (0.200 g, 0.750 mmol) was treated with sodium hydride 
(60% dispersion in mineral oil, 0.036 g, 0.90 mmol) and 4-(chloromethyl)-1,1'-
biphenyl 128 (0.168 g, 0.830 mmol) as described for 207, and subjected to workup 
method 1. The resulting brown gummy solid was purified by column 
chromatography (1% methanol in dichloromethane) to afford the desired product as a 
colourless gummy solid (0.269 g, 83%). 1H NMR (CDCl3) δ 7.66 - 7.56 (4 H, m), 
7.54 - 7.41 (4 H, m), 7.40 - 7.33 (1 H, m), 7.14 (1 H, d, J = 2.6 Hz), 7.06 (1 H, d, J = 
8.5 Hz), 6.94 (1 H, dd, J = 8.5, 2.6 Hz), 5.12 - 5.10 (2 H, m), 4.76 - 4.70 (1 H, m), 
4.66 (1 H, d, J = 16.6 Hz), 4.43 (1 H, d, J = 16.6 Hz), 3.79 (1 H, dd, J = 13.4, 5.4 







N-Protected phenol 206 (0.190 g, 0.720 mmol) was treated with sodium hydride 
(60% dispersion in mineral oil, 0.036 g, 0.90 mmol) and 2-cyclohexylethyl tosylate 
107 (0.230 g, 0.830 mmol) as described for 207, and subjected to workup method 1. 
The resulting brown gummy solid was purified by column chromatography (1% 
methanol in dichloromethane) to afford the desired product as a colourless gummy 
solid (0.106 g, 39%). 1H NMR (CDCl3) δ 7.03 (1 H, d, J = 8.5 Hz), 6.99 (1 H, d, J = 
2.6 Hz), 6.84 (1 H, dd, J = 8.5, 2.6 Hz), 4.73 - 4.66 (1 H, m), 4.40 (1 H, d, J = 16.5 
Hz), 4.05 - 3.94 (3 H, m), 3.80 (1 H, d, J = 5.4 Hz), 3.65 (1 H, d, J = 3.6 Hz), 1.82 - 
1.61 (7 H, m), 1.53 - 1.47 (9 H, m), 1.32 - 1.12 (4 H, m), 0.97 (2 H, dd, J = 11.5, 3.1 
Hz). See pg. 238 for details on the synthesis of 2-cyclohexylethyl tosylate 107. 
11.8.10 6-(Benzyloxy)-1,2,3,4-tetrahydroisoquinolin-4-ol (210)  
 
210 
N-Protected isoquinoline 207 (0.194 g, 0.550 mmol) was dissolved in a mixture of 
anhydrous dichloromethane and trifluoroacetic acid (2:1) and stirred at room 
temperature for 20 minutes, and then subjected to workup method 2. The resulting 
brown gummy solid was purified by column chromatography (5% methanol, 0.5% 
sat. ammonia solution, in dichloromethane) to afford the desired product as a 
colourless gummy solid which slowly crystallised (0.058 g, 41%). m.p. 112.0 - 114.9 
°C; 1H NMR (CDCl3) δ 7.47-7.29 (5 H, m), 7.01 (1 H, d, J = 2.6 Hz), 6.94 - 6.90 (1 
H, m), 6.88 (1 H, dd, J = 8.4, 2.6 Hz), 5.10 - 5.02 (2 H, m), 4.54 - 4.48 (1 H, m), 
3.84 (2 H, s), 3.21 (1 H, dd, J = 12.8, 3.2 Hz ), 3.06 - 2.89 (1 H, m); 13C NMR 
(CDCl3) δ 157.6, 138.0, 137.1, 128.7, 128.3, 128.1, 127.6, 127.4, 115.6, 114.9, 70.2, 
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66.1, 51.1, 47.6; HRMS m/z: [M+H]+ Calcd for C16H18NO2 256.1332; Found 
256.1335. 
11.8.11 6-([1,1'-Biphenyl]-4-ylmethoxy)-1,2,3,4-
tetrahydroisoquinolin-4-ol (211)  
 
211 
N-Protected isoquinoline 208 (0.269 g, 0.620 mmol) was deprotected as described 
for 210, and subjected to workup method 2. The resulting orange gummy solid was 
purified by column chromatography (5% methanol, 0.5% sat. ammonia solution, in 
dichloromethane) to afford the desired product as a white solid (0.112 g, 55%). m.p. 
145.5 - 149°C; 1H NMR (DMSO-d6) δ 7.72 - 7.64 (4 H, m), 7.56 - 7.51 (2 H, m), 
7.50 - 7.44 (2 H, m), 7.40- 7.35 (1 H, m), 7.10 (1 H, d, J = 2.8 Hz), 7.05 (1 H, d, J = 
8.6 Hz), 6.93 (1 H, dd, J = 8.4, 2.8 Hz), 5.15 (2 H, s), 4.61 - 4.53 (1 H, m), 4.05 - 
3.87 (2 H, m), 3.24 - 3.15 (1 H, m), 2.96 (1 H, dd, J = 12.5, 5.8 Hz); 13C NMR 
(DMSO-d6) δ 157.1, 139.8, 139.6, 138.6, 136.3, 128.9, 128.1, 127.5, 126.9, 126.7, 
126.6, 125.1, 114.5, 114.0, 68.8, 63.4, 49.2, 45.4; HRMS m/z: [M+H]+ Calcd for 





N-Protected isoquinoline 209 (0.106 g, 0.280 mmol) was deprotected as described 
for 210, and subjected to workup method 2. The resulting orange gummy solid was 
purified by column chromatography (5% methanol, 0.5% sat. ammonia solution, in 
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dichloromethane) to afford the desired product as a colourless gummy solid (0.085 g, 
>95%). 1H NMR (CDCl3) δ 6.93 - 6.87 (2 H, m), 6.81 - 6.76 (1 H, m), 4.54 - 4.48 (1 
H, m), 4.01 - 3.93 (2 H, m), 3.80 (2 H, s), 3.58 - 3.42 (1 H, m), 3.25 - 3.16 (1 H, m), 
2.99 (1 H, dd, J = 12.9, 3.1 Hz), 1.83 - 1.61 (7 H, m), 1.56 1.43 - (1 H, m), 1.33 - 
1.10 (3 H, m), 1.04 - 0.91 (2 H, m); 13C NMR (CDCl3) δ 158.1, 137.5, 127.2, 126.9, 
115.4, 114.5, 66.2, 65.6, 50.9, 47.1, 36.8, 34.7, 33.4, 26.6, 26.3; HRMS m/z: [M+H]+ 





Phenol 204 (0.050 g, 0.22 mmol) was treated with sodium hydride (60% dispersion 
in mineral oil, 0.009 g, 0.2 mmol), and benzyl bromide (26 μL, 0.22 mmol) as 
described for 207, and subjected to workup method 1. The resulting yellow gummy 
solid was purified by column chromatography (1% methanol in dichloromethane) to 
afford the desired product as a colourless gummy solid (0.051 g, 74%). 1H NMR 
(CDCl3) δ 7.47 - 7.28 (10 H, m), 7.06 (1 H, d, J = 2.6 Hz), 6.94 (1 H, d, J = 8.6 Hz), 
6.88 (1 H, dd, J = 8.6, 2.6 Hz), 5.10 - 5.02 (2 H, m), 4.64 - 4.57 (1 H, m), 3.85 - 3.76 
(3 H, m), 3.45 - 3.36 (1 H, m), 3.15 - 3.07 (1 H, m), 2.75 - 2.68 (1 H, m); 13C NMR 
(CDCl3) δ 157.8, 138.0, 138.0, 137.2, 129.2, 128.7, 128.6, 128.1, 127.6, 127.54, 
127.51, 127.4, 115.7, 114.5, 70.2, 67.6, 62.8, 58.3, 55.45; HRMS m/z: [M+H]+ Calcd 




tetrahydroisoquinolin-4-ol (214)  
 
214 
Phenol 204 (0.050 g, 0.22 mmol) was treated with sodium hydride (60% dispersion 
in mineral oil, 0.009 g, 0.2 mmol), and 4-(chloromethyl)-1,1'-biphenyl 128 (0.045 g, 
0.22 mmol) as described for 207, and subjected to workup method 1. The resulting 
brown gummy solid was purified by column chromatography (1% methanol in 
dichloromethane) to afford the desired product as a colourless gummy solid (0.059 g, 
70%). m.p. 105 - 108.5 °C; 1H NMR (CDCl3) δ 7.64 - 7.58 (4 H, m), 7.53 - 7.42 (4 
H, m), 7.41 - 7.33 (5 H, m), 7.33 - 7.28 (1 H, m), 7.07 (1 H, dd, J = 2.5, 0.4 Hz), 
6.96 (1 H, d, J = 8.3 Hz), 6.90 (1 H, dd, J = 8.3, 2.5 Hz), 5.11 (2 H, dd, J = 1.9, 0.5 
Hz), 4.59 (1 H, t, J = 3.1 Hz), 3.79 (1 H, d, J = 14.5 Hz), 3.75 (2 H, s), 3.37 (1 H, d, 
J = 14.5 Hz), 3.07 (1 H, ddd, J = 11.6, 3.4, 1.4 Hz), 2.68 (1 H, dd, J = 11.6, 2.7 Hz); 
13C NMR (CDCl3) δ 157.8, 141.1, 141.0, 138.0, 137.9, 136.2, 129.2, 128.9, 128.6, 
128.1, 127.60, 127.57, 127.52, 127.49, 127.4, 127.3, 115.7, 114.5, 70.0, 67.6, 62.8, 
58.2, 55.5; HRMS m/z: [M+H]+ Calcd for C29H28NO2 422.2120; Found 422.2113. 
11.8.15 7-Hydroxy-3,4-dihydronaphthalen-1(2H)-one (216)  
 
216 
7-Methoxy-1-tetralone 215 (1.000 g, 5.71 mmol) was added to a suspension of 
aluminium trichloride (1.540 g, 11.55 mol) in anhydrous toluene (40 mL) and the 
reaction mixture heated at reflux for 3.5 hrs. The reaction was quenched with water 
(40 mL) and extracted with ethyl acetate (3×40 mL). The ethyl acetate fractions were 
combined, dried over magnesium sulfate and concentrated under reduced pressure to 
afford an orange solid. This was purified by column chromatography (20% ethyl 
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acetate in petroleum spirits 40-60) to afford the desired product as a white solid 
(0.480 g, 52%). 1H NMR (CDCl3) δ 7.53 (1 H, d, J = 2.8 Hz), 7.15 (1 H, d, J = 8.2 
Hz), 7.03 (1 H, dd, J = 8.2, 2.8 Hz), 5.72 (1 H, s), 2.89 (2 H, t, J = 6.2 Hz), 2.65 – 
2.62 (2 H, m), 2.16 - 2.06 (2 H, m). 
11.8.16 1,2,3,4-Tetrahydronaphthalene-1,7-diol (217)  
 
217 
Ketone 216 (0.480 g, 2.96 mmol) was dissolved in methanol (20 mL) and cooled to 
0°C. Sodium borohydride (0.227 g, 6.00 mmol) was added and the reaction mixture 
allowed to warm to room temperature and then stirred for a further 45 minutes. The 
reaction mixture was concentrated under reduced pressure, diluted with water (30 
mL), and extracted with ethyl acetate (3×30 mL). The ethyl acetate fractions were 
combined, dried over magnesium sulfate, and concentrated under reduced pressure to 
afford a white solid (0.462 g, 95%). m.p 144 - 145.5 °C; 1H NMR (DMSO-d6) δ 8.98 
(1 H, s), 6.83 - 6.81 (2 H, m), 6.54 (1 H, dd, J = 8.4, 2.8 Hz), 4.97 (1 H, d, J = 6 Hz), 
4.67 - 4.24 (1 H, m), 2.62 - 2.54 (2 H, m), 1.89 - 1.78 (2 H, m), 1.66 - 1.55 (2 H, m); 
13C NMR (DMSO-d6) δ 155.1, 141.3, 129.0, 126.5, 114.4, 114.1, 66.6, 32.5, 28.0, 
19.6. 
11.8.17 7-(Benzyloxy)-1,2,3,4-tetrahydronaphthalen-1-ol (218)  
 
218 
Phenol 217 (0.100 g, 0.610 mmol) was treated with sodium hydride (60% dispersion 
in mineral oil, 0.031 g, 0.78 mmol), and benzyl bromide (80 μL, 0.67 mmol) as 
described for 207, and subjected to workup method 1. The resulting brown oil was 
purified by column chromatography (20% ethyl acetate in petroleum spirits 40-60) to 
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afford the desired product as a colourless oil (0.130 g, 84%).1H NMR (CDCl3) δ 7.47 
- 7.42 (2 H, m), 7.42 - 7.36 (2 H, m), 7.35 - 7.30 (1 H, m), 7.09 (1 H, d, J = 2.7 Hz), 
7.03 (1 H, d, J = 8.4 Hz), 6.86 (1 H, dd, J = 8.4, 2.7 Hz), 5.11- 5.02 (2 H, m), 4.75 (1 
H, t, J = 5.2 Hz), 2.83 - 2.73 (1 H, m), 2.71 - 2.59 (1 H, m), 2.08 - 1.71 (4 H, m); 13C 
NMR (CDCl3) δ 157.4, 140.0, 137.3, 130.1, 129.6, 128.7, 128.0, 127.6, 115.3, 114.0, 
70.2, 68.6, 32.5, 28.6, 19.3; HRMS m/z: [M+Na]+ Calcd for C17H18NaO2 277.1204; 
Found 277.1212. 
11.8.18 7-([1,1'-Biphenyl]-4-ylmethoxy)-1,2,3,4-
tetrahydronaphthalen-1-ol (219)  
 
219 
Phenol 217 (0.100 g, 0.610 mmol) was treated with sodium hydride (60% dispersion 
in mineral oil, 0.030 g, 0.75 mmol), and 4-(chloromethyl)-1,1'-biphenyl 128 (0.137 
g, 0.680 mmol) as described for 207, and subjected to workup method 1. The 
resulting brown solid was purified by column chromatography (20% ethyl acetate in 
petroleum spirits 40-60) to afford the desired product as a white solid (0.175 g, 87%). 
m.p. 124 - 126.5 °C; 1H NMR (CDCl3) δ 7.66 - 7.58 (4 H, m), 7.55 - 7.49 (2 H, m), 
7.49 - 7.43 (2 H, m), 7.40 - 7.34 (1 H, m), 7.14 - 7.11 (1 H, m), 7.05 (1 H, d, J = 8.4 
Hz), 6.89 (1 H, dd, J = 8.4, 2.7 Hz), 5.16 - 5.07 (2 H, m), 4.76 (1 H, t, J = 5.2 Hz), 
2.83 - 2.74 (1 H, m), 2.73 - 2.61 (1 H, m), 2.11 - 1.72 (4 H, m); 13C NMR (CDCl3) δ 
157.4, 141.0, 141.04, 140.97, 136.3, 130.2, 129.6, 128.9, 128.1, 127.5, 127.3, 115.3, 
114.0, 70.0, 68.6, 32.6, 28.6, 19.3 (note some signals coincident); HRMS m/z: 
[M+Na]+ Calcd for C23H22NaO2 353.1512; Found 353.1512. 
227 
 
11.9 Substitution of the methylene carbon 
11.9.1 (4R)-2-Methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-4,6-






Phenylephrine hydrochloride (0.201 g, 0.980 mmol) and benzaldehyde (100 μL, 0.98 
mmol) were combined and heated at 130°C for 3 hrs, then subjected to workup 
method 1. The resulting orange gummy solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford isomer A as a cream 
coloured solid (0.035 g, 15%) m.p. 64.5 - 65.9 °C; 1H NMR (DMSO-d6) δ 9.19 (1 H, 
s), 7.36 - 7.19 (5 H, m), 6.77 (1 H, d, J = 2.5 Hz), 6.48 (1 H, dd, J = 8.4, 2.5 Hz), 
6.34 (1 H, d, J = 8.4 Hz), 5.00 (1 H, d, J = 7.6 Hz), 4.52 - 4.43 (1 H, m), 4.15 (1 H, 
s), 2.91 (1 H, dd, J = 12.0, 4.1 Hz), 2.60 (1 H, dd, J = 12.0, 3.8 Hz), 2.07 (3 H, s); 
13C NMR (DMSO-d6) δ 155.9, 143.5, 138.6, 130.0, 129.4, 129.1, 128.3, 127.5, 
115.1, 115.0, 69.6, 65.7, 58.6, 44.1 HRMS m/z: [M+H]+ Calcd for C15H18NO2 
256.1332; Found 256.1333; Further elution afforded isomer B as a pale yellow 
coloured solid (0.051 g, 21%). m.p. 130 - 133.5 °C; 1H NMR (DMSO-d6) δ 9.16 (1 
H, s), 7.38 - 7.17 (5 H, m), 6.94 (1 H, d, J = 2.3 Hz), 6.43 (1 H, dd, J = 8.4, 2.3 Hz), 
6.28 (1 H, d, J = 8.4 Hz), 5.35 (1 H, d, J = 7.1 Hz), 4.87 - 4.75 (1 H, m), 4.09 (1 H, 
s), 3.12 (1 H, dd, J = 10.4, 5.6 Hz), 2.35 (1 H, t, J = 10.4 Hz), 2.07 (3 H, s); 13C 
NMR (DMSO-d6) δ 155.8, 145.0, 141.0, 129.5, 129.3, 128.9, 128.6, 127.6, 114.4, 











Phenylephrine hydrochloride (0.300 g, 1.47 mmol) and 4-methoxybenzaldehyde (180 
μL, 1.47 mmol) were combined and heated at 130°C for 4 hrs then subjected to 
workup method 1. The resulting orange gummy solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford isomer A as a pale 
yellow coloured solid (0.071 g, 17%) m.p. 69.5 - 71.5 °C ;1H NMR (DMSO-d6) δ 
9.18 (1 H, s), 7.23 - 7.11 (2 H, m), 6.92 - 6.82 (2 H, m), 6.77 (1 H, d, J = 2.6 Hz), 
6.48 (1 H, dd, J = 8.4, 2.6 Hz), 6.35 (1 H, d, J = 8.4 Hz), 4.99 (1 H, d, J = 7.6 Hz), 
4.53 - 4.39 (1 H, m), 4.09 (1 H, s), 3.74 (3 H, s), 2.90 (1 H, dd, J = 12.0, 4.0 Hz), 
2.58 (1 H, dd, J = 12.0, 3.7 Hz), 2.06 (3 H, s); 13C NMR (DMSO-d6) δ 158.3, 155.4, 
138.2, 134.9, 130.6, 129.4, 128.7, 114.7, 114.5, 113.3, 68.5, 65.3, 58.1, 55.0, 43.6; 
HRMS m/z: [M+H]+ Calcd for C17H20NO3 286.1438; Found 286.1437; Further 
elution afforded isomer B as a pale yellow coloured solid (0.122 g, 29%) m.p. 149.5 
- 152.9°C; 1H NMR (DMSO-d6) δ 9.14 (1 H, s), 7.13 (2 H, d, J = 8.6 Hz), 6.93 (1 H, 
d, J = 2.4 Hz), 6.85 (2 H, d, J = 8.6 Hz), 6.43 (1 H, dd, J = 8.4, 2.4 Hz), 6.29 (1 H, 
d, J = 8.4 Hz), 5.32 (1 H, d, J = 7.1 Hz), 4.83 - 4.72 (1 H, m), 4.03 (1 H, s), 3.73 (3 
H, s), 3.11 (1 H, dd, J = 10.4, 5.5 Hz), 2.33 (1 H, t, J = 10.4 Hz), 2.06 (3 H, s); 13C 
NMR (DMSO-d6) δ 158.3, 155.3, 140.5, 136.4, 130.1, 129.2, 128.5, 113.9, 113.5, 
111.7, 70.2, 65.6, 60.5, 55.0, 43.6; HRMS m/z: [M+H]+ Calcd for C17H20NO3 










Phenylephrine hydrochloride (0.302 g, 1.47 mmol) and 4-nitrobenzaldehyde (0.223 
g, 1.47 mmol) were combined and heated at 130°C for 4 hrs then subjected to 
workup method 1. The resulting orange gummy solid was purified by column 
chromatography (3% methanol in dichloromethane) to afford isomer A as a yellow 
coloured solid (0.160 g, 36%) m.p. 95 - 97.5 °C; 1H NMR (DMSO-d6) δ 9.30 (1 H, 
s), 8.22 - 8.15 (2 H, m), 7.61 (2 H, d, J = 8.7 Hz), 6.80 (1 H, d, J = 2.5 Hz), 6.51 (1 
H, dd, J = 8.5, 2.5 Hz), 6.34 (1 H, d, J = 8.5 Hz), 5.13 (1 H, d, J = 7.8 Hz), 4.58 - 
4.43 (1 H, m), 4.35 (1 H, s), 2.92 (1 H, dd, J = 12.1, 3.9 Hz), 2.65 (1 H, dd, J = 12.1, 
3.5 Hz), 2.10 (3 H, s); 13C NMR (DMSO-d6) δ 155.7, 151.6, 146.7, 138.1, 130.7, 
128.6, 127.6, 123.2, 115.0, 114.9, 68.2, 65.1, 58.0, 43.6; HRMS m/z: [M+H]+ Calcd 
for C16H17N2O4 301.1183; Found 301.1186; Further elution afforded isomer B as a 
pale yellow coloured solid (0.141 g, 32%). m.p. 93 - 95 °C; 1H NMR (DMSO-d6) δ 
9.26 (1 H, s), 8.17 (2 H, d, J = 8.6 Hz), 7.54 (2 H, d, J = 8.6 Hz), 6.98 (1 H, d, J = 
2.4 Hz), 6.45 (1 H, dd, J = 8.4, 2.4 Hz), 6.28 (1 H, d, J = 8.4 Hz), 5.43 (1 H, d, J = 
6.9 Hz), 4.89 - 4.77 (1 H, m), 4.32 (1 H, s), 3.13 (1 H, dd, J = 10.4, 5.5 Hz), 2.38 (1 
H, t, J = 10.4 Hz), 2.09 (3 H, s); 13C NMR (DMSO-d6) δ 155.7, 152.7, 146.7, 140.7, 
130.2, 128.4, 127.4, 123.5, 114.2, 112.0, 69.7, 65.5, 59.9, 43.6; HRMS m/z: [M+H]+ 










Phenylephrine hydrochloride (0.300 g, 1.47 mmol) and cinnamaldehyde (185 μL, 
1.47 mmol) were combined and heated at 130°C for 7 hrs, then subjected to workup 
method 1. The resulting brown gummy solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford isomer A as a brown 
coloured solid (0.037 g, 9%) m.p. 84.5 - 88 °C; 1H NMR (DMSO-d6) δ 9.22 (1 H, s), 
7.48 - 7.40 (2 H, m), 7.36 - 7.29 (2 H, m), 7.27 - 7.18 (1 H, m), 6.88 - 6.79 (2 H, m), 
6.67 - 6.55 (2 H, m), 6.25 (1 H, dd, J = 15.9, 8.8 Hz), 5.03 (1 H, d, J = 7.4 Hz), 4.54 
- 4.41 (1 H, m), 3.88 (1 H, d, J = 8.9 Hz), 2.87 (1 H, dd, J = 11.8, 5.9 Hz), 2.65 (1 H, 
dd, J = 11.8, 4.7 Hz), 2.33 (3 H, s); 13C NMR (DMSO) δ 155.8, 138.9, 136.6, 132.0, 
130.5, 128.7, 128.2, 127.5, 127.1, 126.3, 114.5, 114.3, 66.5, 65.2, 56.8, 43.4; HRMS 
m/z: [M+H]+ Calcd for C18H20NO2 282.1489; Found 282.1492, and isomer B a 
brown coloured solid (0.064 g, 15%) m.p. 180.2 - 84.5°C; 1H NMR (DMSO-d6) δ 
9.21 (1 H, s), 7.51 - 7.44 (2 H, m), 7.35 - 7.29 (2 H, m), 7.27 - 7.21 (1 H, m), 6.96 - 
6.92 (1 H, m), 6.86 - 6.78 (1 H, m), 6.67 (1 H, d, J = 16.0 Hz), 6.60 - 6.53 (1 H, m), 
6.01 (1 H, dd, J = 16.0, 8.8 Hz), 5.28 (1 H, d, J = 7.1 Hz), 4.69 - 4.56 (1 H, m), 3.73 
(1 H, d, J = 8.9 Hz), 3.08 (1 H, dd, J = 10.7, 5.6 Hz), 2.32 (3 H, s), 2.30 - 2.23 (1 H, 
m); 13C NMR (DMSO-d6) δ 155.8, 140.6, 136.5, 132.4, 131.8, 128.6, 127.9, 127.5, 
126.4, 126.3, 114.0, 112.5, 68.8, 65.4, 59.6, 43.8; HRMS m/z: [M+H]+ Calcd for 










Phenylephrine hydrochloride (0.302 g, 1.47 mmol) and 3-pyridinecarboxaldehyde 
(138 μL, 1.47 mmol) were combined and heated at 130°C for 3 hrs then subjected to 
workup method 1. The resulting yellow solid was purified by column 
chromatography (4% methanol in dichloromethane) to afford isomer A as a pale 
yellow coloured solid (0.041 g, 11%) decomp. 180 °C; 1H NMR (DMSO-d6) δ 9.21 
(1 H, s), 8.51 - 8.43 (1 H, m), 7.66 (1 H, td, J = 7.6, 1.8 Hz), 7.20 (1 H, ddd, J = 7.6, 
4.9, 1.2 Hz), 7.12 - 6.94 (3 H, m), 6.56 (1 H, dd, J = 7.6, 1.3 Hz), 5.33 (1 H, d, J = 
7.4 Hz), 4.85 (1 H, s), 4.72 - 4.62 (1 H, m), 2.83 (1 H, dd, J = 11.4, 8.2 Hz), 2.68 (1 
H, dd, J = 11.4, 5.6 Hz), 2.27 - 2.19 (3 H, m); 13C NMR (DMSO-d6) δ 160.2, 153.3, 
147.9, 140.5, 135.5, 127.1, 123.6, 123.5, 121.7, 117.6, 113.1, 65.0, 63.6, 53.5, 42.7; 
HRMS m/z: [M+H]+ Calcd for C15H17N2O2 257.1285; Found 257.1286; Isomer B 
could not be separated from isomer A. 
11.9.6 (4R)-2-Methyl-1-undecyl-1,2,3,4-tetrahydroisoquinoline-
4,6-diol (225)  
 
225 
Phenylephrine hydrochloride (300 mg, 1.47 mmol) and dodecanal (326 μL, 1.47 
mmol) were combined and heated at 130°C for 7 hrs, and subjected to workup 
method 1. The resulting orange gummy solid was purified by column 
chromatography (5% methanol in dichloromethane) to afford a mixture of isomers A 
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and B (66:34) as an orange gummy solid (213 mg, 43%) 1H NMR (DMSO-d6, 
selected peaks of isomer A) δ 9.09 (1 H, d, J = 5.4 Hz), 6.81 (1 H, d, J = 2.4Hz), 4.86 
(1 H, d, J = 0.8 Hz), 2.79 (1 H, dd, J = 12.6, 7.8 Hz), 2.70 (1 H, dd, J = 12.6, 5.4 Hz), 
2.37 (3 H, s). 1H NMR (DMSO-d6, selected peaks of isomer B) δ 9.22 (1 H, d, J = 8.0 
Hz), 6.92 (1 H, d, J = 8.8 Hz), 5.16 (1 H, d, J = 0.8 Hz), 2.96 (1 H, dd, J = 10.8, 5.2 
Hz), 2.32 (3 H, s), 2.22 (1 H, dd, J = 10.8, 8.8 Hz); 13C NMR (DMSO-d6) δ 155.8, 
155.5, 142, 139.7, 129.4, 128.2, 127.9, 126.8, 114.7, 114.4, 114.2, 112.4, 65.8, 64.0, 
62.8, 62.4, 60.3, 54.6, 43.8, 43.2, 34.3, 32.8, 31.8, 31.7, 29.9, 29.7, 29.5, 29.5, 29.5, 
29.4, 29.2, 29.2, 26.1, 23.4, 22.6, 14.4 (note some peak coincident); HRMS m/z: 
[M+H]+ Calcd for C21H36NO2 334.2741; Found 334.2744. 
11.9.7 (1S,4R)-2-Methyl-1-(4-nitrophenyl)-1,2,3,4-
tetrahydroisoquinoline-4,6-diyl dibenzoate (226)  
 
226 
Phenol 222A (0.020 g, 0.070 mmol) was dissolved in anhydrous dichloromethane 
(2mL). Triethylamine (39 μL, 0.28 mmol) was added followed by benzoyl chloride 
(24 μL, 0.21 mmol) and the reaction mixture stirred at room temperature for 24 hrs. 
A second portion of triethylamine (39 μL, 0.28 mmol) and benzoyl chloride (24 μL, 
0.21 mmol) were added and the reaction mixture was stirred at room temperature for 
a further 24 hrs. The reaction mixture was diluted with water (5 mL) and 
dichloromethane (5 mL). The organic phase was separated, dried over magnesium 
sulfate, and concentrated under reduced pressure to afford an orange gummy solid 
which was purified by column chromatography (10% ethyl acetate in petroleum 
spirits 40-60) to afford the desired product as a colourless gummy solid (0.016 g, 
45%). 1H NMR (CDCl3) δ 8.28 - 8.22 (2 H, m), 8.18 - 8.10 (4 H, m), 7.66 - 7.56 (4 
H, m), 7.52 - 7.43 (4 H, m), 7.37 (1 H, d, J = 2.3 Hz), 7.06 (1 H, dd, J = 8.6, 2.5 Hz), 
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6.73 (1 H, d, J = 8.6 Hz), 6.23 (1 H, t, J = 2.7 Hz), 4.42 (1 H, s), 3.43 (1 H, dd, J = 
13.2, 2.6 Hz), 3.05 - 2.98 (1 H, m), 2.26 (3 H, s); 13C NMR (CDCl3) δ 166.6, 165.2, 
151.0, 149.8, 147.8, 136.3, 133.9, 133.3, 133.2, 130.5, 130.4, 130.3, 130.0, 129.5, 
128.7, 128.6, 128.3, 124.0, 123.01, 122.7, 69.9, 68.6, 56.2, 44.2.  
11.9.8 (1R,4R)-2-Methyl-1-(4-nitrophenyl)-1,2,3,4-
tetrahydroisoquinoline-4,6-diyl dibenzoate (227) 
 
227 
Phenol 222B (0.020 g, 0.070 mmol) was dissolved in anhydrous dichloromethane 
(2mL). Triethylamine (80 μL, 0.57 mmol) was added followed by benzoyl chloride 
(48 μL, 0.42 mmol) and the reaction mixture was stirred at room temperature for 24 
hrs. The reaction mixture was diluted with water (5 mL) and dichloromethane (5 
mL). The organic phase was separated, dried over magnesium sulfate, and 
concentrated under reduced pressure to afford an orange gummy solid which was 
purified by column chromatography (10% ethyl acetate in petroleum spirits 40-60) to 
afford the desired product as a colourless gummy solid (0.027 g, 76%). 1H NMR 
(CDCl3) δ 8.27 - 8.21 (2 H, m), 8.18 - 8.10 (4 H, m), 7.65 - 7.57 (2 H, m), 7.56 - 7.52 
(2 H, m), 7.52 - 7.45 (4 H, m), 7.28 (1 H, dd, J = 2.5, 1.0 Hz), 7.03 (1 H, ddd, J = 
8.5, 2.5, 0.6 Hz), 6.72 (1 H, d, J = 8.5 Hz), 6.56 - 6.50 (1 H, m), 4.55 (1 H, s), 3.56 
(1 H, dd, J = 11.1, 5.7 Hz), 2.79 (1 H, dd, J = 11.1, 9.0 Hz), 2.30 (3 H, s); 13C NMR 
(CDCl3) δ 166.5, 165.2, 150.6, 150.0, 147.8, 135.7, 135.3, 133.9, 133.5, 130.4, 





tetrahydroisoquinolin-4-ol (228)  
 
228 
Isoquinoline 222A (0.050 g, 0.17 mmol) was treated with sodium hydride (60% 
dispersion in mineral oil, 0.008 g, 0.2 mmol) and benzyl bromide (24 μL, 0.20 
mmol) as described for 230, and then subjected to workup method 1. The resulting 
brown gummy solid was purified by column chromatography (3% methanol in 
dichloromethane) to afford the desired product as a pale yellow gummy solid (0.046 
g, 69%). 1H NMR (CDCl3)  8.24 - 8.18 (2 H, m), 7.51 - 7.45 (2 H, m), 7.43 - 7.29 (5 
H, m), 7.01 (1 H, d, J = 2.7 Hz), 6.74 (1 H, dd, J = 8.7, 2.7 Hz), 6.45 (1 H, d, J = 8.7 
Hz), 5.04 (2 H, dd, J = 1.6, 0.5 Hz), 4.64 - 4.56 (1 H, m), 4.27 (1 H, s), 3.22 (1 H, 
dd, J = 12.1, 2.6 Hz), 2.85 (1 H, ddd, J = 12.1, 2.0, 0.6 Hz), 2.23 (3 H, s); 13C NMR 
(CDCl3) δ 157.9, 151.1, 147.7, 137.6, 136.9, 130.3, 129.6, 129.4, 128.8, 128.2, 
127.6, 124.0, 115.9, 114.6, 70.9, 70.2, 67.2, 60.0, 44.2; HRMS m/z: [M+H]+ Calcd 




nitrophenyl)-1,2,3,4-tetrahydroisoquinolin-4-ol (229)  
 
229 
Isoquinoline 222B (0.050 g, 0.17 mmol) was was added to a suspension of sodium 
hydride (60% dispersion in mineral oil, 0.008 g, 0.2 mmol) in anhydrous 
dimethylformamide and the mixture stirred at room temperature for 30 minutes. 4-
(Chloromethyl)-1,1'-biphenyl 128 (0.040 g, 0.19 mmol) was added and the reaction 
mixture stirred at room temperature for 24 hrs. The reaction was quenched with 
methanol (2 mL) and then subjected to workup method 1. The resulting brown 
gummy solid was purified by column chromatography (3% methanol in 
dichloromethane) to afford the desired product as a white solid (0.035 g, 44%). m.p. 
143.5 - 145.5°C; 1H NMR (CDCl3) δ 8.21 - 8.15 (2 H, m), 7.64 - 7.55 (4 H, m), 7.52 
- 7.32 (7 H, m), 7.29 - 7.22 (1 H, m), 6.76 (1 H, dd, J = 8.6, 2.8 Hz), 6.54 6.49 - (1 
H, m), 5.13 - 5.07 (2 H, m), 5.03 (1 H, br. s.), 4.46 (1 H, s), 3.30 (1 H, dd, J = 11.2, 
5.1 Hz), 2.57 (1 H, dd, J = 11.2, 8.3 Hz), 2.23 (3 H, s); 13C NMR (CDCl3) δ 158.0, 
150.5, 147.6, 141.2, 140.9, 139.4, 135.9, 130.4, 129.6, 129.3, 129.0, 128.2, 127.6, 
127.5, 127.3, 123.7, 115.3, 111.7, 70.0, 69.8, 67.3, 59.2, 43.9; HRMS m/z: [M+H]+ 




tetrahydroisoquinolin-4-ol (230)  
 
230 
Isoquinoline 225 (as a mixture of isomers A and B , 0.060 g, 0.18 mmol) was added 
to a suspension of sodium hydride (60% dispersion in mineral oil, 0.009 g, 0.2 
mmol) in anhydrous dimethylformamide and the mixture stirred at room temperature 
for 30 minutes. Benzyl bromide (24 μL, 0.20 mmol) was added and the reaction 
mixture stirred at room temperature for 24 hrs. The reaction was quenched with 
methanol (2 mL) and then subjected to workup method 1. The resulting orange 
gummy solid was purified by column chromatography (3% methanol in 
dichloromethane) to afford the desired product as a pale yellow gummy solid (0.017 
g, 22%). Only one isomer was isolated. 1H NMR (CDCl3) δ 7.46 - 7.36 (4 H, m), 
7.35 - 7.30 (1 H, m), 7.11 (1 H, d, J = 8.5 Hz), 6.93 (1 H, d, J = 2.7 Hz), 6.90 (1 H, 
dd, J = 8.5, 2.7 Hz), 5.09 - 5.02 (2 H, m), 4.48 - 4.39 (1 H, m), 3.42 - 3.35 (1 H, m), 
3.02 (1 H, dd, J = 11.5, 3.3 Hz), 2.70 (1 H, ddd, J = 11.5, 1.6, 0.6 Hz), 2.48 (3 H, s), 
2.08 - 1.93 (1 H, m), 1.91 - 1.79 (1 H, m), 1.38 - 1.06 (18 H, m), 0.91 - 0.82 (3 H, 
m); 13C NMR (CDCl3) δ 157.3, 139.0, 137.2, 130.5, 128.7, 128.1, 127.7, 127.2, 
115.8, 114.1, 70.2, 67.3, 64.0, 59.5, 43.5, 32.2, 32.1, 30.2, 29.80, 29.75, 29.67, 29.5, 





1,2,3,4-tetrahydroisoquinolin-4-ol (231)  
 
231 
Isoquinoline 225 (0.061 g, 0.18 mmol) was treated with sodium hydride (60% 
dispersion in mineral oil, 0.010 g, 0.25 mmol), 4-(chloromethyl)-1,1'-biphenyl 128 
(0.041 g, 0.20 mmol), and sodium iodide (0.055 g, 0.36 mmol) as described for 230, 
and then subjected to workup method 1. The resulting brown gummy solid was 
purified by column chromatography (3% methanol in dichloromethane) to afford the 
desired product as a pale orange gummy solid (0.049 g, 54%). Only one isomer was 
isolated. 1H NMR (CDCl3) δ 7.65 - 7.57 (4 H, m), 7.54 - 7.49 (2 H, m), 7.49 - 7.42 (2 
H, m), 7.39 - 7.34 (1 H, m), 7.14 (1 H, d, J = 8.6 Hz), 6.97 - 6.94 (1 H, m), 6.93 (1 
H, d, J = 2.8 Hz), 5.16 - 5.04 (2 H, m), 4.48 - 4.39 (1 H, m), 3.44 - 3.35 (1 H, m), 
3.06 - 2.93 (1 H, m), 2.71 (1 H, dt, J = 11.5, 1.1 Hz), 2.51 - 2.42 (3 H, m), 2.08 - 
1.93 (1 H, m), 1.92 - 1.80 (1 H, m), 1.35 - 1.15 (18 H, m), 0.93 - 0.84 (3 H, m); 13C 
NMR (CDCl3) δ 157.3, 141.1, 141.0, 139.0, 136.2, 130.5, 128.9, 128.2, 127.5, 127.3, 
115.8, 114.1, 70.0, 67.4, 64.0, 59.6, 43.5, 32.2, 32.1, 30.2, 29.80, 29.76, 29.7, 29.5, 
22.9, 22.8, 14.3 (note some signals coincident); HRMS m/z: [M+H]+ Calcd for 




11.10.1 Phenylethyl tosylate (102)  
 
102 
2-Phenylethanol (2.0 mL, 17 mmol) was dissolved in anhydrous dichloromethane 
and triethylamine (4.7 mL, 34 mmol). 4-Toluenesulfonyl chloride (4.76 g, 25.0 
mmol) was added slowy with cooling at 0°C. The reaction mixture was allowed to 
warm to room temperature and stirred for 24 hrs. The reaction mixture was diluted 
with water and stirred for 1 hour, followed by dilution with ether. This was then 
washed sequentially with water, 1M hydrochloric acid, 5% sodium bicarbonate, and 
finally water. The organic layer was dried over magnesium sulfate, and concentrated 
under reduced pressure. The resulting orange liquid was purified by column 
chromatography (10% ethyl acetate in petroleum spirits 40-60) to afford the desired 
product as a colourless oil (1.64 g, 36%). 1H NMR (CDCl3) δ 7.73 - 7.70 (2 H, m), 
7.32 - 7.24 (5 H, m), 7.15 - 7.13 (2 H, m), 4.24 (2 H, t, J = 7.0 Hz), 2.98 (2 H, t, J = 
7.0 Hz), 2.46 (3 H, s); 13C NMR (CDCl3) δ 144.8, 136.3, 133.1, 129.9, 129.0, 128.7, 
127.9, 126.95, 70.7, 35.4, 21.7.  
11.10.2 2-Cyclohexylethyl tosylate (107)  
 
107 
2-Cyclohexylethanol (1.02 g, 8.00 mmol) was treated with 4-toluenesulfonyl 
chloride (1.84 g, 9.65 mmol) and triethylamine (2.20 mL, 15.6 mmol) as described 
for 102. The resulting colourless oil was used without further purification (2.20 g, 
97%). 1H NMR (CDCl3) δ 7.79 - 7.77 (2 H, m), 7.35 - 7.33 (2 H, m), 4.05 (2 H, t, J 
= 6.6 Hz), 2.44 (3 H, s), 1.67 - 1.54 (6 H, m), 1.51 (2 H, apparent q, J = 6.6 Hz), 
1.37 - 1.27 (1 H, m), 1.22 - 1.04 (2 H, m), 0.87 - 0.77 (2 H, m); 13C NMR (CDCl3) δ 
144.7, 133.3, 129.9, 128.0, 68.9, 36.2, 33.9, 32.9, 26.4, 26.1, 21.7  
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11.10.3 tert-Butyl 4-(3-chloropropyl)piperazine-1-carboxylate (115)  
 
115 
1-BOC-piperazine (1.01 g, 5.24 mmol), and triethylamine (0.900 mL, 6.50 mmol) 
were dissolved in dichloromethane (10 mL). 1-Bromo-3-chloropropane (0.640 mL, 
6.50 mmol) was added and the reaction mixture stirred at room temperature for 2 
days. The reaction mixture was washed with water (10 mL) followed by sat. brine 
(10 mL). The organic phase was dried over magnesium sulfate and concentrated 
under reduced pressure to afford a white gummy solid. This gummy solid was 
purified by column chromatography (20-100% ethyl acetate in petroleum spirits 40-
60) to afford the desired product as a pale yellow oil (0.70 g, 50%). 1H NMR 
(CDCl3) δ 3.59 (2 H, t, J = 6.8 Hz), 3.41 (4 H, t, J = 4.9 Hz), 2.48 (2 H, t, J = 6.8 
Hz), 2.37 (4 H, t, J = 4.9 Hz), 1.97 - 1.90 (2 H, m), 1.45 (9 H, s); 13C NMR (CDCl3) 
δ 154.7, 79.6, 55.4, 53.0, 43.1, 29.8, 28.4.  
11.10.4 4-(3-Chloropropyl)morpholine (117)  
 
117 
Morpholine (2.00 mL, 23.2 mmol) and 1-bromo-3-chloropropane (2.30 mL, 23.2 
mmol), and triethylamine (4.00 mL, 28.7 mmol) were dissolved in anhydrous 
dichloromethane (20 mL) and heated at reflux for 2 hrs. The reaction mixture was 
then diluted with water (40 mL), separated, and the aqueous layer extracted with 
dichloromethane (2 × 40 mL). The dichloromethane fractions were combined, dried 
over magnesium sulfate, and concentrated under reduced pressure to afford a pale 
yellow oil containing a fine white solid. The oil was dissolved in tetrahydrofuran and 
filtered, to remove the white solid, to afford the desired product as a pale yellow oil 
(2.95 g, 78%). 1H NMR (CDCl3) δ 3.69 (4 H, t, J = 4.7 Hz), 3.59 (2 H, t, J = 6.8 
Hz), 2.47 (2 H, t, J = 6.8 Hz), 2.44 - 2.42 (4 H, m), 1.94 (2 H, quin, J = 6.8 Hz); 13C 
NMR (CDCl3) δ 67.0, 55.9, 53.8, 43.2, 29.6.  
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11.10.5 4-(Chloromethyl)-1,1'-biphenyl (128)  
 
128 
4-Biphenymethanol 244 (1.020 g, 5.540 mmol) was treated with thionyl chloride 
(0.800 mL, 10.9 mmol) as described for 240. The resulting white solid was purified 
by column chromatography (10% ethyl acetate in petroleum spirits 40-60) to afford 
the desired product as a white solid (0.392 g, 35%). m.p. 71 - 73°C (68 - 69°C lit216); 
1H NMR (CDCl3) δ 7.62 - 7.58 (4 H, m), 7.49 - 7.44 (4 H, m), 7.40 - 7.35 (1 H, m), 
4.65 (2 H, s); 13C NMR (CDCl3) δ 141.6, 140.7, 136.6, 129.2, 129.0, 127.7, 127.6, 
127.3, 46.2.  
11.10.6 1-(Chloromethyl)-4-methoxybenzene (240)  
 
240 
4-Methoxybenzyl alcohol (1.80 mL, 14.5 mmol) was dissolved in anhydrous ether (2 
mL/mmol of alcohol). Thionyl chloride (2.1 mL, 29 mmol) was added and the 
reaction mixture stirred at room temperature for 24 hrs. The reaction was quenched 
with water, and extracted twice with dichloromethane. The dichloromethane 
fractions were combined and washed with water, dried over magnesium sulfate and 
concentrated under reduced pressure. The resulting pale yellow liquid was used 
without further purification (2.20 g, 97%). 1H NMR (CDCl3) δ 7.34 - 7.30 (2 H, m), 
6.91 - 6.87 (2 H, m), 4.43 (2 H, s), 3.65 (3 H, s); 13C NMR (CDCl3) δ 159.7, 130.1, 
129.7, 114.2, 55.3, 46.3.  
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11.10.7 3-Methylbenzyl chloride (241) 
  
241 
3-Methylbenzyl alcohol (1.50 mL, 12.5 mmol) was treated with thionyl chloride 
(1.80 mL, 25.0 mmol) as described for 240. The resulting colourless oil was used 
without further purification (1.54 g, 88%). 1H NMR (CDCl3) δ 7.28 - 7.13 (4 H, m), 
4.60 (2 H, s), 2.40 (3 H, s); 13C NMR (CDCl3) δ138.6, 137.5, 129.4, 129.3, 128.8, 
125.8, 46.5, 21.4.  
11.10.8 2-Cyclohexylethyl methanesulfonate (242) 
 
242 
2-Cyclohexylethanol (0.504 g, 3.90 mmol) was treated with methanesulfonyl 
chloride (365 μ, 4.70 mmol), and triethylamine (820 μL, 5.90 mmol) as described for 
243. The resulting pale yellow oil (0.794 g, >95%) was used without further 
purification. 1H NMR (CDCl3) δ 4.26 (2 H, t, J = 6.8 Hz), 2.99 (3 H, s), 1.77 - 1.54 
(7 H, m), 1.51 - 1.36 (1 H, m), 1.31 - 1.09 (3 H, m), 1.01 - 0.85 (2 H, m).  
11.10.9 tert-Butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-
carboxylate (243)  
 
243 
N-BOC-4-piperidinemethanol (0.507 g, 2.35 mmol) was dissolved in anhydrous 
dichloromethane and triethylamine (0.50 mL, 3.5 mmol). The reaction mixture was 
cooled to 0°C and methanesulfonyl chloride (0.22 mL, 2.84 mmol) was added. The 
reaction mixture was stirred at 0-10°C for a further 1 hour. The reaction mixture was 
242 
 
diluted with water and stirred for 30 minutes, then diluted with dichloromethane. The 
organic phase was separated, washed with 5% sodium bicarbonate solution, dried 
over magnesium sulfate, and concentrated under reduced pressure. The resulting pale 
yellow oil was purified by column chromatography (50:50: ethyl acetate : petroleum 
spirits 40-60) to afford the desired product as a colourless oil which slowly 
crystallised (0.467 g, 68%). m.p. 81 - 83°C (76 - 78°C lit217); 1H NMR (CDCl3) δ 
4.15 (2 H, d, J = 13.0 Hz), 4.07 (2 H, d, J = 6.5 Hz), 3.01 (3 H, s), 2.75 - 2.67 (2 H, 
m), 1.97 - 1.86 (1 H, m), 1.74 (2 H, d, J = 13.0 Hz), 1.45 (9 H, s), 1.29 - 1.16 (2 H, 
m); 13C NMR (CDCl3) δ 154.9, 79.8, 73.5, 43.4, 37.5, 36.2, 28.6, 28.4.  
11.10.10 1-(3-Chloropropyl)-2-nitro-1H-imidazole (122)  
 
122 
2-Nitroimidazole (0.500 g, 4.42 mmol) was added to a suspension of sodium hydride 
(60% dispersion in mineral oil, 0.212 g, 5.30 mmol) in anhydrous 
dimethylformamide (15 mL) and the mixture stirred at room temperature for 30 
minutes. 1-Bromo-3-chloropropane (525 μL, 5.30 mmol) was added and the mixture 
stirred at room temperature for a further 19 hrs, then subjected to workup method 2. 
The resulting orange gummy solid was purified by column chromatography (50:50, 
ethyl acetate:petroleum spirit 40-60) to afford the desired product as a yellow oil 
which slowly crystallised (0.107 g, 13%). The product contained a small amount of 
the terminal alkene product, obtained from elimination of the chlorine atom, but was 
used without further purification. 1H NMR (DMSO-d6) δ 7.67 (1 H, d, J = 1.2 Hz), 




11.10.11 1-(3-Chloropropyl)-4-nitro-1H-imidazole (125)  
 
125 
4-Nitroimidazole (0.499 g, 4.42 mmol) was added to a suspension of sodium hydride 
(60% dispersion in mineral oil, 0. 212 g, 5.30 mmol) in anhydrous 
dimethylformamide (15 mL) and the mixture stirred at room temperature for 30 
minutes. 1-Bromo-3-chloropropane (524 μL, 5.30 mmol) was added and the mixture 
stirred at room temperature for a further 24 hrs, then subjected to workup method 2. 
The resulting orange gummy solid was purified by column chromatography (50:50, 
ethyl acetate:petroleum spirit 40-60) to afford the desired product as a yellow oil 
which slowly crystallised (0.325 g, 39%). The product contained a small amount of 
the terminal alkene product, obtained from elimination of the chlorine atom, but was 
used without further purification. 1H NMR (DMSO-d6) δ 8.45 (1 H, d, J = 1.6 Hz), 
7.89 (1 H, d, J = 1.6 Hz), 4.26 - 4.13 (2 H, m), 3.62 (2 H, t, J = 6.5 Hz), 2.27 (2 H, 
quin, J = 6.5 Hz).  




Biphenyl-4-carboxylic acid (0.500 g, 2.52 mmol) was dissolved in anhydrous 
tetrahydrofuran (15 mL) and lithium aluminium hydride (0.293 g, 7.72 mmol) was 
added portionwise. The reaction mixture was stirred at room temperature for 4 hrs. 
The reaction was quenched slowly with water (5 mL) and stirring was continued for 
30 minutes. HCl (2 M, 30 mL) was added to dissolve the white precipitate. This was 
then extracted with ether (3 × 40 mL). The ether fractions were combined, dried over 
magnesium sulfate, and concentrated under reduced pressure to afford a white solid 
(0.456 g, 98%) which was used without further purification. 1H NMR (CDCl3) δ 7.63 
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- 7.59 (4 H, m), 7.49 - 7.43 (4 H, m), 7.39 - 7.34 (1 H, m), 4.76 (2 H, s), 1.75 (1 H, 
s). 
11.10.13 2-Phenoxyethyl tosylate (245)  
 
245 
2-Phenoxyethanol (2.01 g, 14.6 mmol) was treated with 4-toluenesulfonyl chloride 
(3.31 g, 17.3 mmol) and triethylamine (4.0 mL, 29 mmol) as described for 102. The 
resulting white solid was used without further purification (3.82 g, 90%). m.p. 76 - 
79°C (80°C lit218); 1H NMR (CDCl3) δ 7.83 - 7.80 (2 H, m), 7.36 - 7.32 (2 H, m), 
7.27 - 7.23 (2 H, m), 6.98 - 6.93 (1 H, m), 6.81 - 6.77 (2 H, m), 4.41 - 4.38 (2 H, m), 
4.18 - 4.16 (2 H, m), 2.47 (3 H, s); 13C NMR (CDCl3) δ 158.1, 145.1, 133.1, 130.0, 




(1)  Moss, G. P. Pure Appl. Chem. 1998, 70 (1), 143–216. 
(2)  World Health Organization. Working to overcome the global impact of 
neglected tropical diseases: First WHO report on neglected tropical diseases 
http://apps.who.int/iris/bitstream/10665/44440/1/9789241564090_eng.pdf 
(accessed May 17, 2016). 
(3)  Brun, R.; Blum, J.; Chappuis, F.; Burri, C. Lancet 2010, 375 (9709), 148–159. 
(4)  Paliwal, S. K. P. Sci. Pharm. 2011, 79 (3), 389–428. 
(5)  Kennedy, P. G. E. Ann. Neurol. 2008, 64 (2), 116–126. 
(6)  Ochiana, S. O.; Pandarinath, V.; Wang, Z.; Kapoor, R.; Ondrechen, M. J.; 
Ruben, L.; Pollastri, M. P. Eur. J. Med. Chem. 2013, 62, 777–784. 
(7)  Malvy, D.; Chappuis, F. Clin. Microbiol. Infect. 2011, 17 (7), 986–995. 
(8)  Simarro, P.; Franco, J.; Diarra, A.; Jannin, J. Clin. Epidemiol. 2014, 6, 257. 
(9)  World Health Organization. Sustaining the drive to overcome the global 
impact of neglected tropical diseases. Second WHO report on neglected 
tropical diseases 
http://www.who.int/iris/bitstream/10665/77950/1/9789241564540_eng.pdf 
(accessed May 17, 2016). 
(10)  Kennedy, P. G. E. Pract. Neurol. 2005, 260–267. 
(11)  Kennedy, P. G. E. J. Clin. Invest. 2004, 113 (4), 496–504. 
(12)  Kennedy, P. G. E. J. Neurol. 2006, 253 (4), 411–416. 
(13)  Sahlas, D. J.; MacLean, J. D.; Janevski, J.; Detsky, A. S. N. Engl. J. Med. 
2002, 347 (10), 749–753. 
(14)  Simarro, P. P.; Franco, J. R.; Cecchi, G.; Paone, M.; Diarra, A.; Ruiz Postigo, 
J. A.; Jannin, J. G. J. Travel Med. 2012, 19 (1), 44–53. 
(15)  Checchi, F.; Filipe, J. A.; Haydon, D. T.; Chandramohan, D.; Chappuis, F. 
BMC Infect. Dis. 2008, 8 (1), 16. 
(16)  Odiit, M.; Kansiime, F.; Enyaru, J. C. East Afr. Med. J. 1997, 74 (12), 792–
795. 
(17)  Steverding, D. Parasit. Vectors 2008, 1 (1), 3. 
246 
 
(18)  Simarro, P. P.; Diarra, A.; Ruiz Postigo, J. a; Franco, J. R.; Jannin, J. G. PLoS 
Negl. Trop. Dis. 2011, 5 (2), e1007. 
(19)  World Health Organization. WHO report on global surveillance of epidemic-
prone infectious diseases 
http://apps.who.int/iris/bitstream/10665/66485/1/WHO_CDS_CSR_ISR_2000
.1.pdf (accessed May 17, 2016). 
(20)  World Health Organization. Control and surveillance of African 
trypanosomiasis: report of a WHO Expert Committee. 
http://apps.who.int/iris/bitstream/10665/42087/1/WHO_TRS_881.pdf 
(accessed May 17, 2016). 
(21)  Franco, J. R.; Simarro, P. P.; Diarra, A.; Ruiz-Postigo, J. A.; Jannin, J. G. 
Parasitology 2014, 141 (6), 748–760. 
(22)  World Health Organization. Global health observatory map gallery 
http://gamapserver.who.int/mapLibrary/app/searchResults.aspx (accessed Apr 
20, 2016). 
(23)  Simarro, P. P.; Cecchi, G.; Franco, J. R.; Paone, M.; Diarra, A.; Priotto, G.; 
Mattioli, R. C.; Jannin, J. G. PLoS Negl. Trop. Dis. 2015, 9 (6), e0003785. 
(24)  World Health Organization. Report of the first WHO stakeholders meeting on 
rhodesiense human African trypanosomiasis elimination; Geneva, 2014. 
(25)  Holmes, P. PLoS Negl. Trop. Dis. 2014, 8 (10), e3244. 
(26)  Steverding, D. Parasit. Vectors 2010, 3 (1), 15. 
(27)  de Koning, H. P. Int. J. Parasitol. 2001, 31 (5–6), 512–522. 
(28)  Seebeck, T.; Maser, P. Antimicrobial Drug Resistance, 1st ed.; Mayers, D. L., 
Ed.; Humana Press: Totowa, NJ, 2009. 
(29)  Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; 
Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi-Kyanza, S.; Ilunga, M.; 
Mutangala, W.; Pohlig, G.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, 
V. Lancet 2009, 374 (9683), 56–64. 
(30)  Tweats, D.; Bourdin Trunz, B.; Torreele, E. Mutagenesis 2012, 27 (5), 523–
532. 
(31)  Rassi, A.; Dias, J. C. P.; Marin-Neto, J. A.; Rassi, A. Heart 2008, 95 (7), 524–
534. 
(32)  Torreele, E.; Bourdin Trunz, B.; Tweats, D.; Kaiser, M.; Brun, R.; Mazué, G.; 
Bray, M. a; Pécoul, B. PLoS Negl. Trop. Dis. 2010, 4 (12), e923. 
247 
 
(33)  World Health Organization. Research priorities for Chagas disease, human 
African trypanosomiasis and leishmaniasis. 
http://apps.who.int/iris/bitstream/10665/77472/1/WHO_TRS_975_eng.pdf 
(accessed May 17, 2016). 
(34)  World Health Organization. Report of the first WHO stakeholders meeting on 
gambiense human African trypanosomiasis elimination 
http://apps.who.int/iris/bitstream/10665/147021/1/9789241508070_eng.pdf 
(accessed May 17, 2016). 
(35)  Drugs for Neglected Diseases Initiative (2012). New Oral Drug Candidate for 
African Sleeping Sickness [Press Release]. http://www.dndi.org/2012/media-
centre/press-releases/new-oral-drug-candidate-hat/. 
(36)  Drugs for Neglected Diseases Initiative. Fexinidazole (HAT) 
http://www.dndi.org/diseases-projects/portfolio/fexinidazole/ (accessed Mar 8, 
2017). 
(37)  Jacobs, R. T.; Nare, B.; Wring, S. a; Orr, M. D.; Chen, D.; Sligar, J. M.; Jenks, 
M. X.; Noe, R. a; Bowling, T. S.; Mercer, L. T.; Rewerts, C.; Gaukel, E.; 
Owens, J.; Parham, R.; Randolph, R.; Beaudet, B.; Bacchi, C. J.; Yarlett, N.; 
Plattner, J. J.; Freund, Y.; Ding, C.; Akama, T.; Zhang, Y.-K.; Brun, R.; 
Kaiser, M.; Scandale, I.; Don, R. PLoS Negl. Trop. Dis. 2011, 5 (6), e1151. 
(38)  Drugs for Neglected Diseases Initiative. Pivotal Clinical Trial to Begin for 
First Oral Drug Candidate Specifically Developed for Sleeping Sickness 
[Press Release]. http://www.dndi.org/2015/media-centre/press-releases/pr-
scyx-7158/ (accessed Jul 8, 2016). 
(39)  Eperon, G.; Balasegaram, M.; Potet, J.; Mowbray, C.; Valverde, O.; Chappuis, 
F. Expert Rev. Anti. Infect. Ther. 2014, 12 (11), 1407–1417. 
(40)  Drugs for Neglected Diseases Initiative. SCYX-1608210 
http://www.dndi.org/diseases-projects/portfolio/oxaborole-backup/ (accessed 
Jan 5, 2016). 
(41)  Drugs for Neglected Diseases Initiative. SCYX-1330682 
http://www.dndi.org/diseases-projects/portfolio/scyx-1330682/ (accessed Jan 
5, 2016). 
(42)  Eder, J.; Sedrani, R.; Wiesmann, C. Nat. Rev. Drug Discov. 2014, 13 (8), 577–
587. 
(43)  Barrett, M. P. Curr. Opin. Infect. Dis. 2010, 23 (6), 603–608. 
248 
 
(44)  Goldsmith, R. B.; Gray, D. R.; Yan, Z.; Generaux, C. N.; Tidwell, R. R.; 
Reisner, H. M. J. Clin. Lab. Anal. 2010, 24 (3), 187–194. 
(45)  Thuita, J. K.; Wang, M. Z.; Kagira, J. M.; Denton, C. L.; Paine, M. F.; 
Mdachi, R. E.; Murilla, G. a; Ching, S.; Boykin, D. W.; Tidwell, R. R.; Hall, J. 
E.; Brun, R. PLoS Negl. Trop. Dis. 2012, 6 (7), e1734. 
(46)  Patrick, D. a.; Bakunov, S. a.; Bakunova, S. M.; Jones, S. K.; Wenzler, T.; 
Barszcz, T.; Kumar, A.; Boykin, D. W.; Werbovetz, K. a.; Brun, R.; Tidwell, 
R. R. Eur. J. Med. Chem. 2013, 67, 310–324. 
(47)  Patterson, S.; Wyllie, S. Trends Parasitol. 2014, 30 (6), 289–298. 
(48)  Borges, N. Expert Opin. Drug Saf. 2005, 4 (1), 69–73. 
(49)  Hirasawa, M.; Pittman, Q. J. Proc. Natl. Acad. Sci. 2003, 100 (10), 6139–
6144. 
(50)  Mattila, M. A.; Larni, H. M. Drugs 1980, 20 (5), 353–374. 
(51)  Raether, W.; Hänel, H. Parasitol. Res. 2003, 90 Supp 1, S19–S39. 
(52)  R. Wilkinson, S.; Bot, C.; M. Kelly, J.; S. Hall, B. Curr. Top. Med. Chem. 
2011, 11 (16), 2072–2084. 
(53)  Bot, C.; Hall, B. S.; Alvarez, G.; Di Maio, R.; Gonzalez, M.; Cerecetto, H.; 
Wilkinson, S. R. Antimicrob. Agents Chemother. 2013, 57 (4), 1638–1647. 
(54)  Wilkinson, S. R.; Taylor, M. C.; Horn, D.; Kelly, J. M.; Cheeseman, I. Proc. 
Natl. Acad. Sci. 2008, 105 (13), 5022–5027. 
(55)  Samant, B. S.; Chakaingesu, C. Bioorg. Med. Chem. Lett. 2013, 23 (5), 1420–
1423. 
(56)  Trunz, B. B.; Jędrysiak, R.; Tweats, D.; Brun, R.; Kaiser, M.; Suwiński, J.; 
Torreele, E. Eur. J. Med. Chem. 2011, 46 (5), 1524–1535. 
(57)  Papadopoulou, M. V.; Bloomer, W. D.; Rosenzweig, H. S.; O’Shea, I. P.; 
Wilkinson, S. R.; Kaiser, M. Eur. J. Med. Chem. 2015, 103, 325–334. 
(58)  Swinney, D. C.; Anthony, J. Nat. Rev. Drug Discov. 2011, 10 (7), 507–519. 
(59)  Richardson, J. L.; Nett, I. R. E.; Jones, D. C.; Abdille, M. H.; Gilbert, I. H.; 
Fairlamb, A. H. ChemMedChem 2009, 4 (8), 1333–1340. 
(60)  Patterson, S.; Jones, D. C.; Shanks, E. J.; Frearson, J. A.; Gilbert, I. H.; Wyatt, 
P. G.; Fairlamb, A. H. ChemMedChem 2009, 4 (8), 1341–1353. 
(61)  Walton, J. G. a; Jones, D. C.; Kiuru, P.; Durie, A. J.; Westwood, N. J.; 
Fairlamb, A. H. ChemMedChem 2011, 6 (2), 321–328. 
(62)  Patterson, S.; Alphey, M. S.; Jones, D. C.; Shanks, E. J.; Street, I. P.; Frearson, 
249 
 
J. a; Wyatt, P. G.; Gilbert, I. H.; Fairlamb, A. H. J. Med. Chem. 2011, 54 (19), 
6514–6530. 
(63)  Sola, I.; Castellà, S.; Viayna, E.; Galdeano, C.; Taylor, M. C.; Gbedema, S. 
Y.; Pérez, B.; Clos, M. V.; Jones, D. C.; Fairlamb, A. H.; Wright, C. W.; 
Kelly, J. M.; Muñoz-Torrero, D. Bioorg. Med. Chem. 2015, 23 (16), 5156–
5167. 
(64)  Ettari, R.; Tamborini, L.; Angelo, I. C.; Micale, N.; Pinto, A.; De Micheli, C.; 
Conti, P. J. Med. Chem. 2013, 56 (14), 5637–5658. 
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Appendix A – Summary of biological results 
No. Structure 
IC50 














Control Pyrimethamine >25 0.10 ± 0.04 25.1 ± 6.9 >100 - 
Control Cycloguanil >25 0.05 ± 0.02 4.9 ± 1.5 >50 - 
Control WR99210 0.20 ± 0.01 0.0034 ± 0.0002 0.005 ± 0.001 >100 - 
Control Ellipticine - - - 2.2 ± 0.3 - 
86 
 
>100 >100 >100 >100 0.37 
87 
 
25.6 ± 0.9 5.2 ± 1.0 15.1 ± 3.9 >100 2.26 
88 
 
2.8 ± 0.1 19.8 ± 1.3 77.9 ± 14.1 65.6 ± 2.3 2.65 





















>100 >100 >100 >100 0.37 
96 
 
16.9 ± 1.2 1.6 ± 0.7 3.0 ± 0.3 >50 2.20 
97 
 
17.5 ± 0.7 7.3 ± 1.4 14.9 ± 2.6 >50 2.10 
98 
 
2.5 ± 0.1 14.4 ± 3.6 5.4 ± 1.2 37.0 ± 6.0 3.03 
99 
 
2.2 ± 0.1 12.2 ± 1.6 5.2 ± 0.8 60.3 ± 34.8 3.03 
100 
 
20.3 ± 0.9 13.7 ± 1.0 10.3 ± 2.2 >50 2.77 
101 
 
20.7 ± 0.6 27.8 ± 3.1 11.0 ± 2.6 >100 2.77 
103 
 





















18.7 ± 0.9 4.3 ± 0.4 0.7 ± 0.1 >50 2.99 
108 
 
2.5 ± 0.1 16.9 ± 1.8 6.6 ± 1.5 >50 3.01 
111 
 
27.6 ± 0.2 >50 >50 >50 0.24 
112 
 





>100 >100 >100 >100 -2.13 
119 
 
>100 59.0 ± 9.4 >100 >100 -1.76 
126 
 
21.7 ± 1.0 5.0 ± 1.7 13.7 ± 6.5 >50 1.12 
127 
 





















2.9 ± 0.1 24.5 ± 0.3 21.3 ± 2.9 23.0 ± 2.1 3.91 
130 
 
2.8 ± 0.1 17.6 ± 1.1 17.0 ± 2.6 10.8 ± 4.2 3.75 
131 
 
2.8 ± 0.1 17.5 ± 4.6 18.3 ± 1.4 25.5 ± 3.0 4.51 
132 
 
0.28 ± 0.1 7.4 ± 0.5 17.6 ± 0.8 24.1 ± 4.3 4.51 
133 
 
1.4 ± 0.1 20.9 ± 2.4 20.1 ± 0.9 33.8 ± 16.7 4.05 
136 
 





















2.9 ± 0.1 12.8 ± 4.1 7.8 ± 3.3 27.3 ± 2.6 4.51 
140 
 
0.28 ± 0.01 3.7 ± 0.2 3.6 ± 0.9 0.28 ± 0.04 5.55 
142 
 
0.24 ± 0.01 7.4 ± 1.1 7.5 ± 1.0 0.31 ± 0.01 4.90 
148 
 
2.7 ± 0.2 3.6 ± 1.0 16.2 ± 5.6 3.4 ± 0.8 3.76 
149 
 
2.7 ± 0.2 2.7 ± 1.0 2.9 ± 1.5 5.6 ± 0.1 3.90 
150 
 
17.9 ± 0.2 52.2 ± 1.1 23.9 ± 2.1 >100 2.18 
151 
 





















2.8 ± 0.1 2.7 ± 1.5 3.2 ± 0.5 19.1 ± 0.6 5.72 
153 
 
>50 >50 >50 >50 0.56 
154 
 
>50 >50 >50 >50 -0.82 
155 
 
2.4 ± 0.1 19.8 ± 1.6 19.4 ± 4.4 18.3 ± 3.7 5.41 
157 
 
>100 66.0 ± 0.9 77.9 ± 14.1 >100 0.85 
158 
 
>100 >100 >100 >100 0.63 
159 
 





















13.0 ± 0.2 20.2 ± 3.2 3.2 ± 0.9 62.7 ± 9.1 3.15 
161 
 
3.1 ± 0.1 21.2 ± 4.3 18.8 ± 6.0 >50 4.04 
162 
 
>100 >100 >100 >100 0.98 
166 
 
>50 >50 >50 >50 2.76 
167 
 





















19.1 ± 0.2 19.6 ± 1.6 28.7 ± 13.1 >50 3.50 
169 
 
2.8 ± 0.2 19.4 ± 4.5 17.1 ± 4.3 23.5 ± 1.4 4.65 
170 
 
2.8 ± 0.2 >10 >10 >10 7.95 
172 
 
2.3 ± 0.2 6.7 ± 1.6 12.8 ± 0.9 23.6 ± 1.5 6.14 
175 
 
>100 >100 >100 >100 0.85 
176 
 
4.4 ± 0.3 57.9 ± 8.4 26.7 ± 3.6 >100 2.74 
177 
 





















2.9 ± 0.1 13.5 ± 2.8 14.0 ± 3.8 25.0 ± 3.9 3.50 
179 
 
25.9 ± 2.2 >50 >50 >50 0.71 
180 
 
16.4 ± 0.7 3.0 ± 0.7 2.3 ± 0.6 10.5 ± 4.1 6.67 
181 
 
16.3 ± 0.7 2.8 ± 0.5 2.8 ± 0.4 12.9 ± 2.3 6.67 
 188 
 
2.7 ± 0.1 4.3 ± 0.4 3.3 ± 0.6 22.2 ± 1.1 5.60 
190 
 
3.0 ± 0.1 26.5 ± 2.9 30.9 ± 13.0 >50 2.29 
191 
 





















2.7 ± 0.1 21.6 ± 1.2 21.4 ± 1.4 24.1 ± 2.2 3.28 
195 
 
19.8 ± 0.6 >100 >100 >100 2.72 
197 
 





>100 >100 >100 >100 -0.06 
201 
 
>100 >100 >100 >100 -0.06 
202 
 
>100 >100 >100 >100 1.08 
203 
 
>100 >100 >100 >100 1.32 
204 
 
70.5 ± 0.5 >50 40.2 ± 6.3 >100 2.73 
205 
 





















17.4 ± 2.3 27.9 ± 10.1 18.3 ± 3.5 >50 1.31 
211 
 
0.25 ± 0.02 7.7 ± 0.4 14.4 ± 2.3 20.8 ± 0.8 2.96 
212 
 
2.5 ±0.2 19.8 ± 0.9 4.8 ± 1.7 >50 2.07 
213 
 
8.4 ± 1.1 3.7 ± 0.3 3.5 ± 0.1 31.8 ± 6.7 4.62 
214 
 
2.7 ± 0.1 3.9 ± 0.4 3.4 ± 0.3 14.8 ± 5.5 6.26 
217 
 
>100 3.3 ± 0.22 >100 >100 1.89 
218 
 





















>100 >100 >100 >100 5.41 
220A 
 
>100 >100 60.6 ± 25.9 >100 2.00 
220B 
 
>100 >100 73.8 ± 7.2 >100 2.00 
221A 
 





















>100 >100 >100 >100 2.07 
222A 
 
>50 >50 >50 >50 2.35 
222B 
 
>50 >50 >50 >50 2.35 
223A 
 





















16.9 ± 0.9 12.0 ± 1.4 19.7 ± 1.8 >50 2.88 
224A 
 
>100 >100 >100 >100 1.17 
225 
 
0.39 ± 0.04 5.2 ± 2.4 3.1 ± 0.9 24.3 ± 2.9 4.83 
228 
 





















19.4 ± 1.0 9.9 ± 1.3 22.1 ± 3.7 37.6 ± 4.1 5.87 
230 
 
0.32 ± 0.01 2.8 ± 0.2 2.1 ± 0.7 3.2 ± 0.2 6.72 
231 
 
2.5 ± 0.2 16.6 ± 4.9 2.9 ± 0.8 3.6 ±0.7 8.37 
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Appendix B –Biological results from different labs 
At the beginning of this research biological testing was originally carried out by the 
School of Veterinary and Biomedical Science at Murdoch University. However, 
shortly thereafter samples were no longer able to be sent to this lab. Following this 
biological testing was carried out by the Eskitis Institute for Cell and Molecular 
Therapies at Griffith University. Assays run at this lab however were for the 
inhibition of T. b. brucei (type that infects only animals) rather than T. b. 
rhodesiense. Finally biological testing was carried out by the BIOTEC Medical 
Molecular Biology Research Unit in Thailand. All samples previously sent to 
Murdoch University and the Eskitis institute were also sent to BIOTEC. Therefore all 
biological activities reported in this thesis have been obtained from BIOTEC. The 
table below shows the results for compounds tested at more than one lab, where the 
IC50 values for most compounds are comparable between labs. 
No. 
IC50 








T. b. brucei 
(μM) 
Eskitis3 
108 2.5 ± 0.1 6.5 7.9 
129 2.9 ± 0.1 6.7 7.4 
87 25.6 ± 0.9 16.5  
96 16.9 ± 1.2 20.1  
97 17.5 ± 0.7 21.8  
100 20.3 ± 0.9 17.4  
101 20.7 ± 0.6 18.2  
103 17.9 ± 1.7 26.8  
105 18.7 ± 0.9 18.2  
150 17.9 ± 0.2 46.7  
169 2.8 ± 0.2 18.2  
88 2.8 ± 0.1  13.2 
98 2.5 ± 0.1  13.3 
99 2.2 ± 0.1  20.0 
111 27.6 ± 0.2  27.6 
130 2.8 ± 0.1  7.3 
136 2.9 ± 0.1  27.3 
132 0.28 ± 0.01  4.0 
131 2.8 ± 0.1  2.8 
138 2.8 ± 0.1  9.7 













T. b. brucei 
(μM) 
Eskitis3 
152 2.8 ± 0.1  8.9 
1 Testing was carried out by Sumalee Kamchonwongpaisan, Jutharat Pengon, and 
Roonglawan Rattanajak from BIOTEC Medical Molecular Biology Research Unit, 
National Science and Technology Development Agency, 113 Thailand Science Park, 
Phahonyothin Road, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand. 
See experimental section for details. 
2 Testing was carried out by the School of Veterinary and Biomedical Science, 
Murdoch University, Murdoch, Western Australia 6150.  
3 Testing was carried out at the Eskitis Institute for Cell and Molecular Therapies, 
Griffith University, Brisbane Innovation Park, Don Young Road, Nathan, 




Appendix C – Crystallography details 
Description of the crystal structure  
The crystal structure of compound 227 was determined via synchrotron X-ray 
diffraction data on single crystals obtained by slow evaporation of a DCM/ 
petroleum ether 40-60 solution. In the unit cell two independent molecules (tagged 
with letters A and B in the discussion) co-exist. Figure A1 shows the molecular 
structure of molecule A with its partial labelling scheme. Selected bond distances are 
listed in Table A2. The molecules possesses two chiral centres (C7 and C10) of 
absolute configuration R, R. The configuration of C7 was known from the retention 
of the chiral centre during the synthetic procedure, and the configuration of C10 
could be assigned by solving the solid-state structure.  
 




Table A1 Crystal data and structure refinement information for 227. 
Compound X 
empirical formula C30H24N2O6 
M 508.51 
crys syst Monoclinic 







ρ /g cm–3 1.337 
 /mm–1 0.091 
F(000) 1064 
total reflections 41787 
unique reflections (Rint) 13671 (0.0439) 
observed reflections [Fo>4σ(Fo)] 12913 
GOF on F2a 1.010 
R indices [Fo>4σ(Fo)]
bR1, wR2 0.0421, 0.1221 
largest diff. peak and hole (eÅ–3) 0.326, -0.316 
aGoodness-of-fit S = [w(Fo2-Fc2)2/ (n-p)]1/2, where n is the number of reflections 













Table A2 Selected bond distances (Å) for 227. 
N1A-O1A 1.223(1) N1B-O1B 1.234(1)  
N1A-O2A 1.226(1) N1B-O2B 1.221(1)  
N2A-C7A 1.467(1) N2B-C7B 1.471(1)  
O3A-C10A 1.445(1) O3B-C10B 1.452(1)  
C13A-O3A 1.342(1) C13B-O3B 1.315(1)  
C13A-O4A 1.209(1) C13B-O4B 1.212(1)  
C24A-O5A 1.368(1) C24B-O5B 1.360(1)  
C24A-O6A 1.200(1) C24B-O6B 1.208(1)  
 
 
Figure A2 Ortep view (20% probability labels) of the two independent molecules of 
compound 227.  
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Appendix D – NMR spectra  
 

























































































































































































































































































































































































































Figure A91 1H NMR spectra of 231 (CDCl3). 
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of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN. 
Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby. 
The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party. 
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non­refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns. 
In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC­BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC­BY
license permits commercial and non­
Creative Commons Attribution Non­Commercial License
The Creative Commons Attribution Non­Commercial (CC­BY­NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution­Non­Commercial­NoDerivs License
The Creative Commons Attribution Non­Commercial­NoDerivs License (CC­BY­NC­ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for­profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id­410895.html
Other Terms and Conditions:
v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1­855­239­3415 (toll free in the US) or
+1­978­646­2777.
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TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or
one of its group companies (each a"Wiley Company") or handled on behalf of a society with
which a Wiley Company has exclusive publishing rights in relation to a particular work
(collectively "WILEY"). By clicking "accept" in connection with completing this licensing
transaction, you agree that the following terms and conditions apply to this transaction
(along with the billing and payment terms and conditions established by the Copyright
Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at the time that
you opened your RightsLink account (these are available at any time at
http://myaccount.copyright.com).
Terms and Conditions
The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright. 
You are hereby granted a personal, non­exclusive, non­sub licensable (on a stand­
alone basis), non­transferable, worldwide, limited license to reproduce the Wiley
Materials for the purpose specified in the licensing process. This license, and any
CONTENT (PDF or image file) purchased as part of your order, is for a one­time
use only and limited to any maximum distribution number specified in the license.
The first instance of republication or reuse granted by this license must be completed
within two years of the date of the grant of this license (although copies prepared
before the end date may be distributed thereafter). The Wiley Materials shall not be
used in any other manner or for any other purpose, beyond what is granted in the
license. Permission is granted subject to an appropriate acknowledgement given to the
author, title of the material/book/journal and the publisher. You shall also duplicate the
copyright notice that appears in the Wiley publication in your use of the Wiley
Material. Permission is also granted on the understanding that nowhere in the text is a
previously published source acknowledged for all or part of this Wiley Material. Any
third party content is expressly excluded from this permission.
With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and no
derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only, the
terms of the license are extended to include subsequent editions and for editions
in other languages, provided such editions are for the work as a whole in situ and
does not involve the separate exploitation of the permitted figures or extracts,
You may not alter, remove or suppress in any manner any copyright, trademark or
other notices displayed by the Wiley Materials. You may not license, rent, sell, loan,
lease, pledge, offer as security, transfer or assign the Wiley Materials on a stand­alone
basis, or any of the rights granted to you hereunder to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all times
remain the exclusive property of John Wiley & Sons Inc, the Wiley Companies, or
their respective licensors, and your interest therein is only that of having possession of
and the right to reproduce the Wiley Materials pursuant to Section 2 herein during the
continuance of this Agreement. You agree that you own no right, title or interest in or
to the Wiley Materials or any of the intellectual property rights therein. You shall have
no rights hereunder other than the license as provided for above in Section 2. No right,
license or interest to any trademark, trade name, service mark or other branding
("Marks") of WILEY or its licensors is granted hereunder, and you agree that you
shall not assert any such right, license or interest with respect thereto
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON­INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU. 
WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN. 
Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby. 
The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party. 
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non­refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns. 
In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC­BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC­BY
license permits commercial and non­
Creative Commons Attribution Non­Commercial License
The Creative Commons Attribution Non­Commercial (CC­BY­NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution­Non­Commercial­NoDerivs License
The Creative Commons Attribution Non­Commercial­NoDerivs License (CC­BY­NC­ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for­profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id­410895.html
Other Terms and Conditions:
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Questions? customercare@copyright.com or +1­855­239­3415 (toll free in the US) or
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